<!DOCTYPE html>

<html>

<head>

<meta charset="utf-8" />
<meta name="generator" content="pandoc" />
<meta http-equiv="X-UA-Compatible" content="IE=EDGE" />




<title>Study Evidence Tables</title>

<script src="site_libs/header-attrs-2.11/header-attrs.js"></script>
<script src="site_libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<meta name="viewport" content="width=device-width, initial-scale=1" />
<link href="site_libs/bootstrap-3.3.5/css/cosmo.min.css" rel="stylesheet" />
<script src="site_libs/bootstrap-3.3.5/js/bootstrap.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/html5shiv.min.js"></script>
<script src="site_libs/bootstrap-3.3.5/shim/respond.min.js"></script>
<style>h1 {font-size: 34px;}
       h1.title {font-size: 38px;}
       h2 {font-size: 30px;}
       h3 {font-size: 24px;}
       h4 {font-size: 18px;}
       h5 {font-size: 16px;}
       h6 {font-size: 12px;}
       code {color: inherit; background-color: rgba(0, 0, 0, 0.04);}
       pre:not([class]) { background-color: white }</style>
<script src="site_libs/jqueryui-1.11.4/jquery-ui.min.js"></script>
<link href="site_libs/tocify-1.9.1/jquery.tocify.css" rel="stylesheet" />
<script src="site_libs/tocify-1.9.1/jquery.tocify.js"></script>
<script src="site_libs/navigation-1.1/tabsets.js"></script>
<link href="site_libs/highlightjs-9.12.0/textmate.css" rel="stylesheet" />
<script src="site_libs/highlightjs-9.12.0/highlight.js"></script>
<script src="site_libs/kePrint-0.0.1/kePrint.js"></script>
<link href="site_libs/lightable-0.0.1/lightable.css" rel="stylesheet" />

<link rel="icon" href="https://github.com/workflowr/workflowr-assets/raw/main/img/reproducible.png">
<!-- Add a small amount of space between sections. -->
<style type="text/css">
div.section {
  padding-top: 12px;
}
</style>



<style type="text/css">
  code{white-space: pre-wrap;}
  span.smallcaps{font-variant: small-caps;}
  span.underline{text-decoration: underline;}
  div.column{display: inline-block; vertical-align: top; width: 50%;}
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  ul.task-list{list-style: none;}
    </style>

<style type="text/css">code{white-space: pre;}</style>
<script type="text/javascript">
if (window.hljs) {
  hljs.configure({languages: []});
  hljs.initHighlightingOnLoad();
  if (document.readyState && document.readyState === "complete") {
    window.setTimeout(function() { hljs.initHighlighting(); }, 0);
  }
}
</script>




<style type="text/css">
/* for pandoc --citeproc since 2.11 */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>




<style type = "text/css">
.main-container {
  max-width: 940px;
  margin-left: auto;
  margin-right: auto;
}
img {
  max-width:100%;
}
.tabbed-pane {
  padding-top: 12px;
}
.html-widget {
  margin-bottom: 20px;
}
button.code-folding-btn:focus {
  outline: none;
}
summary {
  display: list-item;
}
pre code {
  padding: 0;
}
</style>


<style type="text/css">
.dropdown-submenu {
  position: relative;
}
.dropdown-submenu>.dropdown-menu {
  top: 0;
  left: 100%;
  margin-top: -6px;
  margin-left: -1px;
  border-radius: 0 6px 6px 6px;
}
.dropdown-submenu:hover>.dropdown-menu {
  display: block;
}
.dropdown-submenu>a:after {
  display: block;
  content: " ";
  float: right;
  width: 0;
  height: 0;
  border-color: transparent;
  border-style: solid;
  border-width: 5px 0 5px 5px;
  border-left-color: #cccccc;
  margin-top: 5px;
  margin-right: -10px;
}
.dropdown-submenu:hover>a:after {
  border-left-color: #adb5bd;
}
.dropdown-submenu.pull-left {
  float: none;
}
.dropdown-submenu.pull-left>.dropdown-menu {
  left: -100%;
  margin-left: 10px;
  border-radius: 6px 0 6px 6px;
}
</style>

<script type="text/javascript">
// manage active state of menu based on current page
$(document).ready(function () {
  // active menu anchor
  href = window.location.pathname
  href = href.substr(href.lastIndexOf('/') + 1)
  if (href === "")
    href = "index.html";
  var menuAnchor = $('a[href="' + href + '"]');

  // mark it active
  menuAnchor.tab('show');

  // if it's got a parent navbar menu mark it active as well
  menuAnchor.closest('li.dropdown').addClass('active');

  // Navbar adjustments
  var navHeight = $(".navbar").first().height() + 15;
  var style = document.createElement('style');
  var pt = "padding-top: " + navHeight + "px; ";
  var mt = "margin-top: -" + navHeight + "px; ";
  var css = "";
  // offset scroll position for anchor links (for fixed navbar)
  for (var i = 1; i <= 6; i++) {
    css += ".section h" + i + "{ " + pt + mt + "}\n";
  }
  style.innerHTML = "body {" + pt + "padding-bottom: 40px; }\n" + css;
  document.head.appendChild(style);
});
</script>

<!-- tabsets -->

<style type="text/css">
.tabset-dropdown > .nav-tabs {
  display: inline-table;
  max-height: 500px;
  min-height: 44px;
  overflow-y: auto;
  border: 1px solid #ddd;
  border-radius: 4px;
}

.tabset-dropdown > .nav-tabs > li.active:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li.active:before {
  content: "&#xe258;";
  border: none;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open:before {
  content: "";
  font-family: 'Glyphicons Halflings';
  display: inline-block;
  padding: 10px;
  border-right: 1px solid #ddd;
}

.tabset-dropdown > .nav-tabs > li.active {
  display: block;
}

.tabset-dropdown > .nav-tabs > li > a,
.tabset-dropdown > .nav-tabs > li > a:focus,
.tabset-dropdown > .nav-tabs > li > a:hover {
  border: none;
  display: inline-block;
  border-radius: 4px;
  background-color: transparent;
}

.tabset-dropdown > .nav-tabs.nav-tabs-open > li {
  display: block;
  float: none;
}

.tabset-dropdown > .nav-tabs > li {
  display: none;
}
</style>

<!-- code folding -->



<style type="text/css">

#TOC {
  margin: 25px 0px 20px 0px;
}
@media (max-width: 768px) {
#TOC {
  position: relative;
  width: 100%;
}
}

@media print {
.toc-content {
  /* see https://github.com/w3c/csswg-drafts/issues/4434 */
  float: right;
}
}

.toc-content {
  padding-left: 30px;
  padding-right: 40px;
}

div.main-container {
  max-width: 1200px;
}

div.tocify {
  width: 20%;
  max-width: 260px;
  max-height: 85%;
}

@media (min-width: 768px) and (max-width: 991px) {
  div.tocify {
    width: 25%;
  }
}

@media (max-width: 767px) {
  div.tocify {
    width: 100%;
    max-width: none;
  }
}

.tocify ul, .tocify li {
  line-height: 20px;
}

.tocify-subheader .tocify-item {
  font-size: 0.90em;
}

.tocify .list-group-item {
  border-radius: 0px;
}


</style>



</head>

<body>


<div class="container-fluid main-container">


<!-- setup 3col/9col grid for toc_float and main content  -->
<div class="row">
<div class="col-xs-12 col-sm-4 col-md-3">
<div id="TOC" class="tocify">
</div>
</div>

<div class="toc-content col-xs-12 col-sm-8 col-md-9">




<div class="navbar navbar-default  navbar-fixed-top" role="navigation">
  <div class="container">
    <div class="navbar-header">
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse" data-target="#navbar">
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      <a class="navbar-brand" href="index.html">NMB</a>
    </div>
    <div id="navbar" class="navbar-collapse collapse">
      <ul class="nav navbar-nav">
        <li>
  <a href="soe.html">Strength of Evidence</a>
</li>
<li>
  <a href="kq1.html">NMM Technical</a>
</li>
<li>
  <a href="kq2.html">NMM Diagnostic</a>
</li>
<li>
  <a href="kq3.html">NMM Outcomes</a>
</li>
<li>
  <a href="reversal.html">Reversal</a>
</li>
<li>
  <a href="evidence_tables.html">Evidence Tables</a>
</li>
<li class="dropdown">
  <a href="#" class="dropdown-toggle" data-toggle="dropdown" role="button" aria-expanded="false">
    Appendices
     
    <span class="caret"></span>
  </a>
  <ul class="dropdown-menu" role="menu">
    <li>
      <a href="prisma.html">PRISMA</a>
    </li>
    <li>
      <a href="outcome_importance.html">Outcome Importance</a>
    </li>
  </ul>
</li>
<li>
  <a href="about.html">About</a>
</li>
<li>
  <a href="license.html">License</a>
</li>
      </ul>
      <ul class="nav navbar-nav navbar-right">
        
      </ul>
    </div><!--/.nav-collapse -->
  </div><!--/.container -->
</div><!--/.navbar -->

<div id="header">



<h1 class="title toc-ignore">Study Evidence Tables</h1>
<h4 class="date">11 January, 2022 (08:08)</h4>

</div>


<p>
<button type="button" class="btn btn-default btn-workflowr btn-workflowr-report" data-toggle="collapse" data-target="#workflowr-report">
<span class="glyphicon glyphicon-list" aria-hidden="true"></span> workflowr <span class="glyphicon glyphicon-exclamation-sign text-danger" aria-hidden="true"></span>
</button>
</p>
<div id="workflowr-report" class="collapse">
<ul class="nav nav-tabs">
<li class="active">
<a data-toggle="tab" href="#summary">Summary</a>
</li>
<li>
<a data-toggle="tab" href="#checks"> Checks <span class="glyphicon glyphicon-exclamation-sign text-danger" aria-hidden="true"></span> </a>
</li>
<li>
<a data-toggle="tab" href="#versions">Past versions</a>
</li>
</ul>
<div class="tab-content">
<div id="summary" class="tab-pane fade in active">
<p>
<strong>Last updated:</strong> 2022-01-11
</p>
<p>
<strong>Checks:</strong> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> 6 <span class="glyphicon glyphicon-exclamation-sign text-danger" aria-hidden="true"></span> 1
</p>
<p>
<strong>Knit directory:</strong> <code>nmb/</code> <span class="glyphicon glyphicon-question-sign" aria-hidden="true" title="This is the local directory in which the code in this file was executed."> </span>
</p>
<p>
This reproducible <a href="https://rmarkdown.rstudio.com">R Markdown</a> analysis was created with <a
  href="https://github.com/workflowr/workflowr">workflowr</a> (version 1.7.0). The <em>Checks</em> tab describes the reproducibility checks that were applied when the results were created. The <em>Past versions</em> tab lists the development history.
</p>
<hr>
</div>
<div id="checks" class="tab-pane fade">
<div id="workflowr-checks" class="panel-group">
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongRMarkdownfilestronguncommittedchanges"> <span class="glyphicon glyphicon-exclamation-sign text-danger" aria-hidden="true"></span> <strong>R Markdown file:</strong> uncommitted changes </a>
</p>
</div>
<div id="strongRMarkdownfilestronguncommittedchanges" class="panel-collapse collapse">
<div class="panel-body">
<p>The R Markdown file has unstaged changes. To know which version of the R Markdown file created these results, you’ll want to first commit it to the Git repo. If you’re still working on the analysis, you can ignore this warning. When you’re finished, you can run <code>wflow_publish</code> to commit the R Markdown file and build the HTML.</p>
</div>
</div>
</div>
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongEnvironmentstrongempty"> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> <strong>Environment:</strong> empty </a>
</p>
</div>
<div id="strongEnvironmentstrongempty" class="panel-collapse collapse">
<div class="panel-body">
<p>Great job! The global environment was empty. Objects defined in the global environment can affect the analysis in your R Markdown file in unknown ways. For reproduciblity it’s best to always run the code in an empty environment.</p>
</div>
</div>
</div>
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongSeedstrongcodesetseed20211025code"> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> <strong>Seed:</strong> <code>set.seed(20211025)</code> </a>
</p>
</div>
<div id="strongSeedstrongcodesetseed20211025code" class="panel-collapse collapse">
<div class="panel-body">
<p>The command <code>set.seed(20211025)</code> was run prior to running the code in the R Markdown file. Setting a seed ensures that any results that rely on randomness, e.g. subsampling or permutations, are reproducible.</p>
</div>
</div>
</div>
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongSessioninformationstrongrecorded"> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> <strong>Session information:</strong> recorded </a>
</p>
</div>
<div id="strongSessioninformationstrongrecorded" class="panel-collapse collapse">
<div class="panel-body">
<p>Great job! Recording the operating system, R version, and package versions is critical for reproducibility.</p>
</div>
</div>
</div>
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongCachestrongnone"> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> <strong>Cache:</strong> none </a>
</p>
</div>
<div id="strongCachestrongnone" class="panel-collapse collapse">
<div class="panel-body">
<p>Nice! There were no cached chunks for this analysis, so you can be confident that you successfully produced the results during this run.</p>
</div>
</div>
</div>
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongFilepathsstrongrelative"> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> <strong>File paths:</strong> relative </a>
</p>
</div>
<div id="strongFilepathsstrongrelative" class="panel-collapse collapse">
<div class="panel-body">
<p>Great job! Using relative paths to the files within your workflowr project makes it easier to run your code on other machines.</p>
</div>
</div>
</div>
<div class="panel panel-default">
<div class="panel-heading">
<p class="panel-title">
<a data-toggle="collapse" data-parent="#workflowr-checks" href="#strongRepositoryversionstrongahrefhttpsgithubcommdgrantNMBtreea99c6db3826fd0e9859dc2f36545c9f7bbc45afftargetblanka99c6dba"> <span class="glyphicon glyphicon-ok text-success" aria-hidden="true"></span> <strong>Repository version:</strong> <a href="https://github.com/mdgrant/NMB/tree/a99c6db3826fd0e9859dc2f36545c9f7bbc45aff" target="_blank">a99c6db</a> </a>
</p>
</div>
<div id="strongRepositoryversionstrongahrefhttpsgithubcommdgrantNMBtreea99c6db3826fd0e9859dc2f36545c9f7bbc45afftargetblanka99c6dba" class="panel-collapse collapse">
<div class="panel-body">
<p>
Great! You are using Git for version control. Tracking code development and connecting the code version to the results is critical for reproducibility.
</p>
<p>
The results in this page were generated with repository version <a href="https://github.com/mdgrant/NMB/tree/a99c6db3826fd0e9859dc2f36545c9f7bbc45aff" target="_blank">a99c6db</a>. See the <em>Past versions</em> tab to see a history of the changes made to the R Markdown and HTML files.
</p>
<p>
Note that you need to be careful to ensure that all relevant files for the analysis have been committed to Git prior to generating the results (you can use <code>wflow_publish</code> or <code>wflow_git_commit</code>). workflowr only checks the R Markdown file, but you know if there are other scripts or data files that it depends on. Below is the status of the Git repository when the results were generated:
</p>
<pre><code>
Ignored files:
    Ignored:    .DS_Store
    Ignored:    .Rhistory
    Ignored:    .Rproj.user/
    Ignored:    _@@/
    Ignored:    analysis/index (original).Rmd
    Ignored:    analysis/kq2 (original 2).Rmd
    Ignored:    code/helpers.R
    Ignored:    code/rob_summary.R
    Ignored:    code/rob_traffic_light.R
    Ignored:    code/rob_traffic_light_mg.R
    Ignored:    used_files_dates.txt
    Ignored:    used_rob_files_dates.txt

Untracked files:
    Untracked:  .temp.lb
    Untracked:  analysis/.gitignore
    Untracked:  code/.gitignore
    Untracked:  code/misc_calcs.R
    Untracked:  code/rob_111921 (original).R
    Untracked:  code/rob_111921.R
    Untracked:  code/rob_summary_mg.R
    Untracked:  data/

Unstaged changes:
    Modified:   analysis/evidence_tables.Rmd
    Modified:   analysis/kq1.Rmd
    Modified:   analysis/reversal.Rmd
    Modified:   code/readfiles_nmb_102721.R

</code></pre>
<p>
Note that any generated files, e.g. HTML, png, CSS, etc., are not included in this status report because it is ok for generated content to have uncommitted changes.
</p>
</div>
</div>
</div>
</div>
<hr>
</div>
<div id="versions" class="tab-pane fade">

<p>
These are the previous versions of the repository in which changes were made to the R Markdown (<code>analysis/evidence_tables.Rmd</code>) and HTML (<code>docs/evidence_tables.html</code>) files. If you’ve configured a remote Git repository (see <code>?wflow_git_remote</code>), click on the hyperlinks in the table below to view the files as they were in that past version.
</p>
<div class="table-responsive">
<table class="table table-condensed table-hover">
<thead>
<tr>
<th>
File
</th>
<th>
Version
</th>
<th>
Author
</th>
<th>
Date
</th>
<th>
Message
</th>
</tr>
</thead>
<tbody>
<tr>
<td>
Rmd
</td>
<td>
<a href="https://github.com/mdgrant/NMB/blob/9d6453a293772bbdf637e31441613aefa3b49e96/analysis/evidence_tables.Rmd" target="_blank">9d6453a</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-12-30
</td>
<td>
updates to kq2 kq3
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/9d6453a293772bbdf637e31441613aefa3b49e96/docs/evidence_tables.html" target="_blank">9d6453a</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-12-30
</td>
<td>
updates to kq2 kq3
</td>
</tr>
<tr>
<td>
Rmd
</td>
<td>
<a href="https://github.com/mdgrant/NMB/blob/e61ab05c5ccbea133f735179dca41c8398b06171/analysis/evidence_tables.Rmd" target="_blank">e61ab05</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-21
</td>
<td>
updates study category display
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/e61ab05c5ccbea133f735179dca41c8398b06171/docs/evidence_tables.html" target="_blank">e61ab05</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-21
</td>
<td>
updates study category display
</td>
</tr>
<tr>
<td>
Rmd
</td>
<td>
<a href="https://github.com/mdgrant/NMB/blob/95451693a1c43e2141df2bd73a31883370a81aa7/analysis/evidence_tables.Rmd" target="_blank">9545169</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
fix indents
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/95451693a1c43e2141df2bd73a31883370a81aa7/docs/evidence_tables.html" target="_blank">9545169</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
fix indents
</td>
</tr>
<tr>
<td>
Rmd
</td>
<td>
<a href="https://github.com/mdgrant/NMB/blob/810df6b0d13175b62d941aae27ddfd637ec6f015/analysis/evidence_tables.Rmd" target="_blank">810df6b</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
fix misc and bib
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/810df6b0d13175b62d941aae27ddfd637ec6f015/docs/evidence_tables.html" target="_blank">810df6b</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
fix misc and bib
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/22d871bc3d33eae40ca0529a22396142b2072a13/docs/evidence_tables.html" target="_blank">22d871b</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
update yml
</td>
</tr>
<tr>
<td>
Rmd
</td>
<td>
<a href="https://github.com/mdgrant/NMB/blob/de88d889e1672061f2674a442c195fa1ca499390/analysis/evidence_tables.Rmd" target="_blank">de88d88</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
update all pages for outline
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/de88d889e1672061f2674a442c195fa1ca499390/docs/evidence_tables.html" target="_blank">de88d88</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-17
</td>
<td>
update all pages for outline
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/626f5ea0b8b133859b465e3a3d5e81e03c6c5676/docs/evidence_tables.html" target="_blank">626f5ea</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-09
</td>
<td>
fix home
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/4bda671aebc9a38f50a3f73a2de12bc64e5d7d09/docs/evidence_tables.html" target="_blank">4bda671</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-09
</td>
<td>
Update headers
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/b84549649e3b404d53a3db3f546e52974f994fd2/docs/evidence_tables.html" target="_blank">b845496</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-09
</td>
<td>
update headers
</td>
</tr>
<tr>
<td>
Rmd
</td>
<td>
<a href="https://github.com/mdgrant/NMB/blob/c17b5a28925ccff686ea93bcb39a3f8cae44a0f6/analysis/evidence_tables.Rmd" target="_blank">c17b5a2</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-09
</td>
<td>
update appendix
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/c17b5a28925ccff686ea93bcb39a3f8cae44a0f6/docs/evidence_tables.html" target="_blank">c17b5a2</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-09
</td>
<td>
update appendix
</td>
</tr>
<tr>
<td>
html
</td>
<td>
<a href="https://rawcdn.githack.com/mdgrant/NMB/014d39896334c80878bdc47fdb153e3c05bf38ab/docs/evidence_tables.html" target="_blank">014d398</a>
</td>
<td>
Mark Grant
</td>
<td>
2021-11-09
</td>
<td>
add files for site
</td>
</tr>
</tbody>
</table>
</div>
<hr>
</div>
</div>
</div>
<style type="text/css">
  body{
  font-size: 9.5pt;
  font-family: Source Sans Pro;
}

.list-group-item.active, .list-group-item.active:hover, .list-group-item.active:focus {
  color: #090909;
  background-color: #0909093d;
}

.lightable-classic.lightable-hover tbody tr:hover {
    background-color: #c5d4e4;
}
.btn-xs, .btn-group-xs>.btn { 
display: none; 

}

.btn-default {
display: none !important; 
}

:target {  /* fix target location so caption appears */
    display: block;
    position: relative;
    top: -60px;
    visibility: display;
}

</style>
<div id="technical-performance-kq1" class="section level1">
<h1><strong>Technical Performance KQ1</strong></h1>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; ">
<thead>
<tr>
<th style="text-align:left;font-weight: bold;">
Study
</th>
<th style="text-align:center;font-weight: bold;">
N
</th>
<th style="text-align:left;font-weight: bold;">
Inclusion/Exclusion Criteria
</th>
<th style="text-align:left;font-weight: bold;">
Results
</th>
<th style="text-align:left;font-weight: bold;">
Comment
</th>
</tr>
</thead>
<tbody>
<tr grouplength="24">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Adult</strong>
</td>
</tr>
<tr grouplength="5">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
RCT
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1669"></a>Capron <br> 2004
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neurmuscular disease, hepatic or renal disease, abnormal airway anatomy, deviation from ideal body mass of &gt;= 25%, pregnancy, medication influencing neuromuscular blockade.
</td>
<td style="text-align:left;width: 20em; ">
AMG TOFR for recovery should be 1.0 to avoid low degrees of rNMB. When MMG records TOFR &gt;= 0.9 the normalized AMG TOFR = 0.89 (0.63-1.06) and non-normalized = 0.97 (0.68-1.18).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1794"></a>Kopman <br> 2005
</td>
<td style="text-align:center;width: 4em; ">
50
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 20-64 years.<br>Exclude: Neuromuscular disease, BMI &lt; 35.
</td>
<td style="text-align:left;width: 20em; ">
AMG TOFR &lt; 0.9 is indicative of incomplete recovery. AMG TOFR 0.95-1.0 when EMG TOF = 0.9 should be sought.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2192"></a>Suzuki <br> 2009
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 20-60 years, female.<br>Exclude: Neuromuscular, hepatic and renal disorders, or were taking any drug known to interact with neuromuscular blocking agents, BMI &lt; 18.5 or &gt;=25.
</td>
<td style="text-align:left;width: 20em; ">
The time for neostigmine-facilitated recovery to TOFR 0.9 was shorter in the CSM group than in the APM [11.4 (3.8) vs. 16.2 (6.0) min; p=0.016].
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3316"></a>Mazzinari <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
50
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age &gt;18; surgery not involving airway and lasting &gt;=90 min.<br>Exclude: Pregnant; diseases or drugs affecting neuromuscular function; chronic renal or hepatic failure; allergy to study drugs; hemodynamic instability; potentially large intraoperative blood loss.
</td>
<td style="text-align:left;width: 20em; ">
A difference was not detected in time to TOFR &gt;=0.9 (non-normalized and normalized) among patients receiving tetanic stimulus prior to monitor calibration (n=22) compared with patients given standard monitor calibration (n=24).
</td>
<td style="text-align:left;width: 24em; ">
To evaluate if the staircase phenomenon affects AMG monitoring. this study exposed one group to tetanic stimulation prior to calibration and one group had standard calibration.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="719"></a>Trevien <br> 1995
</td>
<td style="text-align:center;width: 4em; ">
52
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-65; orthopedic surgical procedure requiring curarization for tracheal intubation, but needing no further curarization.<br>Exclude: Anatomic conditions predisposing difficult intubation; neuromuscular, renal, cardiac, hepatic, or respiratory diseases; malignant hyperthermia; drug or alcohol abuse; drugs affecting neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR &gt;=0.8 was significantly shorter in patients receiving neostigmine administered at twitch height 10% at the adductor pollicis muscle (n=14) compared with patients receiving no reversal agent (n=15), p&lt;0.05. Time to TOFR &gt;=0.8 was significantly shorter in patients receiving neostigmine administered at first response at the orbicularis oculi muscle (n=16) compared with patients receiving no reversal agent (n=15), p&lt;0.05.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="18">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Fully Paired
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1429"></a>Pelgrims <br> 2001
</td>
<td style="text-align:center;width: 4em; ">
25
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 18-65 years, male.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Within patients no statistically significant differences were observed between pre-load and no preload for time to reach TOFR 0.9 (52.7 vs 52.8 min). The average time to reach TOFR 0.9 between TOF-Guard and ParaGraph was 68.0 and 63.8.
</td>
<td style="text-align:left;width: 24em; ">
This is a two part study that compared TOF-Guard with and without preload and between two different AMGs TOF-Guard and ParaGraph.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1431"></a>Plaud <br> 2001
</td>
<td style="text-align:center;width: 4em; ">
24
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 18-60 years.<br>Exclude: Difficult airway, neuromuscular, cardiovascular, hepatic, and renal disease, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 was similar when measure at adductor pollicis and corrugator supercilli (20 vs 22 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1476"></a>Dubois <br> 2002
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neuromuscular disease, medications altering neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach a TOFR 0.9 was longer when measured by TOF-tube than TOF-watch with arm board (35.29 vs 34.02, p&lt;0.001) .
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1518"></a>Larsen <br> 2002
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neuromuscular disease, medications know to interfere with neuromuscular transmission, obese.
</td>
<td style="text-align:left;width: 20em; ">
Neuromuscular monitoring with AMG from the orbital part of the orbicularis muscle as used in this study was subject to a large uncertainty as a measure of paralysis during anesthesia, and it cannot therefore be recommended for routine monitoring.
</td>
<td style="text-align:left;width: 24em; ">
Conclusions would have been stronger with bland-altman or sensitivity/specificity analysis. Based on digitized data, when the TOFR reached 0.9 at AA the median TOFR reported for OO was 0.82.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1769"></a>Dubois <br> 2005
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular disease, medications known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Use of TOF-tube (TOFR = 0.89) reduces measurement variability of an AMG when comparing to MMG TOFR 0.9 reference measure.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1810"></a>Motamed <br> 2005
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neuromuscular disease, renal or hepatic disease, medications known to interfere with neuromuscular function, difficult airway.
</td>
<td style="text-align:left;width: 20em; ">
No difference in time to reach TOFR 0.9 between AMG PTC mode and AMG TOF mode (m=48 min, p=1).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2120"></a>Claudius <br> 2009
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, 18-65 years, surgery in supine position, within 20% of ideal body weight.<br>Exclude: Neuromuscular, renal, or hepatic disease, pregnancy, breast-feeding women.
</td>
<td style="text-align:left;width: 20em; ">
Preload increases the precision of acceleromyography, and normalization of the TOF ratios decreases bias in relation to mechanomyography (bias 0.17, LoA 0.06-0.28).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2383"></a>Schreiber <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;18; elective orthopedic surgery under general anesthesia with endotracheal intubation; supine position and at least one arm available.<br>Exclude: Neuromuscular disease.
</td>
<td style="text-align:left;width: 20em; ">
In patients undergoing orthopedic surgery (n=96), Bland-Altman analysis of calibrated and non-calibrated TOFR measurements by the TOF Watch were: mean (SD), 0.01 (0.07) and limits of agreement, -0.15 to 0.15. Mean TOFR (SD) at the end of surgery was 1.03 (0.12) calibrated and 1.01 (0.19) non-calibrated.
</td>
<td style="text-align:left;width: 24em; ">
If TOFR &lt;0.9 used as threshold of neuromuscular block, K statistic=0.52. If TOFR &lt;1.0 used as threshold, K statistic=0.84.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2479"></a>Phillips <br> 2012
</td>
<td style="text-align:center;width: 4em; ">
38
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;18; surgery requiring NMBA; arm available for electrodes.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
In a study of 31 patients in which EMG was used to measure TOF at 3 different muscle sights, the following bias (limits of agreement) were reported at TOFR=0.9: abductor digiti minimi and adductor pollicis, 0.10 (-0.10 to 0.30); abductor digiti minimi and first dorsal interosseous, 0.09 (-0.10 to 0.28); and adductor pollicis and first dorsal interosseous, 0.01 (-0.27 to 0.28).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2820"></a>Yamamoto <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; elective orthopedic, gynecological, and urological surgery under general anesthesia.<br>Exclude: Neuromuscular, hepatic, or renal disorders; drugs affecting neuromuscular function; BMI &gt;30 kg/m2; BMI &lt;18.5 kg/m2.
</td>
<td style="text-align:left;width: 20em; ">
In both patient age groups, 20-60 (n=40) and &gt;=70 (n=38), and both sugammadex dosage groups (2 mg/kg and 4 mg/kg), time to TOFR &gt;=1.0 was significantly longer when measured at the adductor pollicis compared with the corrugator supercilii. In both patient age groups, time to TOFR &gt;=1.0 was significantly longer in patients receiving 2 mg/kg compared with patients receiving 4 mg/kg. In addition, patients &gt;=70 receiving 4 mg/kg sugammadex had significantly longer time to TOFR &gt;=1.0 compared with patients 20-60 when measured at the adductor pollicis.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2952"></a>Vega <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
10
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I; age 18-65; elective surgery under general anesthesia.<br>Exclude: Pregnant; BMI &gt;25 mg/kg2; anticipated difficult airway; anticipated blood loss &gt;500 ml; diagnosis of any disease; allergy to NMBD; drugs affecting NMBD (aminoglycosides, anticonvulsants, calcium channel antagonists, digitalis, antidepressants, diuretics, corticosteroids).
</td>
<td style="text-align:left;width: 20em; ">
A difference was not detected in time to TOFR &gt;=0.9 among patients (n=10) monitored by AMG at both the adductor pollicis muscle (29.9 +/- 6.7 min) and the masseter muscle (29.3 +/- 8.1) min) (p=0.77).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3464"></a>Le <br> Merrer 2020
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age &gt;=18; elective surgery with a hand and a foot available.<br>Exclude: Diabetes; neuropathy; emergency surgery; anticipated difficult airway; allergy to atracurium.
</td>
<td style="text-align:left;width: 20em; ">
Among patients receiving neostigmine, a difference was not detected in time to TOFR &gt;0.9 at the flexor hallucis muscle compared with the adductor pollicis muscle. Among patients recovering spontaneously (n=41), time to TOFR &gt;0.9 was significantly shorter at the flexor hallucis muscle compared with the adductor pollicis muscle (p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3537"></a>Thudium <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
35
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;18; hip or knee arthroplasty using general anesthesia and NMBA.<br>Exclude: Emergency surgery; missing pulmonary function test or missing TOF measurements.
</td>
<td style="text-align:left;width: 20em; ">
In patients undergoing hip or knee arthroplasty (n=20), earlier recovery to TOFR&gt;=0.9 was recorded at the corrugator supercilii muscle compared with the adductor pollicis muscle, median (IQR) difference: 20 (12.8-28) minutes.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4140"></a>Eriksson <br> 1991
</td>
<td style="text-align:center;width: 4em; ">
8
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I; scheduled for extirpation of neurinoma of acoustic nerve.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
In 8 healthy patients undergoing extirpation of a neurinoma of the acoustic nerve in which one arm is maintained at skin temperature 33 deg C/muscle temperature 34 deg C and one arm is cooled to skin temperature of 27 deg C/muscle temperature of 31 deg C, MMG measurements at the end of the study showed TOFR=0.97 +/- 0.02 and TOFR=0.90 +/- 0.04 in the warm and cool arms, respectively (p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="5309"></a>Sugi <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
29
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-70; otolaryngologic or ophthalmic surgery under general anesthesia.<br>Exclude: Drugs affecting neuromuscular function; hepatic, renal, metabolic, endocrine, or neuromuscular dysfunction; BMI &gt;30 kg/m2.
</td>
<td style="text-align:left;width: 20em; ">
When the flexor hallucis brevis muscle (FHBM) had recovered to TOFR=0.9 (measured by AMG), the TOFR at the first dorsal interosseous muscle (FDIM) was 0.44 +/- 0.23 (measured by EMG). Time to TOFR=0.9 from administration of neuromuscular block was significantly longer when measured at the FDIM compared with the FHBM, mean additional time: 27 (19.2-35.6) minutes.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7005"></a>Baykara <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
130
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-65; surgery under general anesthesia requiring muscle relaxants lasting at least 1 h; within 20% of ideal body weight.<br>Exclude: Surgeries associated with massive blood loss or fluid replacement; hepatic, renal, or neuromuscular disease; pregnant; drugs affecting neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
To detect incidence of PORC (TOFR &lt;1.0) in the PACU, the use of non-normalized AMG values identified 67 patients (549%) compared with the use of normalized AMG values identifying 77 patients (63.1%) (p&lt;0.05). To detect incidence of severe PORC (TOFR &lt;0.7) in the PACU, the use of non-normalized AMG values identified 12 patients (10%) compared with the use of normalized AMG values identifying 22 patients (18.3%) (p=NS).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7072"></a>Santanen <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
24
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; eye surgery (vitrectomy and/or ablation).<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Compared to a baseline EMG of 100 when muscle and skin temperatures are warm (muscle 36 deg C and skin 35-36 deg C), mean EMG measurement under cooler conditions (muscle 34-35 deg C and skin 32 deg C) was 108.9 +/- 1.2 (100.8-119.5).
</td>
<td style="text-align:left;width: 24em; ">
Change in EMG/deg C cooler in muscle: 8.0 +/- 0.8 (range 0.3-16.5); change in EMG/deg C cooler in skin: 4.1 +/- 1.6 (range 0.3-37.9)
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="868"></a>Abdulatif <br> 1997
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; male; diagnostic endoscopic surgery.<br>Exclude: Cardiac, vascular, respiratory, hepatic, renal, or neuromuscular disorders; smokers; previous head and neck surgery; history of small joint arthritis; drugs affecting neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR=0.9 was significantly longer at the adductor pollicis muscle compared with the orbicularis oculi muscle, among patients (n=30) monitored with the AMG TOF Guard at both sites simultaneously.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Prospective Cohort</strong>
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 4em;width: 8em; " indentlevel="2">
<a id="2490"></a>Thilen <br> 2012
</td>
<td style="text-align:center;width: 4em; ">
150
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV; age 18-80; elective surgery with anticipated use of NMBA.<br>Exclude: Neuromuscular disorders.
</td>
<td style="text-align:left;width: 20em; ">
Patients monitored qualitatively intraoperatively at the eye muscle (n=99) experienced significantly more rNMB (defined as TOFR &lt;0.9) in the PACU compared with patients monitored qualitatively intraoperatively at the adductor pollicis (n=51), 52% vs 22%, respectively (p&lt;0.01).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
</tbody>
</table>
<p><br/></p>
</div>
<div id="diagnostic-accuracy-kq2" class="section level1">
<h1><strong>Diagnostic Accuracy KQ2</strong></h1>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; ">
<thead>
<tr>
<th style="text-align:left;font-weight: bold;">
Study
</th>
<th style="text-align:center;font-weight: bold;">
N
</th>
<th style="text-align:left;font-weight: bold;">
Inclusion/Exclusion Criteria
</th>
<th style="text-align:left;font-weight: bold;">
Results
</th>
<th style="text-align:left;font-weight: bold;">
Comment
</th>
</tr>
</thead>
<tbody>
<tr grouplength="23">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Fully Paired
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="1064"></a>K-Nielsen <br> 1998
</td>
<td style="text-align:center;width: 4em; ">
52
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, females age 18-60 years.<br>Exclude: Neuromuscular disease, body weight &gt; 80 kg, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Bias and limits of agreement for TOFR 0.7 between TOF-Guard and MMG was -8.1 and 12.1 to -28.4 and 2.0 and 210.7 to -6.7 between MMG and MMG.
</td>
<td style="text-align:left;width: 24em; ">
This seminal study demonstrates that MMG and AMG data cannot be interchangeably where the limits of agreement was &gt;10%.
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="1429"></a>Pelgrims <br> 2001
</td>
<td style="text-align:center;width: 4em; ">
25
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 18-65 years, male.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Within patients no statistically significant differences were observed between pre-load and no preload for time to reach TOFR 0.9 (52.7 vs 52.8 min). The average time to reach TOFR 0.9 between TOF-Guard and ParaGraph was 68.0 and 63.8.
</td>
<td style="text-align:left;width: 24em; ">
This is a two part study that compared TOF-Guard with and without preload and between two different AMGs TOF-Guard and ParaGraph.
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="1472"></a>Dahaba <br> 2002
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-59; ASA I-II; short elective surgery in supine position; surgery lasting 1 hr.<br>Exclude: Neuromuscular disease; small joint arthritis; drugs altering neuromuscular function; pregnant; breast-feeding.
</td>
<td style="text-align:left;width: 20em; ">
Among patients (n=20) monitored by both MMG and AMG, there was no difference detected in time to TOFR=0.8.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="1833"></a>Samet <br> 2005
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular, hepatic, or renal diseases, abnormal airway, ideal body mass &gt;=25%, pregnancy, medication interfering with neuromuscular blockade.
</td>
<td style="text-align:left;width: 20em; ">
AMG detected rNMB better than PNS-DBS or PNS-TET patterns (specificity = 88%, 100%, 55% respectively) but not reliably at lesser degree of rNMB.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="1864"></a>Capron <br> 2006
</td>
<td style="text-align:center;width: 4em; ">
32
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular, hepatic, or renal disease, difficult tracheal intubation, BMI &gt;= 32 Kg/m, pregnancy, medications interfering with neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
AMG obtained TOFR of 1.0 corresponded to an MMG of 0.89 ± 0.06. Did not account for dependent (multiple) observations in individual patients. No normalization of AMG results. Also concluded TOF fade and DBS were inadequate to exclude rNMB.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="1925"></a>Trager <br> 2006
</td>
<td style="text-align:center;width: 4em; ">
14
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular disease, medications known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
MMG and KMG showed excellent agreement for determination of TOF-recovery at TOFR 0.90for clinical purpose (corr coeff 0.92).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="2120"></a>Claudius <br> 2009
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, 18-65 years, surgery in supine position, within 20% of ideal body weight.<br>Exclude: Neuromuscular, renal, or hepatic disease, pregnancy, breast-feeding women.
</td>
<td style="text-align:left;width: 20em; ">
Preload increases the precision of acceleromyography, and normalization of the TOF ratios decreases bias in relation to mechanomyography (bias 0.17, LoA 0.06-0.28).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="2226"></a>Drobnik <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
91
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, 18-64 years.<br>Exclude: Neuromuscular, hepatic, or renal disease, medications interfering with neuromuscular function, family hx malignant hyperthermia, arthritis.
</td>
<td style="text-align:left;width: 20em; ">
Mean difference between time to reappearance of T4 (PNS) and time to recovery of the TOF ratio to 0.9 (AMG) was 0.8 min with sugammadex 4.0 mg/kg administered 15 min after rocuronium.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="2566"></a>Liang <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
26
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular disease.
</td>
<td style="text-align:left;width: 20em; ">
TOFR at approximately 1.0 by AMG overestimated EMG by 0.15 (95% CI, 0.12 to 0.18; LOA, -0.06 to 0.35). Found better precision with EMG than AMG.
</td>
<td style="text-align:left;width: 24em; ">
AMG measures were not normalized and the device used limits upper TOFR to 1.0. Included multiple observations per subject without accounting for dependence.
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="2698"></a>Stewart <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: Elective surgery requiring general anesthesia with muscle relaxation.<br>Exclude: Neuromuscular disease.
</td>
<td style="text-align:left;width: 20em; ">
Among patients monitored by both KMG and EMG (n=16), at TOFR=0.9, the bias between KMG and EMG was 0.08, with 95% limits of agreement of -0.08 to 0.25.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="2844"></a>Colegrave <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
38
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 25-78; ASA I-III; elective surgery with general anesthesia and orotracheal intubation and both arms in abduction.<br>Exclude: Rapid sequence induction; qge &lt;18; pregnant; allergy to NMBA; previous difficult ventilation or intubation.
</td>
<td style="text-align:left;width: 20em; ">
No difference was detected in time to TOFR&gt;=0.9 with an AMG monitor requiring calibration (TOF Watch) compared with an AMG monitor not requiring calibration (TOF Scan).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="2877"></a>Khandkar <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
18
</td>
<td style="text-align:left;width: 20em; ">
Include: Surgery requiring NMBA.<br>Exclude: Age&lt;18; neuromuscular conditions; allergy to electrode adhesive; difficult access to study hand.
</td>
<td style="text-align:left;width: 20em; ">
Among 18 patients monitored by both the KMG and the EMG, the bias of KMG TOFR compared with EMG TOFR in the 0.8 to 0.99 range was 0.08 (95% CI, 0.06 to 0.09) with 95% limits of agreement of -0.12 to 0.27.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3094"></a>Unterbuchner <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
118
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; elective low risk surgery.<br>Exclude: Currently participating in other study; BMI&gt;30; age&lt;18; age&gt;65; neuromuscular disease; gastroesophageal reflux.
</td>
<td style="text-align:left;width: 20em; ">
Using EMG as the gold standard, the sensitivity and specificity of the ability to detect TOFR&lt;0.9 for clinical algorithm is 92.5% and 42.9%, for PNS fading is 33.7% and 0%, and for uncalibrated AMG is 93.6% and 100.0%.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3095"></a>Veiga <br> Ruiz 2017
</td>
<td style="text-align:center;width: 4em; ">
37
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-65; ASA I-III; elective surgery lasting &gt;30 min requiring NMBA.<br>Exclude: Concomitant disease that could prevent adherence to study protocol; predicted difficult aiarway; pregnancy; breast-feeding; drugs affecting neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
Difference in time to TOFR 0.9 was not detected among pts monitored by both MMG and TOF Cuff, receiving either neostigmine or sugammadex. Sensitivity, specificity, positive and negative predictive value of TOF Cuff compared with MMG was 46%, 91%, 84%, and 62%, repectively.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3180"></a>Murphy <br> (b) 2018
</td>
<td style="text-align:center;width: 4em; ">
25
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age 18-80; elective surgeries with duration &gt;90 min.<br>Exclude: Need for succinylcholine for rapid sequence intubation; renal insufficiency (serum creatinine &gt;2 mg/dl) or failure; liver disease; neuromuscular disease; drugs affecting neuromuscular function; BMI&gt;=30 kg/m2; access to both arms not possible.
</td>
<td style="text-align:left;width: 20em; ">
A triaxial AMG (TOFscan) showed good agreement with a uniaxial AMG (TOF Watch), Bland-Altman bias (95% CI) over all TOFR measurements: 0.015 (95% CI, -0.002 to 0.31).
</td>
<td style="text-align:left;width: 24em; ">
Administered reversal (neostigmine) based on clinical criteria at mean TOFR exceeding 0.90 in both arms, but similar TOFR prior to reversal with either NMM (TOFR 0.94±0.06, TOF-Watch SX calibrated; 0.92±0.07 TOFscan uncalibarated; mean difference 0.02 (95% CI, 0.01-0.04). Bias lower with normalized TOF-Watch SX (0.015 vs. 0.021) and more narrow limits of agreement, but clinical relevance unclear. Did not include MMG as a reference standard. Single-center study. The number of anesthetists and experience not reported may hinder applicability of results.
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3293"></a>Kameyama <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age&gt;=65; elective artificial knee joint replacement surgery under general anesthesia.<br>Exclude: Allergy to NMBA; drugs that interact with NMBA.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR&gt;0.9 similar when measured by TOF Watch and TOF Cuff, Bland-Altman bias (95% CI) and limits of agreement: 12.6 (6.7-18.5) and -14.3 to 39.6.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3392"></a>Bowdle <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
43
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular abnormalities.
</td>
<td style="text-align:left;width: 20em; ">
When patients were monitored by MMG, EMG, and AMG, EMG was reported to more closely resemble MMG. Bias and 95% limits of agreement for MMG vs EMG (n=25, 808 data pairs) were 0.047 (-.25 to .35). Bias and 95% limits of agreement for AMG vs. MMG (n=19, 263 data pairs) were 0.98 (-.32 to .51). Bias and limits of agreement for AMG vs EMG (n=31, 615 data pairs) were .15 (-.13 to .43) [values converted from scale presented in the paper and rounded].
</td>
<td style="text-align:left;width: 24em; ">
Potential issues to consider when interpreting results include: lack of clarity on how patients were selected for each device comparison pair; an author is CEO of the company manufacturing the EMG; no normalization of AMG value; and multiple observations per individual without specifying appropriate analysis performed.
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3393"></a>Bussey <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
11
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV.<br>Exclude: Neuromuscular abnormalities.
</td>
<td style="text-align:left;width: 20em; ">
When manual palpation of train-of-four count was compared to train-of-four count determined by the monitors, 70% of data pairs were identical between palpation and TwitchView train-of-four count, while 30% of data pairs were identical between palpation and GE train-of-four count.
</td>
<td style="text-align:left;width: 24em; ">
Palpation was performed by only one investigator, who was not blinded to the twitch measurements, that could contribute to consistency of measurements. Patients that were managed under deep block for most of the surgical procedure limited the opportunity to measure train-of-four. These patients had fewer data points.
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3481"></a>Markle <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: Surgery requiring general anesthesia and NMBA; BMI &lt;35 kb/m2; half study population had both arms accessible to anesthetist, other half had one arm adducted alongside body for surgical positioning (restricted).<br>Exclude: Emergency surgery; rapid sequence induction required; second dose NMBA required after induction; contraindiction to use of atracurium; pregnant; neuromuscular disease.
</td>
<td style="text-align:left;width: 20em; ">
In pts monitored by both the TOF Scan and the TOF Cuff (n=40), mean time to TOFR=0.9 was significantly longer with the TOF Scan, Bland-Altman mean bias (95% CI) was 8.9 min (5.8-12.0).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3521"></a>S <br> Machado 2020
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-65; ASA I-II; elective surgery &gt;=60 min duration using general anesthesia and requiring NMBA.<br>Exclude: Allergy to propofol or rocuronium; drugs affecting neuromuscular function; BMI&lt;19 or &gt;28 kg/m2; expected difficult airway; surgeries requiring repeated NMBA; rapid sequence induction.
</td>
<td style="text-align:left;width: 20em; ">
In 27 pts monitored by both the TOF Watch and TOF Cuff, time (min) to TOFR=0.9 was shorter with the TOF Cuff, mean bias 16.4 and limits of agreement, -6.1 to 39.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3632"></a>Motamed <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
32
</td>
<td style="text-align:left;width: 20em; ">
Include: Adults; surgery requiring general anesthesia with orotracheal intubation facilitated by NMBA; both forearms accessible.<br>Exclude: Age &lt;18; pregnant; breastfeeding; allergy to NMBA; potential difficult intubation; both arms not accessible.
</td>
<td style="text-align:left;width: 20em; ">
In 30 pts monitored by both the TOF Scan (AMG, triaxial) and the M-NMT (KMG), time to TOFR=0.9 was shorter with the M-NMT, mean bias -0.6 and limits of agreement, -23.1 to 21.8.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="3644"></a>Renew <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: Adult; elective surgery requiring NMBA.<br>Exclude: Unilateral disorders (eg stroke, carpal tunnel syndrome); neuromuscular disease; significant organ dysfunction.
</td>
<td style="text-align:left;width: 20em; ">
In 115 pts monitored by both the TOF Scan (AMG, triaxial) and the TetraGraph (EMG), TOFR upon arrival in the PACU was comparable, mean bias (SD) 0.03 (0.16) and median (range) 0.03 (-0.92 to 0.43).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;width: 8em; ">
<a id="443"></a>Harper <br> 1994
</td>
<td style="text-align:center;width: 4em; ">
13
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neuromuscular disease, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Limits of agreement were wide for TOFR 0.7 between MMG and AMG -0.3 to 0.3.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Pediatric</strong>
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Fully Paired
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4215"></a>Gaffar <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
24
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 2-6; ASA I-II; 18&lt;=BMI&lt;=25 kg/m2; weight&lt;20 kg; body surface surgery not requiring intense muscle relaxation.<br>Exclude: Cardiovascular, hepatic, renal, small joint arthritis, neuromuscular disorders; anticonvulsant or oral muscle relaxant medication known to interact with neuromuscular blocking drugs (eg antibiotics, antiarrhythmics, magnesium sulfate); expected difficult intubation; major operations; upper limb or thoracic operations.
</td>
<td style="text-align:left;width: 20em; ">
In 24 pediatric pts monitored by both the MechanoSensor (KMG) and an EMG monitor, time to TOFR=0.9 was comparable, mean bias (95% CI) -0.06 (-2.3 to 1.2).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
</tbody>
</table>
<p><br/></p>
</div>
<div id="monitoring-patient-outcomes-kq3" class="section level1">
<h1><strong>Monitoring Patient Outcomes KQ3</strong></h1>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; ">
<thead>
<tr>
<th style="text-align:left;font-weight: bold;">
Study
</th>
<th style="text-align:center;font-weight: bold;">
N
</th>
<th style="text-align:left;font-weight: bold;">
Inclusion/Exclusion Criteria
</th>
<th style="text-align:left;font-weight: bold;">
Results
</th>
<th style="text-align:left;font-weight: bold;">
Comment
</th>
</tr>
</thead>
<tbody>
<tr grouplength="15">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Adult</strong>
</td>
</tr>
<tr grouplength="10">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
RCT
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1045"></a>Fruergaard <br> 1998
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular disease, hepatic or renal failure, medications that alter neuromuscular function, weight &gt;30% of ideal body weight.
</td>
<td style="text-align:left;width: 20em; ">
Intraoperative TOF monitoring decreased incidence of rNMB when compared to clinical assessment (24% vs 57%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1489"></a>Gatke <br> 2002
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular disease, hepatic or renal disease, medications interfering with neuromuscular transmission, weight +- 20% of ideal body weight.
</td>
<td style="text-align:left;width: 20em; ">
TOF measurements using AMG decreased rNMB when compared with clinical assessment (3% vs 16%, p=0.03). Time to extubate was longer in the AMG group when compared with clinical assessment.(12.5 vs 10 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="164"></a>Ueda <br> 1991
</td>
<td style="text-align:center;width: 4em; ">
90
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular disease or drugs interfering with neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
Manual evaluation of DBS at end of surgery reduces the number of patients with rNMB (6.7% TOFR &lt; 0.7) when compared to clinical assessment (83.3% TOFR &lt; 0.7).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2071"></a>Murphy <br> 2008
</td>
<td style="text-align:center;width: 4em; ">
185
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular disease, renal insufficiency, hepatic dysfunction, age &lt; 18 and &gt; 70 years, ASA IV-V, weight &gt; 30% ideal body weight.
</td>
<td style="text-align:left;width: 20em; ">
Greater number of severe rNMB in patients monitored with PNS when compared with AMG (13% vs 0%, p&lt;0.001), hypoxemia was found in 10% of patients monitored by PNS vs 0% by AMG when arriving to PACU (p=0.003).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2367"></a>Murphy <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
150
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular, hepatic, renal diseases, medications known to interfere with neuromuscular transmission, age &lt; 18 years.
</td>
<td style="text-align:left;width: 20em; ">
AMG monitoring reduces incidence of rNMB when compared to PNS (14% vs 50%, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3105"></a>Adembesa <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
168
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-65; ASA I-II; elective surgery under general anesthesia.<br>Exclude: Pregnant; neuromuscular disease; drugs affecting neuromuscular function; renal, hepatic, or respiratory disease; BMI&gt;30; cisatracurium allergy; brain surgery.
</td>
<td style="text-align:left;width: 20em; ">
Patients monitored clinically experienced significantly higher rates of mild hypoxia first 30 minutes iin PACU, required airway maneuvers, tactile stimulation, and snoring compared with pts monitored with AMG. No differences were detected in rates of severe hypoxia or reintubation.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3369"></a>Wardhana <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-60; ASA I-II; elective non-head/neck surgery using general anesthesia with intubation.<br>Exclude: Elective surgery &lt;1 hr duration; awake extubation or postsurgery intensive care admission; BMI &gt;35 kg/m2; hepatic disease (liver enzyme &gt;50% normal); renal insufficiency (serum creatinine &gt;1.8 mg/dL); neuromuscular disease; drugs affecting neuromuscular function; contraindications to neostigmine and atropine; allergy to anesthetic agents; difficult access to ulnar nerve.
</td>
<td style="text-align:left;width: 20em; ">
A difference in TOFR in the PACU was not detected among pts clinically monitored (n=36) compared with pts monitored with AMG (TOF Watch); however, 6 pts experienced rNMB in the clinically monitored group and 1 experienced rNMB in the quantitative monitored group.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="60"></a>Pedersen <br> 1990
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular disease, renal or hepatic failure, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Perioperative manual evaluation of the response or TOF nerve stimulation did not influence the incidence of rNMB (TOFR &lt; 0.7).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="664"></a>Mortensen <br> 1995
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; elective plastic surgery; surgery duration &gt;=1 hr.<br>Exclude: Neuromuscular disease; renal failure; hepatic failure; drugs altering neuromuscular function; exceeding &gt;30% ideal body weight.
</td>
<td style="text-align:left;width: 20em; ">
Patients monitored with AMG (n=19) exhibited significantly fewer clinical signs of rNMB and experienced significantly longer times to extubation compared with patients monitored clinically (n=21).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="697"></a>Shorten <br> 1995
</td>
<td style="text-align:center;width: 4em; ">
39
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neuromuscular disease, medications influencing neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
Use of PNS monitoring intraoperatively reduces rNMB when compared to clinical assessment (TOFR &lt; 0.7; 15% vs 47%, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="2">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Quasi-Experimental
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2703"></a>Todd <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
197
</td>
<td style="text-align:left;width: 20em; ">
Include: Adult; “largely” elective surgeries using NMB agents.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
More patients experienced TOFR&gt;=0.9 16 months after implementation of a quality improvement program compared with the beginning of the program (p=0.01).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3209"></a>Thilen <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
88
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV.<br>Exclude: Neuromuscular disease, age &lt;18 yr, pregnant or lactating women, and non English-speaking patients.
</td>
<td style="text-align:left;width: 20em; ">
The incidence of severe postoperative residual neuromuscular block (TOFR &lt; 0.7) was significantly reduced after the protocol was introduced (3% vs 32%, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="2">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Prospective Cohort
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3140"></a>Goyal <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
190
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I, age 18-45 years.<br>Exclude: Neuromuscular disease, diabetes, myasthenia gravis, hepatorenal impairment.
</td>
<td style="text-align:left;width: 20em; ">
With the use of TOFR 0.9 for extubation, patients safely recovered from neuromuscular blockade, without using neostigmine, with no difference in the mean recovery time (14.48 ± 1.138 min) as compared to the control group with neostigmine and clinical assessment (12.14 ± 1.067 min, P = 0.139). There was no incidence of reintubation in post-operative period.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3303"></a>Kirmeier <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
17150
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt; 18 years.<br>Exclude: Ambulatory surgeries, preoperative ICU admission.
</td>
<td style="text-align:left;width: 20em; ">
Odds ratio for developing postoperative pulmonary complications was significantly associated with the use of NMBA (1.86, p&lt;0.0001), and neuromuscular monitoring (1.31, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
POPULAR is the first multicenter cohort study to provide prospective data for postoperative pulmonary complications and the use and management of neuromuscular blocking agents in Europe.
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Retrospective Cohort
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3270"></a>Domenech <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
240
</td>
<td style="text-align:left;width: 20em; ">
Include: Elective surgery requiring NMB.<br>Exclude: Scheduled recovery in ICU.
</td>
<td style="text-align:left;width: 20em; ">
Retrospective chart review reported rNMB incidence of 1.6% and 32% in pts monitored and not monitored quantitatively during surgery.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
</tbody>
</table>
<p><br/></p>
</div>
<div id="reversal" class="section level1">
<h1><strong>Reversal</strong></h1>
<table class="table table-striped table-hover table-condensed lightable-classic lightable-hover" style=" font-family: Source Sans Pro; width: auto !important; ">
<thead>
<tr>
<th style="text-align:left;font-weight: bold;">
Study
</th>
<th style="text-align:center;font-weight: bold;">
N
</th>
<th style="text-align:left;font-weight: bold;">
Inclusion/Exclusion Criteria
</th>
<th style="text-align:left;font-weight: bold;">
Results
</th>
<th style="text-align:left;font-weight: bold;">
Comment
</th>
</tr>
</thead>
<tbody>
<tr grouplength="135">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Adult</strong>
</td>
</tr>
<tr grouplength="104">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
RCT
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1034"></a>Carroll <br> 1998
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-65 years.<br>Exclude: Renal or hepatic dysfunction, drugs interfering with neuromuscular transmission, body weight &gt; 30% or &lt; 20% of ideal weight for height.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach TOFR 0.8 was longer between neostigmine given at 10% or 25% recovery (9.3 vs 5.9 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1081"></a>Nelskyla <br> 1998
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: Healthy women.<br>Exclude: Obesity (body mass index &gt;27 kg/m) and known allergy to ketoprofen.
</td>
<td style="text-align:left;width: 20em; ">
Neostigmine with glycopyrrolate did not increase the occurrence of PONV in PACU versus placebo (46% vs 52%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1155"></a>Fuchs-Buder <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
48
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neuromuscular disease or receiving medications known to interact with neuromuscular function, patients with electrolyte abnormalities.
</td>
<td style="text-align:left;width: 20em; ">
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1188"></a>Lien <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
16
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, male.<br>Exclude: Hepatic, renal, cardiopulmonary, and neuromuscular disease.
</td>
<td style="text-align:left;width: 20em; ">
Times to recovery to a TOFR 0.9 did not differ between the neostigmine and spontaneous recovery group (18.0 vs 17.7 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1199"></a>McCourt <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
90
</td>
<td style="text-align:left;width: 20em; ">
Include: Adult patients.<br>Exclude: Neuromuscular disorders, hepatic or renal diseases, pregnancy, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach TOFR 0.8 was significantly shorter when neostigmine was administered at T1-25% versus spontaneous recovery (5.7 vs 36.7 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="121"></a>Goldhill <br> 1991
</td>
<td style="text-align:center;width: 4em; ">
36
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I.<br>Exclude: Medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Times to reach TOFR 0.9 was significant between the three neostigmine groups and spontaneous recovery (p=0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1282"></a>Hayes <br> 2000
</td>
<td style="text-align:center;width: 4em; ">
45
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Neurological, hepatic, or renal diseases, medications known to interfere with neuromuscular transmission, pregnancy.
</td>
<td style="text-align:left;width: 20em; ">
Spontaneous recovery to a TOFR 0.8 took 33.4 [20.0±79.0] min with rapacuronium but this was reduced to about 21.2 [13.9± 33.7] min when neostigmine was administered at 25% recovery of first twitch of the TOF.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1414"></a>Lovstad <br> 2001
</td>
<td style="text-align:center;width: 4em; ">
90
</td>
<td style="text-align:left;width: 20em; ">
Include: Healthy women, ASA I-II.<br>Exclude: Chronic antiemetic and analgesic drug usage, medication with bambuterol and obesity (body weight &gt;100 kg).
</td>
<td style="text-align:left;width: 20em; ">
High dose of neostigmine increases post-operative nausea (30% vs 11%, p=0.03) and the use of antiemetic drugs (28% vs 7%, p=0.01) during the first 6 h after administration.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1511"></a>Kirkegaard <br> 2002
</td>
<td style="text-align:center;width: 4em; ">
64
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Age &lt; 18 and &gt; 60 years, neuromuscular disease, medications known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
To achieve rapid (within 10 min) reversal to a TOF ratio of 0.7 in more than 87% of patients, three or four tactile responses should be present at the time of neostigmine administration.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1850"></a>Adamus <br> 2006
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Age &lt;18, &gt; 75 years, obesity, anticipated difficult airways, neuromuscular disease, medications known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 was much faster in the neostigmine group as compared to spontaneous recovery (9.8 vs 43.1 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1917"></a>Sorgenfrei <br> 2006
</td>
<td style="text-align:center;width: 4em; ">
27
</td>
<td style="text-align:left;width: 20em; ">
Include: Male, ASA I-II, ages 18-64 years.<br>Exclude: Neuromuscular, hepatic, or renal diseases, difficult intubation, family history of malignant hyperthermia, medications known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex decreased median recovery time in a dose-dependent manner from 21.0 min in the placebo group to 1.1 min in the group receiving 4.0 mg/kg. Drug-related adverse events were reported in 54% of patients across all doses.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1951"></a>de <br> Boer 2007
</td>
<td style="text-align:center;width: 4em; ">
46
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, ages 18-64 years.<br>Exclude: Anticipated difficult airway, neuromuscular, hepatic, or renal diseases, malignant hyperthermia, pregnant or breast-feeding patients, female patients not on acceptable birth control, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach a TOFR 0.9 was significantly shorter in the sugammadex 2 and 4 mg groups as compared to placebo (56.5 vs 15.8 vs 122.1 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2000"></a>Sacan <br> 2007
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Difficult airway, reactions to opioid analgesics, pregnancy, family history of malignant hyperthermia, breast feeding patients.
</td>
<td style="text-align:left;width: 20em; ">
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2003"></a>Sparr <br> 2007
</td>
<td style="text-align:center;width: 4em; ">
99
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, male ages 18-64 years.<br>Exclude: Difficult airway, neuromuscular, hepatic, or renal dysfunction, hx of malignant hyperthermia, medications known to interfere with muscle relaxants.
</td>
<td style="text-align:left;width: 20em; ">
Reversal time to a TOFR 0.9 was significant in the sugammadex 2 or 4 mg group as compared to placebo (2.7 vs 2.1 vs 35.6) when given 15 min after NMBA administration.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2004"></a>Suy <br> 2007
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age &gt; 18 years.<br>Exclude: Difficult airway, neuromuscular, hepatic, or renal dysfunction, hx of malignant hyperthermia, medications known to interfere with muscle relaxants.
</td>
<td style="text-align:left;width: 20em; ">
Reversal time to a TOFR 0.9 was significant in the sugammadex 2 or 4 mg group as compared to placebo (1.7 vs 1.1 vs 31.8) when administered at the reappearance of T2.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2005"></a>Suzuki <br> 2007
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II female patients, age 27-57 years.<br>Exclude: Neuromuscular disease, hepatic or renal disorders, BMI &gt;= 25 or &lt;= 18.5, on medications known to interact with neuromuscular blocking agents.
</td>
<td style="text-align:left;width: 20em; ">
Neostigmine administered at 25% of control in T1 shortened recovery from neuromuscular block when compared to spontaneous recovery (5.8 vs 35.9 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2040"></a>Flockton <br> 2008
</td>
<td style="text-align:center;width: 4em; ">
84
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx of malignant hyperthermia, medications known to interfere with neuromuscular transmission, pregnant or breastfeeding patients, women not using adequate contraception.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex 2.0 mg/kg administered at reappearance of T2 was significantly faster in reversing rocuronium-induced blockade than neostigmine was in reversing cisatracurium induced block (1.9 vs 9.0 min, p&lt;0.0001). General muscle weakness was seen in 11.5% in the sugammadex group compared to 6.5% in the neostigmine group after extubation. Drug-related adverse events were seen in 17% in the sugammadex group and 2.6% in the neostigmine group.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2049"></a>Jones <br> 2008
</td>
<td style="text-align:center;width: 4em; ">
88
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx of malignant hyperthermia, medications known to interfere with neuromuscular transmission, pregnant or breastfeeding patients, women not using adequate contraception.
</td>
<td style="text-align:left;width: 20em; ">
Recovery to TOFR 0.9 from profound rocuronium-induced neuromuscular blockade was significantly faster with sugammadex versus with neostigmine 92.7 vs 49.9 min). Procedural pain and muscle weakness did not differ between the two groups (70% vs 76%; 11% vs 8%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2073"></a>Puhringer <br> 2008
</td>
<td style="text-align:center;width: 4em; ">
176
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx of malignant hyperthermia, medications known to interfere with neuromuscular transmission, pregnant or breastfeeding patients, women not using adequate contraception.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex provides a rapid and dose-dependent reversal of profound neuromuscular blockade induced by high-dose rocuronium (1.0 or 1.2 mg/kg) in adult surgical patients.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2088"></a>Staals <br> 2008
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: Ages &gt;= 18 years, ASA I-III, end-stage renal failure, healthy renal function.<br>Exclude: Pregnant and breastfeeding women, patients with known or suspected neuromuscular disorders, a history of malignant hyperthermia, or allergy to narcotics, NMBAs, or other medication used during general anaesthesia were excluded, as were patients receiving medication known to interfere with the action of rocuronium.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex was well tolerated by all patients. Time to reach TOFR 0.9 in the renal failure group was 2 mins compared to 1.65 in the control group.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2124"></a>Dahl <br> 2009
</td>
<td style="text-align:center;width: 4em; ">
121
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA II-IV, cardiac patients (NYHA II-III), age &gt;= 18 years.<br>Exclude: Patients with pacemaker, paroxysmal atrial fibrillation, neuromuscular disorders, renal dysfunction, hx malignant hyperthermia, pregnant or breastfeeding women, women not using adequate birth control, medications know to interfere with NMBAs.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex 2 mg/kg and 4 mg/kg resulted in considerably shorter time to recovery of the T4/T1 ratio to 0.9 compared with placebo (1.7 vs 1.4 vs 34.2).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2209"></a>Blobner <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
98
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx of malignant hyperthermia, medications known to interfere with neuromuscular transmission, pregnant or breastfeeding patients, women not using adequate contraception.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex achieved significantly faster recovery of neuromuscular function after rocuronium to a TOF ratio of 0.9 compared with neostigmine (1.5 vs 18.6 min, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2234"></a>Fuchs-Buder <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Difficult airway, neuromuscular, hepatic, or renal disease, deviation from ideal body weight by more than or equal to 25%; pregnancy; being on medication that influences neuromuscular blockade.
</td>
<td style="text-align:left;width: 20em; ">
Reduced dose (30 ug/kg) of neostigmine when given at a TOFR 0.4 is effective in antagonizing shallow atracurium block when compared with placebo (6 vs 19 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2251"></a>Khuenl-Brady <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex provided significantly faster reversal (TOFR 0.9) of vecuronium-induced neuromuscular blockade compared with neostigmine (2.7 vs 17.9 min, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2254"></a>Lederer <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age &gt;= 18 years, BMI 18-28 kg/m2.<br>Exclude: Emergency surgery, neuromuscular disease, renal dysfunction, hepatic disease, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Neostigmine 0.05 mg/kg accelerates recovery when administered 5 minutes after injection of IV rocuronium 0.4 mg/kg when compared to spontaneous recovery (19.4 vs 39.0 min, p=0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2260"></a>Lemmens <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
94
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV, age &gt;= 18 years.<br>Exclude: Neuromuscular disease, renal dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women, women not using adequate contraceptives.
</td>
<td style="text-align:left;width: 20em; ">
Recovery (TOFR &gt; 0.9) from profound vecuronium-induced block is significantly faster with sugammadex, compared with neostigmine (4.5 vs 66.2 min, p&lt; 0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2281"></a>Puhringer <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
49
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 20 and &lt; 65 years, Caucasian.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women, women not using adequate method of contraception.
</td>
<td style="text-align:left;width: 20em; ">
During sevoflurane maintenance anesthesia, sugammadex (2 or 4 mg) provides well tolerated, effective reversal of moderate rocuronium-induced NMB when compared to placebo (1.4 vs 1.5 vs 96.3 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2287"></a>Schaller <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
99
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-65 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Low dose sugammadex and neostigmine effectively and comparably reverse a rocuronium-induced shallow residual neuromuscular block at a TOF ratio of 0.5 (1.0 vs 2.0 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2308"></a>Adamus <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
22
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II.<br>Exclude: Difficult airway, neuromuscular, renal, metabolic, or hepatic dysfunction, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Intraoperative reversal of shallow rocuronium-induced block with either sugammadex or neostigmine to a TOFR &gt;=0.9 was significant (2.0 vs 15.9 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2335"></a>Illman <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
50
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV, ages 18-70 years, BMI &lt; 32.5.<br>Exclude: Clinically significant renal, hepatic, or ventilatory dysfunction, increased intracranial pressure, pregnancy, or lactation. Patients with muscular dystrophies, myopathy, or cerebral palsy, on medication known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex in comparison with neostigmine allows a quicker reversal of a moderate NMB when relying on visual evaluation of the TOF response (1.7 vs 13.3 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2338"></a>Jeong <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
52
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 16-65 years.<br>Exclude: Heart disease, renal, liver, or central nervous system dysfunction, medications know to interfere with neuromuscular transmission, pregnant women.
</td>
<td style="text-align:left;width: 20em; ">
Pyridostigmine may enhance recovery from sevoflurane anesthesia as compared to placebo (TOFR at end of study 90.3 vs 67.1, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2361"></a>McDonagh <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
162
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt; 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women, women not taking contraceptives.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach a TOFR &gt; 0.9 was longer in the elderly group (2.9 vs 2.3 min) than adults after sugammadex.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2382"></a>Sauer <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
114
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, ages 18-80 years.<br>Exclude: Neuromuscular disease, chronic pain requiring opioids, medications know to interfere with neuromuscular transmission, obese (&gt;20% of ideal body weight), OSA, severe asthma, COPD.
</td>
<td style="text-align:left;width: 20em; ">
Minimal residual block was associated with hypoxemia in the PACU with our without neostigmine (14% vs 15.8%, p=0.79).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2438"></a>Gaszynski <br> 2012
</td>
<td style="text-align:center;width: 4em; ">
70
</td>
<td style="text-align:left;width: 20em; ">
Include: Morbidly obese (BMI &gt; 40 kg/m2).<br>Exclude: Muscular disease, cardiovascular disease (NYHA &gt;2).
</td>
<td style="text-align:left;width: 20em; ">
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2439"></a>Geldner <br> 2012
</td>
<td style="text-align:center;width: 4em; ">
140
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Patients receiving sugammadex recovered 3.4 times faster than patients receiving neostigmine (geometric mean (95% CI) recovery times of 2.4 (2.1–2.7) and 8.4 (7.2–9.8) min, respectively, p &lt; 0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2502"></a>Alkenany <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, ages 16-50 years.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2514"></a>Carron <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic disease, hx of malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex allowed a faster recovery from profound rocuronium-induced NMB than neostigmine did in patients with morbid obesity (3.1 vs 48.6 min, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2534"></a>Fuchs-Buder <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
48
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic disease, medications know to interfere with neuromuscular transmission, pregnant women.
</td>
<td style="text-align:left;width: 20em; ">
Under desflurane anesthesia, neostigmine 30 ug/kg is effective in antagonizing shallow atracurium block (reversal at TOFR 0.6) compared to placebo (time to TOFR &gt;0.9 4 vs 14 minutes, p&lt;0.01).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2591"></a>Pongracz <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-65 years, BMI 18.5-25 kg/m2.<br>Exclude: Difficult airway, asthma, COPD, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women, glaucoma.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach a TOFR 0.9 was longer in the neostigmine group as compared to sugammadex (8.5 vs 3.5 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2618"></a>Woo <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, Korean descent not having left Korea.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex was well tolerated and provided rapid reversal of moderate rocuronium-induced NMB in Korean patients, with a recovery time 8.1 times faster than neostigmine.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2632"></a>Czarnetzki <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
32
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, male, age 18-60 years.<br>Exclude: Difficult airway, BMi&lt; 19 or &gt; 28, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Average time for reversal of moderate block was 1.69 min (SD, 0.81) in patients pretreated with MgSO4 and 1.76 min (1.13) in those pretreated with placebo (P = 0.897). Average time for reversal of deep block was 1.77 min (0.83) in patients pretreated with MgSO4 and 1.98 min (0.58) in those pretreated with placebo (P = 0.572). Pretreatment with a single intravenous dose of MgSO4 60mg/kg does not decrease the efficacy of recommended doses of sugammadex for the reversal of a moderate and deep neuromuscular block induced by an intubation dose of rocuronium.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2673"></a>Martini <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: ASA &gt;III, age &lt; 18 years, BMI &gt;=35 kg/m2, neuromuscular disease, renal insufficiency, hx malignant hyperthermia.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach a TOFR &gt; 0.9 was longer in the neostigmine group compared to sugammadex (10.9 vs 5.1) when administered at the end of surgery.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2710"></a>Wu <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
308
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age18-64 years, Chinese-born participants.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Both Chinese and Caucasian subjects recovered from NMB significantly faster after sugammadex 2 mg/kg vs neostigmine 50 μg/kg, with a ~5.7 times (p &lt; 0.0001) faster recovery with sugammadex vs neostigmine in Chinese subjects. Sugammadex was generally well tolerated.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2725"></a>Brueckmann <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
154
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;=18; elective laparoscopic or open abdominal surgery under general anesthesia with rocuronium-induced NMBA.<br>Exclude: Anticipated difficult intubation; neuromuscular disorder; renal insufficiency (creatinine clearance &lt;30 ml/min); hepatic dysfunction; malignant hyperthermia; allergies to sugammadex, opioids, NMBAs, other drugs used for general anesthesia; toremifene 24 h before or after sugammadex administration; planned ICU after surgery or PACU overnight; cardiac pacemaker; pregnant; breast-feeding; investigational drugs within 20 days randomization; other clinical trial within 30 days.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing laparoscopic or open abdominal surgery, zero patients receiving sugammadex (n=74) had a TOFR &lt;0.9 upon PACU arrival compared with 33 (43.4%) patients receiving neostigmine, (OR=0.0, 95% CI: 0-0.06, p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2729"></a>Cheong <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 18-65 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic disorders, cardiovascular disease, pregnancy.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 was much longer in the neostigmine versus the sugammadex group after moderate rocuronium block (15.8 vs 2.9 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2738"></a>Germano <br> Filho 2015
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 18-65, BMI 18.5-24.9.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hypomagnesia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Pre-treatment with magnesium did not significantly affect sugammadex reversal time of moderate neuromuscular blockade induced by rocuronium (1.92 vs 2.0 min) when compared to placebo.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2757"></a>Karwacki <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
38
</td>
<td style="text-align:left;width: 20em; ">
Include: Women.<br>Exclude: Obesity, cardiovascular diseases, diabetes mellitus, renal or hepatic failure.
</td>
<td style="text-align:left;width: 20em; ">
Times of the return of spontaneous breathing, extubation, eye opening (both spontaneous and in response to a verbal command) were found to be longer in the spontaneous recovery group than sugammadex group.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2764"></a>Koyuncu <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV.<br>Exclude: BMI &gt;= 27 Kg/m2, contraindication to sugammadex or neostigmine, emergency procedures, hepatic or renal impairment.
</td>
<td style="text-align:left;width: 20em; ">
PONV was observed in 20% of neostigmine group and 6% in the sugammadex group. 14% of neostigmine and 2% of participants in the sugammadex cohort developed bradycardia.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2793"></a>Rahe-Meyer <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
140
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, allergic to opioids cyclodextrins muscle relaxants, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR &gt;0.9 was much longer in the placebo group compared to sugammadex (89 vs 2z.2 min, p&lt;0.0001). Number of patients with adverse events were not significant between the two groups (87% vs 77%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2802"></a>Song <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
51
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-65; elective ear surgery.<br>Exclude: Neuromuscular, renal, hepatic disease; drugs affecting neuromuscular function; BMI &gt;30 kg/m2.
</td>
<td style="text-align:left;width: 20em; ">
In patients undergoing ear surgery and monitored by AMG (TOF Watch), median (IQR) time to TOFR &gt;=0.9 by time of neostigmine reversal was: appearance of fourth twitch (n=16), 11 (9-15.5); loss of fade to TOF (n=16), 8 (4-13.5); and loss of fade to double burst (n=16), 7 (4-13.5) minutes. Length of time was significantly shorter for the group receiving neostigmine at loss of fade to double burst compared to the group receiving neostigmine at appearance of fourth twitch (p=0.046).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2806"></a>Tassonyi <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
50
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-65 years, BMI 18.5-25 kg/m2.<br>Exclude: Difficult airway, asthma, COPD, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, glaucoma, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex adequately and rapidly reverses pipecuronium-induced moderate NMB during sevoflurane anesthesia. Once the train-of-four count has spontaneously returned to 2 responses following pipecuronium administration, a dose of 2.0 mg/kg of sugammadex is sufficient to reverse the NMB.
</td>
<td style="text-align:left;width: 24em; ">
Small sample size to adequately determine sugammadex dose for reversal of moderate pipercuronium NMB.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2809"></a>Unal <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
74
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, OSA, age 19-65 years.<br>Exclude: Medications that would interact with muscle relaxants and patients having neuromuscular, respiratory, liver and renal diseases, morbid obese, pregnant and lactating patients were excluded.
</td>
<td style="text-align:left;width: 20em; ">
This study confirmed the efficacy of sugammadex over neostigmine for the reversal of rocuronium-induced neuromuscular block. The incidence of post-operative respiratory complications and related costs in patients with OSA were less in the sugammadex group as compared to neostigmine.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2864"></a>Hakimoglu <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 18-65 years.<br>Exclude: Hypertension, chronic diseases, allergy to tetracaine.
</td>
<td style="text-align:left;width: 20em; ">
Extubation time (time from withdrawal of anesthetic gas to extubation) was shorter in the sugammadex group (3.03 vs 4.18, p = 0.003) than in the neostigmine atropine group.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2875"></a>Kaufhold <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
99
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Time to recovery from reversal agent given at TOFR 0.2 was longer in the neostigmine group as compared to sugammadex (4.2 vs 1.8 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2880"></a>Kim <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 20-64 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic disease, medications know to interfere with neuromuscular transmission, pregnant women, obesity (BMI &gt;= 30).
</td>
<td style="text-align:left;width: 20em; ">
TOFR 5 and 10 mins after reversal administration was higher in the sugammadex group as compared to neostigmine (5 min; 0.66 vs 104.7, 10 min; 83.1 vs 105.4) after moderate rocuronium-induced NMB.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2917"></a>Preault <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
64
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-75 years.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, unstable coronaropathy, severe asthma, glaucoma, urinary obstruction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnancy, BMI &gt; 32 kg/m2.
</td>
<td style="text-align:left;width: 20em; ">
Under sevoflurane anaesthesia, in absence of tactile or visual TOF fade, neostigmine 40 mg/kg was effective in antagonizing shallow cisatracurium block when compared to placebo (5.5 vs 17 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2918"></a>Putz <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, females age 18-80 years.<br>Exclude: Neuromuscular disease, renal or hepatic dysfunction, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
The maintenance of a moderate to deep NMB during laparoscopic hysterectomy with reversal at the end of the procedure with sugammadex enabled faster and more predictable OR discharges than did the classical combination of shallower NMB reversed with neostigmine (2.37 vs 9.56, p=0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2975"></a>Alsaeed <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
110
</td>
<td style="text-align:left;width: 20em; ">
Include: BMI &gt; 40.<br>Exclude: Muscular disease, severe cardiovascular diseases.
</td>
<td style="text-align:left;width: 20em; ">
The time to reach 90% TOF was significantly shorter with sugammadex versus neostigmine when administered at the end of surgery (3.5 vs 10.9 min, p &lt; 0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2979"></a>Asztalos <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
65
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-65 years, BMI 18.5-25.<br>Exclude: Difficult airway, bronchial asthma, chronic obstructive pulmonary disease, neuromuscular disease, suspected malignant hyperthermia, significant hepatic or renal dysfunction, glaucoma, allergy to the drugs used in this study, and taking medication known to alter the effect of neuromuscular blocking agents, pregnant or breastfeeding.
</td>
<td style="text-align:left;width: 20em; ">
Incomplete recovery was reported in 23% of neostigmine patients and 0% in sugammadex 2 mg/kg. Time to recover to a normalized TOFR &gt;0.9 was 11.3 min in the neostigmine group and 2.6 in the sugammadex group.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2995"></a>Choi <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
44
</td>
<td style="text-align:left;width: 20em; ">
Include: Elective laryngeal micro-surgery needing tracheal intubation.<br>Exclude: Age &lt;18; age &gt;70; ASA I-III; BMI &lt;18.5 kg/m2; BMI &gt;25 kg/m2; drugs affecting neuromuscular function; hepatic or renal disease; moderate to severe respiratory or cardiac disease.
</td>
<td style="text-align:left;width: 20em; ">
In laryngeal micro-surgery, use of rocuronium 0.9 mg/kg with sugammadex reversal associated with better surgical conditions and shorter recovery time compared with rocuronium 0.45 mg/kg with neostigmine reversal.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3058"></a>Nemes <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
134
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-65 years, BMI 18.5 - 27 kg/m, supine position, surgery lasting 90 minutes.<br>Exclude: History of myopathy, polyneuropathy, severe kidney or liver disease, myasthenia or stroke, patients treated with aminoglycoside antibiotics or magnesium or any medication known to influence neuromuscular function, an expected difficult airway, pregnancy, breastfeeding, emergency surgery, chronic obstructive pulmonary disease, glaucoma and any patient who had participated in another study within the previous month.
</td>
<td style="text-align:left;width: 20em; ">
Pharmacological reversal based on clinical signs was superior to spontaneous recovery but did not prevent PORNB, irrespective of the reversal agent (sug 3.7%, neo 15.3%, spont rec 26%, placebo 45.4%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3063"></a>Loh <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: Ages 18-70; ASA I-III; elective or emergency surgery under general anesthesia requiring NMBA.<br>Exclude: Planned postoperative intubation; tracheostomized; BMI &gt;40 mg/kg; raised intracranial or itraocular pressures; coagulopathy; rNMB weakness affecting cough and gag; pregnant; contraindications to sugammadex (eg renal failure with creatinine clearance &lt;60 ml/min.
</td>
<td style="text-align:left;width: 20em; ">
In a comparison of neostigmine, sugammadex in one dose, and sugammadex in staggered doses (n=40 each), a difference was not detected in PONV, desaturation, or agitation. Postoperative cough (p=0.005) and sore throat (p=0.019) were significantly higher in the single dose sugammadex group compared with the other groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3089"></a>Tas <br> Tuna 2017
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; laparoscopic cholecystectomy under general anesthesia.<br>Exclude: ASA &gt;=III; age &lt;18; age &gt;65; BMI &gt;30 kg/m2; hypersensitivity to study drugs; PONV history; high risk for PONV (Apfel score &gt;II); pregnant; menstruating; antiemetic drugs within 24 hrs.
</td>
<td style="text-align:left;width: 20em; ">
Patients receiving sugammadex (n=40) experienced less PONV and required less rescue emetics within 24 hrs post-surgery compared with patients receiving neostigmine (n=40), though the difference was not significant.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3098"></a>Yagan <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-65; elective surgery using general anesthesia with endotracheal intubation.<br>Exclude: Neurosurgery, laparoscopic, oncologic, gynecologic, breast, strabismus and mid ear surgery; drug or alcohol abuse; BMI &gt;30 mg/m2; analgesic, sedative, or antiemetic drug use within 24 hrs; psychiatric and neurological disorders; allergy or contraindication to study drugs; surgery time &gt;2 hrs.
</td>
<td style="text-align:left;width: 20em; ">
Patients receiving sugammadex (n=50) experienced significantly less PONV in the first hour post-operatively compared with patients receiving neostigmine (n=48), p=0.016. Over the 24 hr post-operative period, the incidence of PONV was not significantly different between the groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3104"></a>Abdulatif <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-60; liver resection surgery.<br>Exclude: Neuromuscular disease; BMI &gt;35 kg/m2; renal impairment; drugs affecting neuromuscular function; allergy to study drugs; major intraoperative blood loss.
</td>
<td style="text-align:left;width: 20em; ">
Among pts with normal liver function, time to TOFR=0.9 and time to TOFR=1.0 was significantly shorter in the arm receiving sugammadex compared with neostigmine (p&lt;0.001). Among pts with liver cirrhosis, time to TOFR=0.9 and time to TOFR=1.0 was significantly shorter in the arm receiving sugammadex compared with neostigmine (p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3190"></a>Paech <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
307
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;=18; age &lt;=70; scheduled day-surgical laparoscopic gynecological procedure &lt;1 hr duration under general anesthesia with rocuronium.<br>Exclude: Need to avoid iv induction or NMB; nausea or vomiting within 48 hr of surgery; pregnant; contraindication to study drug or anesthesia drug; likelihood of extensive surgical procedure; major peri-operative change to surgical plan.
</td>
<td style="text-align:left;width: 20em; ">
No difference in PONV was detected among patients receiving sugammadex (n=153) compared with patients receiving neostigmine (n=154).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3233"></a>Alday <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
130
</td>
<td style="text-align:left;width: 20em; ">
Include: Scheduled major abdominal surgery; use of postoperative epidural analgesia.<br>Exclude: Mechanical ventilation in postop recovery room; hypersensitivity to drugs; severe or mild asthma; myocardial infarction or coronary occlusion 3 months prior; myasthenia gravis; emergency surgery; pulmonary fibrosis; severe chronic obstructive lung disease (GOLD IV).
</td>
<td style="text-align:left;width: 20em; ">
Differences were not detected in respiratory complications or other postoperative complications among patients receiving sugammadex (n=62) compared with neostigmine (n=64).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3261"></a>Claroni <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
109
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; robot-assisted radical cystectomy for bladder cancer.<br>Exclude: Age &lt;18; BMI &gt;30 kg/m2; cerebrovascular diseases.
</td>
<td style="text-align:left;width: 20em; ">
A difference in PONV was not detected among patients undergoing robot-assisted radical cystectomy for bladder cancer, receiving sugammadex (n-54) compared with neostigmine (n=55). Time to recovery (TOFR &gt;0.9) was significantly shorter in the sugammadex arm.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3285"></a>Gunes <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
137
</td>
<td style="text-align:left;width: 20em; ">
Include: Thyroid surgery; ASA I-III; age 18-80; multinodular goiter, substernal goiter, differentiated thyroid carcinoma, toxic goiter, or recurrent multinodular goiter.<br>Exclude: Recurrent laryngeal nerve paralysis; pregnant.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing thryroidectomy, patients receiving sugammadex (n=65) experienced significantly shorter time to TOFR &gt;0.9 compared with patients receiving no reversal agent (n=64) p&lt;0.001.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3302"></a>Kim <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
90
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular disease, renal or hepatic dysfunction, hx of malignant hyperthermia, medications known to interfere with neuromuscular blockade, BMI &gt; 30 kg/m.
</td>
<td style="text-align:left;width: 20em; ">
Time to extubation was greater in the neostigmine group as compared to sugammadex group (7.94 vs 6.08 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3338"></a>Quang <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
70
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-60; ASA I-III; laparoscopic donor nephrectomy using general anesthesia; normal results for complete blood count, physiochemical tests, and echocardiogram; surgery duration &gt;60 min.<br>Exclude: Renal or hepatic dysfunction; malignant hyperthermia or neuromuscular disease; difficult airway; diabetes; neurological complication; BMI &lt;17 kg/m2; BMI &gt;30 kg/m2; drugs affecting neuromuscular relaxants (anticonvulsants, magnesium, antibiotics); allergy to opiod, NMBA, anesthetics.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing laparoscopic donor nephrectomy, patients receiving sugammadex (n=35) experienced significantly shorter time to TOFr &gt;0.9 and significantly less nausea, bradycardia, and headache compared with patients receiving neostigmine (n=35) (all p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3353"></a>Schepens <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
75
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;= 18 years.<br>Exclude: BMI &gt; 30 kg/m2, smokers, medications known to interfere with neuromuscular blocking agents, upper airway infection, hepatic dysfunction, congestive heart failure, pregnant or breastfeeding women, hx of malignant hyperthermia.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex group reached TOFR &gt; 0.9 quicker than the neostigmine group (2 vs 17 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3376"></a>Abola <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
62
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;=18; ASA I-III; planned use of NMBA and endotracheal intubation; planned extubation in OR.<br>Exclude: Neuromuscular disorder; allergy to muscle relaxants; malignant hyperthermia; contraindication for neostigmine or sugammadex; serum creatinine &gt;2 mg/dL; inaccessible arm; plan to extubate under deep anesthesia.
</td>
<td style="text-align:left;width: 20em; ">
A difference was not detected in measurements of post-operative strength among patients receiving sugammadex (n=29) compared with patients receiving neostigmine (n=27).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3390"></a>Boggett <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
350
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;18; operative laparoscopic or robot-assisted laparoscopic procedure undergoing general anesthesia, lasting &gt; 1hr.<br>Exclude: Diagnostic laparoscopic surgery only; pregnant; allergy to rocuronium, desflurane, sugammadex, or neostigmine.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing laparoscopic surgery of over 1 hr duration, no differences were detected in quality of recovery (cognitive, physiological, emotive, inadequate reversal) in patients receiving sugammadex to reverse a deep block (n=175) compared with patients receiving neostimine to reverse a moderate block (n=175).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3410"></a>Deana <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
49
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;=18; neuromuscular transmission data from TOF Watch from anesthesia induction until extubation.<br>Exclude: ASA &gt;III; neuromuscular disease; NMBA other than rocuronium; BMI &lt;18 kg/m2; BMI &gt;40 kg/m2; impaired renal function (glomerular filtration rate &lt;30 ml/min/1.73 m2); incorrect reversal dose (0.05 mg/kg neostigmine, 2 mg/kg sugammadex); inner temp &lt;35 deg C or thenar temp &lt;32 deg C at reversal; hemodynamic instability (norepinephrine &gt;0.1 mcg/kg.min and/or dobutamine &gt;3 mcg/kg.min and/or epinephrine &gt;0.1 mcg/kg.min at reversal and/or mean arterial pressure &lt;60 mmHg and/or HR &gt;100 bpm; acidosis (arterial pH &lt;7.3 at reversal).
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing liver transplantation, time to recovery of TOFR &gt;=0.9 was significantly faster in patients receiving sugammadex (n=21) compared with patients receiving neostigmine (n=20), mean time +/- SD times of 9.4 +/- 4.6 min and 34.6 +/- 24.9, respectively (p&lt;0.0001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3468"></a>Lee <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-69; ASA I-II; elective laparoscopic cholecystectomy.<br>Exclude: BMI &gt;=30 kg/m2; neuromuscular, renal, or hepatic disease; drugs affecting neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing laparoscopic cholecystectomy, TOFR at arrival in the PACU was 0.97 +/- 0.02 for patients receiving sugammadex (n=37) and 0.88 +/- 0.10 for patients receiving neostigmine (n=36), p&lt;0.001.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3487"></a>Moon <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
92
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA II-IV, age &gt;= 18 years,.<br>Exclude: Difficult airway, neuromuscular disease, renal or hepatic dysfunction, pre-existing muscle weakness, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex provides faster reversal of moderate neuromuscular blockade (10 vs 40 min, p&lt;0.001) compared with neostigmine. The incidence of hypoxia was not significant (41% vs 54%, p=0.288) between sugammadex and neostigmine.
</td>
<td style="text-align:left;width: 24em; ">
A double-blinded study that focused on thoracic surgical patients at a single center that may have been inadequately powered.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3492"></a>Niu <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
104
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-75; BMI &gt;25 kg/m2; nasopharyngeal surgery (benign neoplasms resection of nasopharynx) under general anesthesia.<br>Exclude: Difficult airway; contraindications for neostigmine; neuromuscular disease; minor arthritis; malignant hyperthermia; hapatic or renal dysfunction; allergy to NMBAs; cerebral infarction; diabetes; heart disease; mental illness; alcoholism or drug abuse; preoperative acid or base balance disorders; drugs affecting NMBAs.
</td>
<td style="text-align:left;width: 20em; ">
Among obese patients undergoing resection of benign neoplasms in the nasopharynx, patients administered rocuronium reversed with sugammadex (n=34) experienced significantly shorter times to TOFR &gt;=0.9, lower incidence of PORC, and reported less pain compared with patients receiving either rocuronium (n=34) or cisatracurium (n=34) and reversed by neostigmine. A difference between the groups in PONV and critical respiratory events was not detected.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3540"></a>Togioka <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
200
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;=70; surgery duration &gt;=3 h under general anesthesia.<br>Exclude: Surgical or medical contraindication to NMBA; kidney disease (&gt;=stage 4); liver disease (AST or ALT &gt;twice upper limit of institutional normal); allergies to study drugs.
</td>
<td style="text-align:left;width: 20em; ">
In patients &gt;=70 undergoing prolonged surgery, patients receiving sugammadex experienced significantly less rNMB (OR=0.11, 95% CI: 0.04-0.25, p&lt;0.001) and fewer 30-day hospital readmissions (OR=0.30, 95% CI: 0.08-0.91, p=0.03) compared with patients receiving neostigmine. A difference in pulmonary complications was not detected between the groups (OR=0.74, 95% CI: 0.40-1.37, p=0.30).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3553"></a>Williams <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;=65; robotic prostatectomy.<br>Exclude: Hypersensitivity to rocuronium or sugammadex; severe renal insufficiency (glomerular filtration rate &lt;=30 ml/min); severe liver disease (serum alanine aminotransferase and aspartate aminotransferase &gt;1.5 times normal with serum albumin &lt;3 g/dl or international normalised ratio &gt;=1.5 institute lab).
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing robotic prostatectomy, patients receiving sugmmadex to reverse a deep block had a higher normalised TOFR (median [IQR] 0.98 (0.79-1.11) compared with patients receiving neostigmine to reverse a moderate block (0.85 [0.74-1.00]), p=0.008. A difference was not detected between the groups in shoulder pain, overall pain, or PONV.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3566"></a>Zhu <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
132
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age 65-92; radical section of gastrointestinal tumor; weight 40-93 kg; 16.8<bmi kg mini-mental state examination>23; education level &gt;junior high school.<br>Exclude: Contraindication to neostigmine; infection or respiratory complications; liver or kidney dysfunction; electrolyte or blood glucose abnormalities; severe visual or hearing impairment; drug or alcohol abuse; glaucoma; bromide allergy; neurological or psychiatric disease; hyperthyroidism; sedatives, analgesics, or antidepressants within 1 month of study; postoperative infection; perioperative infusion &gt;3 units red blood cells; insufficient postoperative analgesia. </bmi>
</td>
<td style="text-align:left;width: 20em; ">
Among elderly patients undergoing radical section of gastrointestinal tumors, a difference was not detected in pain or PONV in patients receiving neostigmine (n=78) compared with patients not receiving a reversal agent (n-42).
</td>
<td style="text-align:left;width: 24em; ">
Patients receiving neostigmine showed significantly less early postoperative cognitive decline (p=0.013), which was the primary outcome, compared with patients receiving no reversal agent.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3594"></a>Farag <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
69
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;=18; elective catheter-based endovascular neurointerventional procedure using general anesthesia.<br>Exclude: Suspected difficult intubation; neuromuscular disorder; renal impairment (creatinine &gt;=2 mg/dl; hepatic dysfunction; malignany hyperthermia; allergy to NMBA, sugammadex, neostigmine, glycopyrrolate; perioperative respiratory infection or pneumonia; intubated or unresponsive; pregnant; breast feeding.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing catheter-based endovascular neurointerventional procedures, patients receiving sugammadex (n=35) experienced significantly shorter times to TOFR &gt;=0.9 compared with patients receiving neostigmine (n=33), median difference 5 minutes (95% CI, 3-6 minutes), p&lt;0.001. A difference in time to tracheal intubation was not detected.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3608"></a>Han <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 20-70; laparoscopic cholecystectomy.<br>Exclude: Neuromuscular disease; allergy to rocuronium, sugammadex, neostigmine; congnitive impairment.
</td>
<td style="text-align:left;width: 20em; ">
A difference was not detected in Quality of Recovery - 15 score, modified Aldrete score, pain, or rescue anti-emetic use among patients undergoing laparoscopic cholecystectomy receiving sugammadex (n=37) compared with patients receiving neostigmine (n=38).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3612"></a>Horrow <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
207
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA III; age &gt;=18; BMI &gt;=40 kg/m2; elective surgery using rocuronium or vecuronium.<br>Exclude: ABW &lt;100 kg; pacemaker or implantable cardioverter-defibrillator precluding assessment of arrthymias; plan not to reverse NMB at end of surgery; neuromuscular disorder; sever renal insufficiency (CrCl &lt;30 mL/min); malignany hyperthermia; allergy to perioperative medications; toremifene within 24 h before or after study drug administration.
</td>
<td style="text-align:left;width: 20em; ">
Among obese patients, time to TOFR &gt;=0.9 was significantly faster in patients receiving sugammadex dosed using actual body weight (ABW) (2 mg/kg or 4 mg/kg, moderate or deep sedation) compared with patients receiving sugammadex dosed using ideal body weight (IBW) (2 mg/kg or 4 mg/kg, moderate or deep sedation), p&lt;0.0001. Median (95% CI) times to TOFR &gt;=0.9 were 1.8 (1.6-2.1) for the ABW group and 3.3 (2.6-4.1) for the IBW group.
</td>
<td style="text-align:left;width: 24em; ">
Study was funded by Merck, with 1 author a current and 1 author a former employee of Merck. Unclear why results were pooled across different doses (2 mg/kg and 4 mg/kg), sedation level (moderate and deep), and NMB (rocuronium and vecuronium).
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3621"></a>Lee <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
102
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;18; elective video-assisted thoracoscopic lobectomy (VATS).<br>Exclude: VATS open conversion.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing elective video-assisted thoracoscopic lobectomy, a difference was not detected in postoperative pulmonary complications (prolonged air leak, pneumonia, atelectasis, desaturation, reintubation) in patients receiving sugammadex (n=46) compared with patients receiving neostigmine (n=47), risk difference 0.08 (95% CI: -0.12 to 0.27), p=0.434.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3625"></a>Li <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
125
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age 18-60; BMI &gt;=40 kg/m2; laparoscopic bariatric surgery under general anesthesia using rocuronium for tracheal intubation and maintenance of deep NMB.<br>Exclude: Contraindications to aminosteroid muscle relaxants; hepatic or renal dysfunction; neuromuscular disease; drugs affecting NMB agents; allergy to sugammadex or general anesthetic agents.
</td>
<td style="text-align:left;width: 20em; ">
A 4 mg/kg sugammadex dose based on corrected body weight was not inferior to a 4 mg/kg sugammadex dose based on total body weight for the reversal of rocuronium-induced deep NMB in morbidly obese patients undergoing laparoscopic bariatric surgery. Time to TOFR &gt;=0.9 was under 5 minutes in both study groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4003"></a>Citil <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: Elective pulmonary resection (lobectomy, pneumectomy, wedge resection).<br>Exclude: Inadequate left ventricle function (EF &lt;40%); renal or hepatic dysfunction; carotid lesions; abnormal mental function; BMI &lt;18.5 kg/m2; BMI &gt;25 kg/m2.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing lung resection surgery, patients receiving sugammadex (n=30) experienced shorter time to TOFR &gt;=0.9 compared with patients receiving neostigmine (n=30), p=0.001. A difference in adverse events (PONV, sore throat, bradycardia) between the groups was not detected. A difference in complications (pneumonia, atelectasia) between the groups was not detected.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="414"></a>Baurain <br> 1994
</td>
<td style="text-align:center;width: 4em; ">
24
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; adult; elective lower limb surgery; hepatic or renal damage; normal plasma cholinesterase activity.<br>Exclude: Neuromuscular disease; drugs affecting neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
At 15 minutes after twitch height recovery of 25%, 6 of 12 patients recovering spontaneously and 12 of 12 patients receiving neostigmine, experienced TOFR&gt;=0.9.
</td>
<td style="text-align:left;width: 24em; ">
Unclear if allocation to study groups was randomized.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4148"></a>Evron <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
57
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;=18; elective laparoscopic sleeve gastrectomy under general anesthesia and NMBA.<br>Exclude: Neuromuscular disorders; difficult intubation; renal or liver disease; malignant hyperthermia; pregnant; breast feeding; allergy to non-depolarizing blocking agents, sugammadex, opioids, other anesthetic drugs.
</td>
<td style="text-align:left;width: 20em; ">
Among obese patients undergoing laparoscopic sleeve gastrectomy, patients receiving sugammadex (n=32) experienced significantly higher mean and minimum oxygen saturation levels (SpO2) in the PACU compared with patients receiving neostigmine (n=25). A difference in respiratory rates was not detected. No postoperative respiratory complications in either group were reported.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="418"></a>Boeke <br> 1994
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-75; body weight 50-100 kg.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing hernia repair and vein stripping, patients receiving neostigmine (n=40) received anti-emetics significantly less compared with patients recovering spontaneously (n=40), p&lt;0.05.
</td>
<td style="text-align:left;width: 24em; ">
While nurses assessing nausea were blinded to study allocation, unclear how decision to give anti-emetics was made, as the numbers receiving anti-emetics is not consistent with numbers of patients reported having nausea and/or vomiting.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4631"></a>Kurcaloglu <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age 18-65; Glasgow Coma Score 15; intracranial supratentorial mass resection patients.<br>Exclude: Mental disability; pregnant; allergy; late recovery from previous anesthesia experience; planned intensive care after surgery.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing intracranial supratentorial mass resection, the group receiving sugmmadex (n=30) experienced TOFR 0.9 significantly faster than the group receiving neostigmine (n=30), p&lt;0.05. No differences were detected between the groups in post-anesthetic complications (nausea, tachycardia, pain requiring medication). No bradycardia, recurarization, hypoxia, or vomiting reported.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4663"></a>Ledowski <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
180
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA III-IV; age &gt;=75; planned surgery under general anesthesia using NMBA.<br>Exclude: Emergency surgery; pre-existing chest infection; septicemia; severe neuromuscular disease; cardiothoracic surgery.
</td>
<td style="text-align:left;width: 20em; ">
Among patients &gt;=75 yrs, ASA III-IV, patients receiving sugammadex (n=85) experienced a reduced probability of increased pulmonary outcomes compared with patients receiving neostigmine (n=83), 0.052 versus 0.122 at postoperative day 7. The probability of pulmonary outcomes were comparable between groups at postoperative day 1 and day 3. Significantly more patients receiving neostigmine were diagnosed with pneumonia compared with patients receiving sugammadex (9.6% versus 2.4%, p=0.046).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="472"></a>Maddineni <br> 1994
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-65; elective orthopedic or general surgery.<br>Exclude: Drugs affecting neuromuscular function; body weight outside 20% of ideal for height; malignant hyperthermia; asthma; drug or alcohol abuse.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR &gt;=0.8 was significantly shorter among patients receiving neostigmine compared to patients reversing spontaneously (p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4788"></a>Mekawy <br> 2012
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 20-45; chronic sinusitis undergoing endoscopic sinus surgery with or without septoplasty.<br>Exclude: Cardiovascular system pathology; coagulation defects; bronchial asthma; COPD; neuromuscular disorder or muscle disease; renal, hepatic disease; drugs affecting renal function or blood coagulation; difficult intubation.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 was significantly shorter among patients receiving sugammadex (n=20) compared with patients receiving neostigmine (n=20), p&lt;0.0001. A difference in respiratory complications, as measured by the Postoperative Respiratory System Evaluation Score at 5 and 10 minutes after extubation, was not detected between the groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4943"></a>Ornek <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: BMI &gt; 40.<br>Exclude: Neuromuscular disease, renal dysfunction, severe cardiopulmonary disease, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
The time to TOFR &gt;= 0.9 was shortest in sugammadex dose based on ABW compared to CBW and IBW (2.28 vs 2.84 vs 3.37, p=0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="5414"></a>Van <br> Dong 2020
</td>
<td style="text-align:center;width: 4em; ">
120
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 18-70; absominal laparoscopic surgery for cholecystectomy, gastrectomy, hepatectomy, or pancreatoduodenectomy.<br>Exclude: Liver failure; kidney failure; allergy to rocuronium, neostigmine, or sugammadex; epilepsy; mental illness and communication difficulties; neurological complications of diabetes or neuropathy; serious surgical complications.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR &gt;=0.9 and extubation time were significantly shorter among patients receiving sugammadex (n=42) compared with patients receiving neostigmine (n=42), p&lt;0.05. Bradycardia occurred more frequently in patients receiving neostigmine (p&lt;0.001) and nausea was comparable between the groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="6002"></a>Sabo <br> 2011
</td>
<td style="text-align:center;width: 4em; ">
106
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age 18-65; elective open abdominal surgery under general anesthesia requiring NMBA; arm accessible for TOF Watch.<br>Exclude: Neuromuscular disorder; malignant hyperthermia; renal (creatinine clearance &lt;30 mL/min) or hepatic dysfunction; allergy to opioids, muscle relaxants, or general anesthesia drugs; pregnant; breast feeding; childbearing potential and not using contraception.
</td>
<td style="text-align:left;width: 20em; ">
Patients receiving sugammadex (n=51) experienced TOFR &gt;=0.9 at extubation more frequently than patients receiving neostigmine (n=46), p&lt;0.0001. Adverse events (pain, nausea, vomiting) were comparable between study groups.
</td>
<td style="text-align:left;width: 24em; ">
Two authors are Merck employees and one author is on the speakers’ bureau.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="604"></a>Gyermek <br> 1995
</td>
<td style="text-align:center;width: 4em; ">
32
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-60; surgical patients.<br>Exclude: Significant neuromuscular, musculoskeletal, cardiac, renal, hepatic, or pulmonary diseases.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing pipecuronium-induced neuromuscular block, TOFR at 15 minutes post-reversal was 72 (19.5) with pyridostigmine and 72 (18.1) with neostigmine. Among patients undergoing pancuronium-induced neuromuscular block, TOFR mean (SD) at 15 minutes post-reversal was 84 (10.2) with pyridostigmine and 81 (7.9) with neostigmine.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7015"></a>Duranteau <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;18; BMI &lt;30 kg/m2; elective ENT surgery lasting &gt;4 h.<br>Exclude: Pregnant; breast-feeding; allergy to sugammadex; neuromuscular, renal, or hepatic disease; in another clinical trial within 3 months.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR &gt;=0.9 was evaluated by administration depth (TOFC1 or TOFC2) between sugammadex and placebo. Patients receiving sugammadex, at either depths, experienced shorter recovery times compared with patients receiving placebo.
</td>
<td style="text-align:left;width: 24em; ">
Thirty percent exclusion rate is due to 1) one physician not understanding protocol and data from this physician (n=19) were excluded from analysis, and 2) missing values (n=5).
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7078"></a>Suganuma <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: Female aged &gt;= 20 years.<br>Exclude: Morbid obesity, GERD, coagulopathy, full stomach, renal dysfunction, hx of gastric or esophageal surgery, severe co-morbidities.
</td>
<td style="text-align:left;width: 20em; ">
Time to recovery from a TOFC 3 to TOFR &gt;= 0.9 was similar in both sugammadex and neostigmine groups (11.7 vs 12.4 min).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7109"></a>Castro <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
88
</td>
<td style="text-align:left;width: 20em; ">
Include: Morbidly obese; laparoscopic bariatric surgery.<br>Exclude: Chronic pain; enrollment in another study (pregabalin effect as preemptive analgesia in obese surgical patients).
</td>
<td style="text-align:left;width: 20em; ">
Among morbidly obese patients undergoing laparoscopic bariatric surgery, patients receiving sugammadex (n=44) reported significantly less PONV and lower VAS pain scores at 30 minutes and 60 minutes in the PACU compared with patients receiving neostigmine (n=44), p &lt;0.05. A difference in VAS pain scores at PACU arrival and at PACU discharge was not detected between the two groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7226"></a>El <br> Sherbeny 2017
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 20-40 years.<br>Exclude: Difficult airway, BMI &gt;= 25%, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, or pregnant breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
Time between sugammadex administration at TOF 0.2 until recovery of a TOFR of 0.9 was shorter than in neostigmine (1.3 vs 3.55 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="781"></a>Kao <br> 1996
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 18-60; orthopedic, gynecologic, or plastic surgery under general anesthesia.<br>Exclude: Neurological, musculoskeletal, cardiovascular, or endocrinological pathology.
</td>
<td style="text-align:left;width: 20em; ">
Patients receiving neostigmine (n=10) experienced significantly longer times to TOFR 0.9 compared with patients recovering spontaneously (n=10), p &lt;0.05.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="924"></a>Hovorka <br> 1997
</td>
<td style="text-align:center;width: 4em; ">
162
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 35-65; abdominal hysterectomy.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
A difference was not detected in PONV among women undergoing abdominal hysterectomy receiving neostigmine (n=80) compared with women receiving no reversal agent (n=80).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Quasi-Experimental
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3460"></a>Krause <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
7316
</td>
<td style="text-align:left;width: 20em; ">
Include: Adults.<br>Exclude: ASA &gt; IV.
</td>
<td style="text-align:left;width: 20em; ">
The system-wide transition of the standard pharmacologic reversal agent from neostigmine to sugammadex was associated with a 31% reduction in the incidence of composite respiratory outcome and an immediate reduction on the odds for hypoxic events (OR 0.72, CI 0.58-0.88).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="8">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Nonrandomized Studies of Interventions
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2523"></a>Della <br> Rocca 2013
</td>
<td style="text-align:center;width: 4em; ">
376
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-IV, age &gt;= 18 years.<br>Exclude: Inability to read, participation in previous trials, contraindication to any drug used in study.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex confirms to be faster drug than neostigmine as a reversal agent for both shallow and deep block after rocuronium administration (shallow 2.3 vs 7.8; deep 2.4 vs 20.9).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2600"></a>Sanfilippo <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA II-III, age 18-54 years, BMI &gt; 38.<br>Exclude: Chronic alcoholism or drug abuse, liver and renal dysfunction, disabling neuropsychiatric disorders, hx stroke, brain trauma in the last 12 months, hypersensitivity to anesthetics, hx of myocardial infarction, adrenal insufficiency, congestive heart failure, and lack of cooperation or legal incapacity, OSA.
</td>
<td style="text-align:left;width: 20em; ">
Recovery times to 0.9 after sugammadex were similar in both IBW and RBW groups without observing any postoperative residual curarization (151 vs 121, p=0.07).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2615"></a>von <br> Quillfeldt 2013
</td>
<td style="text-align:center;width: 4em; ">
43
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Neuromuscular deficiency, allergies to drugs used in study.
</td>
<td style="text-align:left;width: 20em; ">
The TOF ratio at the time of tracheal extubation was greater in group sugammadex (median 1.03) than in group neostigmine (median 0.62).
</td>
<td style="text-align:left;width: 24em; ">
There may have been some bias because the anesthetists involved all had thorough experience in the field and knew that anesthetic practice was being evaluated. Therefore, the results may actually represent a best-case scenario, as routine muscle relaxation monitoring without supervision may be conducted even more insufficiently (or possibly omitted completely).
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2961"></a>Yazar <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;=65; laparoscopic cholecystectomy.<br>Exclude: Renal or hepatic failure; musculoskeletal disease; malignany hyperthermia; BMI &gt;30; failed laparoscopic intervention; surgery &gt;2 h; admission to intensive care with intubation.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing laparoscopic cholecystectomy and receiving sugammadex for NMBA reversal, time to TOFR &gt;=0.9 was significantly longer in patients &gt;=75 years (n=29) compared with patients 65-74 years (n=30), p&lt;0.001. Differences in VAS pain, bradycardia, nausea, vomiting, PORC, and reintubation were not detected between the age groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3178"></a>Muramatsu <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: Adults.<br>Exclude: Severe co-morbidities, difficult airway, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Elderly patients are at greater risk for recurarization (35% vs 5%, p=0.04) when low-dose sugammadex (50 ug/kg/min) is administered.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3491"></a>Murphy <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
200
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age 18-80; thoracoscopic surgical procedures.<br>Exclude: Open thoracic procedures; esophagectomies; allergy to either reversal agent; drugs known to affect neuromuscular transmission; succinylcholine for rapid sequence intubation; renal insufficiency (serum creatinine &gt;2.0 mg/dL) or renal failure; liver disease (hepatic failure or cirrhosis); neuromuscular disease.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing thoracoscopic surgical procedures, patients receiving sugammadex (n=197) experienced higher TOFR at PACU arrival compared with patients receiving neostigmine (n=100): median (IQR) 0.98 (0.96-1.01) and 0.84 (0.71-0.96), respectively. Muscle weakness symptoms were less common in sugammadex patients (1 [0-2] compared with neostigmine patients (4 [1-8]). A difference in adverse airway events was not detected between the groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4465"></a>Johnson <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: BMI &gt;35 kg/m2; elective laparoscopic cholecystectomy or bariatric surgery under general anesthesia.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Among obese patients undergoing either laparoscopic cholecystectomy or bariatric surgery in this NRSI, patients receiving sugammadex experienced significantly shorter time to TOFR&gt;=0.9 (p=0.0002) and reported less pain (p=0.010). A difference in anti-emetic use was not detected.
</td>
<td style="text-align:left;width: 24em; ">
Patients were not randomized to reversal agent. Under one general surgical consultant, 2 anesthetists were involved in the study. One anesthetist used neostigmine and one anesthetist used sugammadex.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4997"></a>Pecek <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
20
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; adult; surgery requiring general anesthesia and endotracheal intubation.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 was significantly shorter among patients receiving sugammadex (n=11) compared with patients receiving neostigmine (n=9), p&lt;0.05. Sugammadex dosing varied by amount of vecuronium administered and TOF at the end of surgery.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="12">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Prospective Cohort
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1166"></a>Joshi <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
100
</td>
<td style="text-align:left;width: 20em; ">
Include: Healthy patients.<br>Exclude: Cardiovascular, pulmonary, or metabolic diseases; impaired renal or hepatic function; morbid obesity; and history of alcohol or drug abuse, neuromuscular disease or those receiving medication known to influence neuromuscular transmission, anticipated airway difficulties.
</td>
<td style="text-align:left;width: 20em; ">
Incidence of nausea (15% vs 18%) and vomiting (12% vs 8%) and the need for antiemetics (13.3% vs 12.8%) do not increase with the use of neostigmine and glycopyrrolate for reversal of residual muscle paralysis.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1921"></a>Suzuki <br> 2006
</td>
<td style="text-align:center;width: 4em; ">
45
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, female age 27-57 years.<br>Exclude: Neuromuscular, hepatic and renal disorders, or were taking any drug known to interact with neuromuscular blocking agents.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 following neostigmine 0.04 mg/kg is longer in overweight and obese female patients compared with normal weight patients when vecuronium 0.1 mg/kg is administered on the basis of their RBW (14.6 vs 25.9 vs 6.9 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2304"></a>Yip <br> 2010
</td>
<td style="text-align:center;width: 4em; ">
102
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Neuromuscular disease, no consent.
</td>
<td style="text-align:left;width: 20em; ">
RNMB (TOFR &lt; 0.9) in PACU was observed in 31% of patients. In these patients 21% required airway support and 3% had episodes of desaturation when compared to patients without rNMB (5% and 2%).
</td>
<td style="text-align:left;width: 24em; ">
Incidence of rNMB was 31% in patients that were monitored intraoperatively with a PNS. rNMB detected in PACU using EMG. This study did not report anesthetics or reversal agent administered.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2419"></a>Cammu <br> 2012
</td>
<td style="text-align:center;width: 4em; ">
624
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt; 18 years.<br>Exclude: Renal, hepatic, metabolic and/or neuromuscular disorders; ejection fraction &lt;20%; admission for cardiac surgery; or reoperation during the same hospital admission.
</td>
<td style="text-align:left;width: 20em; ">
Percent of patients with a TOFR &lt; 0.9 in the PACU was similar in the neostigmine and spontaneous recovery groups but less in the sugammadex group ( 15% vs 2%, p=0.06).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2550"></a>Kadoi <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
17
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Hx of cardiovascular, hepatic, renal, or neuromuscular disease, BMI &gt;35.
</td>
<td style="text-align:left;width: 20em; ">
Time to recovery to a TOFR of 0.9 after sugammadex 8 mg/kg was shorter in the young group as compared to elderly group (6.7 vs 7.4 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2557"></a>Kotake <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
591
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt; 18 years.<br>Exclude: Neuromuscular disease, patients known or suspected of having an allergy to NMBDs, medication known to interfere with NMBDs.
</td>
<td style="text-align:left;width: 20em; ">
TOFR &lt;0.9 after tracheal extubation after sugammadex remains as high as 9.4% in a clinical setting in which neuromuscular monitoring (objective or subjective) was not used.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2560"></a>Ledowski <br> 2013
</td>
<td style="text-align:center;width: 4em; ">
146
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Intubated at the end of surgery.
</td>
<td style="text-align:left;width: 20em; ">
Those reversed with sugammadex showed fewer episodes of postoperative oxygen desaturation (15% vs. 33%; P&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
Difficult to interpret as outcomes data not reported completely.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2644"></a>Fujita <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
37
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt;= 18 years.<br>Exclude: Neuromuscular disease, renal dysfunction, hx of malignant hyperthermia, BMI &gt;= 35, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
The mean time from the administration of sugammadex to recovery of TOFR to 0.9 was not significantly different between the liver dysfunction group and the control group (2.2 vs.2.0 minutes in the2 mg/kg administration group, p=0.44 and 1.9 vs.1.7 minutes in the 4 mg/kg administration group, p=0.70, respectively).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2731"></a>de <br> Souza 2015
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 18-65 years, normal renal function, renal failure.<br>Exclude: Neuromuscular disease, liver failure, hx of malignant hyperthermia, pregnancy, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
After sugammadex administration, the mean time for recovery of the TOF ratio to 0.9 was prolonged in the renal failure group compared with the control group (5.6 vs 2.7 min, p= 0.003).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2831"></a>Badaoui <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
75
</td>
<td style="text-align:left;width: 20em; ">
Include: Adult patients, candidates for laparoscopic bariatric surgery consisting of sleeve gastrectomy.<br>Exclude: Severe renal failure.
</td>
<td style="text-align:left;width: 20em; ">
Reversal of deep neuromuscular blockades by sugammadex in obese subjects can be performed at doses of 4 mg/kg of ideal weight plus 35–50% with no clinical consequences and no accentuation of adverse effects.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2834"></a>Batistaki <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
528
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt; 18 years.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
RNMB occurred in 9% of patients receiving sugammadex as compared to 13% with neostigmine (p=0.2).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2896"></a>Martinez-Ubieto <br> 2016
</td>
<td style="text-align:center;width: 4em; ">
558
</td>
<td style="text-align:left;width: 20em; ">
Include: PACU admission with spontaneous ventilation.<br>Exclude: Age &lt; 18 years, ASA IV-V, neuromuscular disease, procedures involving intraoperative hypothermia.
</td>
<td style="text-align:left;width: 20em; ">
RNMB in the PACU is associated to a greater incidence of major and minor respiratory complications when compared to no rNMB (62% vs 38%; 93% vs 7%). Major respiratory complications were seen in patients given neostigmine after cis-atricurium than sugammadex after rocuronium (8.7% vs 1.1%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="10">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Retrospective Cohort
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2197"></a>White <br> 2009
</td>
<td style="text-align:center;width: 4em; ">
171
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III.<br>Exclude: Difficult airway, neuromuscular disorders, significant renal dysfunction, malignant hyperthermia, allergy to medications used in general anesthesia, medications known to interfere with NMBAs, of child-bearing potential, pregnant, and breast feeding.
</td>
<td style="text-align:left;width: 20em; ">
The time to achieve a TOFR 0.9 was prolonged when sugammadex was administered at 0 twitch compared with the &gt;1 twitch response (2.88 vs 1.73 min, P &lt; 0.05).
</td>
<td style="text-align:left;width: 24em; ">
This is a post hoc analysis of an unpublished multicenter observational study.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3176"></a>Miyazaki <br> 2018
</td>
<td style="text-align:center;width: 4em; ">
15479
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: NA
</td>
<td style="text-align:left;width: 20em; ">
The overall incidence of intraoperative hypersensitivity reaction was 0.22% (95% confidence interval [CI], 0.17%–0.29%), and the incidence of anaphylaxis was 0.059% (95% CI, 0.032%–0.10%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3237"></a>Arslantas <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
42
</td>
<td style="text-align:left;width: 20em; ">
Include: Records of kidney transplant patients diagnosed with end-stage renal disease and had renal transplantation with living or deceased donors.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
No difference in risk of serious adverse effects on short-term (28 days) graft functions were detected among patients undergoing kidney transplantation and receiving sugammadex compared with neostigmine.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3441"></a>John <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
277
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Ages &lt; 18 years, pregnant or breastfeeding, ASA &gt;= IV.
</td>
<td style="text-align:left;width: 20em; ">
The median time from NMB administration to OR exit was similar for neostigmine and sugammadex (16 vs. 15.5 minutes, p=0.11). Sugammadex had lower rates of bradycardia (5.6 vs. 2.2%) or nausea and vomiting (18 vs. 11%) when compared to neostigmine.
</td>
<td style="text-align:left;width: 24em; ">
Very poorly reported methods and outcomes.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3451"></a>Kheterpal <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
45712
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;=18; surgery using general anesthesia with endotracheal tube and receiving NMBA (vecuronium or rocuronium) by bolus or infusion; neostigmine or sugammadex (dose 1.8 to 4.4 mg/kg).<br>Exclude: Age &lt;18; outpatient procedure; emergency, cardiac, liver, or lung transplantation surgery; intubation prior to OR; ASA V-VI; renal failure (ICD 9 code or glomerular filtration rate &lt;30 ml/min; sugammadex and neostigmine both used; redosing of NMBA; median intraoperative positive end-expiratory pressure &gt;10 cm H2O; institutional use of sugammadex &lt;10% of NMBA pts; pts only included once within 30-day period; patients over 90 recorded as 90 (per US privacy regulations).
</td>
<td style="text-align:left;width: 20em; ">
Results from a retrospective matched cohort analysis (n=22,856 per arm) reported 3.5% of patients receiving sugammadex and 4.8% of patients receiving neostigmine experienced a pulmonary complication, defined as 1) pneumonia, 2) respiratory failure, or 3) other major pulmonary complication. Rates of pneumonia were 1.3% and 2.2% in the sugammadex and neostigmine groups, respectively. Rates of respiratory failure were 0.8% and 1.7% in the sugammadex and neostigmine groups, respectively.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3667"></a>Yu <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
914
</td>
<td style="text-align:left;width: 20em; ">
Include: Patients undergoing RALP.<br>Exclude: Incomplete medical records.
</td>
<td style="text-align:left;width: 20em; ">
The incidence of atelectasis (18.6% vs 39.2%) after RALP was lower in patients receiving sugammadex (moderate: after TOFC &gt;= 2) than in those receiving neostigmine (shallow: after TOFC = 4).
</td>
<td style="text-align:left;width: 24em; ">
In this single-center retrospective study, the authors minimized selection bias by performing a propensity score-matched analysis.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3929"></a>Burbridge <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
19821
</td>
<td style="text-align:left;width: 20em; ">
Include: Patients with manual entry of anaphylactic reaction to sugammadex in EMR.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
The incidence of anaphylaxis to sugammadex in this cohort of patients was 2 of 19,821 patients.
</td>
<td style="text-align:left;width: 24em; ">
This retrospective analysis found a low risk of anaphylaxis of approximately 1 of 10,000. This was a single-center, retrospective study using EMR data. Cases may have been inadvertently overlooked during the chart review process.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3986"></a>Cho <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
54
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III; age &gt;20; video-assisted thoracoscopic surgery (VATS).<br>Exclude: VATS converted to open surgery or bilateral surgery.
</td>
<td style="text-align:left;width: 20em; ">
Among patients undergoing video-assisted thoracoscopic surgery, patients receiving sugammadex (n=19) experienced significantly fewer total pulmonary complications (prolonged air leak, pneumonia, atelectasis) compared with patients receiving pyridostigmine (n=31), p=0.049.
</td>
<td style="text-align:left;width: 24em; ">
Total pulmonary complications were significantly different between the groups; however, a statistically significant difference was not detected when each complication was viewed separately (prolonged air leak, pneumonia, atelectasis).
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4560"></a>Kim <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
15586
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt;=18; surgery under general anesthesia; use of sugammadex or neostigmine.<br>Exclude: Repeat surgery within 24 hr after anesthesia; lack of consciousness after surgery; ventilator therapy after anesthesia; nausea or vomiting before anesthesia; follow-up duration &lt;24 hrs; &gt;=2 types NMB agents used.
</td>
<td style="text-align:left;width: 20em; ">
In this propensity matched study (n=7793 each arm) of 5 hospitals, the odds of PONV were significantly lower among patients receiving sugammadex compared with patients receiving neostigmine: OR=0.65; 95% CI, 0.59-0.72; p&lt;0.0001.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4692"></a>Li <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
10491
</td>
<td style="text-align:left;width: 20em; ">
Include: Age &gt; 18 years.<br>Exclude: Transplantation cases, and those cases that resulted from complications of another diagnostic or surgical procedure within the previous 30 days, patients who received cisatracurium, patients receiving both sugammadex and neostigmine.
</td>
<td style="text-align:left;width: 20em; ">
The overall incident rate of POPC was 5.9% for the neostigmine subgroup and 4.2% for the sugammadex subgroup (OR 0.89, 0.65-1.22, p=0.468).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="5">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>All Ages</strong>
</td>
</tr>
<tr grouplength="4">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
RCT
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1132"></a>Bevan <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
176
</td>
<td style="text-align:left;width: 20em; ">
Include: Pediatric patients age 2-12 years, women age 20-65 years, ASA I-II, normal body weight.<br>Exclude: Pregnant women; patients with a history of hypersensitivity to dairy products, asthma, epilepsy, neuromuscular disease, or drug abuse; and patients who had recently taken medication affecting neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Return of neuromuscular function after reversal was not influenced by the timing of neostigmine administration in both adults and children.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="1198"></a>McCourt <br> 1999
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: Not specified.<br>Exclude: Weight &gt;30% from IBW, medications interfering with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2177"></a>Plaud <br> 2009
</td>
<td style="text-align:center;width: 4em; ">
94
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, ages 28 days - 65 yr.<br>Exclude: Neuromuscular disease, renal dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission, pregnant or breastfeeding women.
</td>
<td style="text-align:left;width: 20em; ">
After placebo, median recovery time to TOFR 0.9 was 21.0, 19.0, 23.4, and 28.5 min in infants, children, adolescents, and adults, respectively. After 2.0 mg/kg sugammadex TOFR 0.9 was attained in 0.6, 1.2, 1.1, and 1.2 min, respectively.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="732"></a>Abdulatif <br> 1996
</td>
<td style="text-align:center;width: 4em; ">
90
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; children age 2-10 yrs; adults age 18-60; low risk elective surgery.<br>Exclude: Cardiac, vascular, respiratory, hepatic, renal, neuromuscular disorders; small joint arthritis; drugs affecting neurouscular function.
</td>
<td style="text-align:left;width: 20em; ">
In a study of children and adults receiving either no reversal agent or neostigmine from 0.005 to 0.05 mg/kg, overall recovery from NMBA was faster in children compared with adults. After 10 minutes, children receiving neostigmine doses of .02 to .05 mg/kg experienced TOFR &gt;=0.9. After 10 minutes, no adults at any dose of neostigmine experienced TOFR &gt;=0.9.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Retrospective Cohort
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3495"></a>Orihara <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
33119
</td>
<td style="text-align:left;width: 20em; ">
Include: Surgery under general anesthesia.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
Records from 4 hospitals of patients undergoing surgery with general anesthesia were reviewed. Among patients receiving sugammadex (n=29962), 6 cases of anaphylaxis were reported (incidence = 0.020, 95% CI: 0.007-0.044). Among patients receiving neostigmine (n=3157), 0 cases of analphylaxis were reported.
</td>
<td style="text-align:left;width: 24em; ">
Anaphylaxis defined by 2 or more: 1)clinical monitoring scoring system (net score &gt;=8); 2) skin test or BAT positive reaction; 3) blood sample showing elevation in histamine or tryptase.
</td>
</tr>
<tr grouplength="17">
<td colspan="5" style="border-top: 1px solid;color: black !important;background-color: #EBEBEB !important;">
<strong>Pediatric</strong>
</td>
</tr>
<tr grouplength="12">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
RCT
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="124"></a>Gwinnutt <br> 1991
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I.<br>Exclude: Drugs known to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to reach TOFR 0.8 was less when neostigmine was given at T1 10% versus PTC1 10% (4.8 vs 11.8 min, p&lt;0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2681"></a>Ozgun <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 2-12 years.<br>Exclude: Difficult airway, neuromuscular disease, renal dysfunction, hx malignant hyperthermia, medications know to interfere with neuromuscular transmission.
</td>
<td style="text-align:left;width: 20em; ">
Time to TOFR 0.9 and extubation times were significantly longer in neostigmine than sugammadex group (392 vs 68 min, p&lt; 0.001). Comparison of adverse effects yielded no difference (hypoxia 7% vs 7%).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2741"></a>Ghoneim <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age 7-18 years.<br>Exclude: Neuromuscular disease, renal dysfunction, hx malignant hyperthermia, Glasgow Coma Scale &lt;15, midline shift.
</td>
<td style="text-align:left;width: 20em; ">
Sugammadex rapidly reversed rocuronium-induced NMB in pediatric patients undergoing neurosurgery when administered at reappearance of T2 of TOF at dose 4 mg/kg when compared to neostigmine (1.4 vs 25.1 min, p&lt;0.05).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2976"></a>Ammar <br> 2017
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II, age 2-10 years.<br>Exclude: BMI &gt; 40, neuromuscular disease, renal or hepatic dysfunction, hx malignant hyperthermia, mental retardation.
</td>
<td style="text-align:left;width: 20em; ">
The mean recovery and extubation times were significantly shorter (P = 0.002 and 0.005) in sugammadex group compared with neostigmine (2.5 and 2.0 min vs. 12.6 min and 4.3 min respectively) in children.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3306"></a>Korkmaz <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
70
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 5-13; adenotonsillectomy with recurrent/chronic tonsillitis or obstructive sleep apnea.<br>Exclude: Allergy to general anesthesia medication; neurological disease; asthma; bleeding diathesis.
</td>
<td style="text-align:left;width: 20em; ">
Among children undergoing adenotonsillectomy, time to extubation was significantly shorter (p&lt;0.001) and PONV significantly less (p=0.048) among children receiving sugammadex (n=35) compared with children receiving neostigmine (n=35). A difference in hypoxia was not detected.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3556"></a>Xiaobing <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA II-III; age 2-6; congenital heart disease (atrial septal defect or ventricular septal defect).<br>Exclude: Respiratory tract infection and other infectious diseases; severe pulmonary hypertension; hepatic or renal dysfunction; severe malnutrition; cardiopulmonary bypass &gt;90 min and arterial blocking time &gt;50 min; serious perioperative complications.
</td>
<td style="text-align:left;width: 20em; ">
In pediatric patients with congenital heart disease, patients receiving sugammadex (n=30) experienced significantly shorter time to TOFR &gt;=0.9 and extubation time compared with patients reversing spontaneously (n=30). No differences in pulmonary complications (pneumonia, atelectasis, and re-intubation) were detected between the groups.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3628"></a>Li <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
60
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA II-III; age 1-6; cardiac surgery.<br>Exclude: Severe pulmonary hypertension; hepatic or renal dysfunction; severe malnutrition; cardiopulmonary bypass &gt;90 minutes; serious perioperative complications.
</td>
<td style="text-align:left;width: 20em; ">
Among pediatric patients undergoing cardiac surgery, patients receiving sugammadex (n=30) experienced significantly faster time to TOFR &gt;=0.9 compared to patients receiving neostigmine (n=30), p&lt;0.01. Postoperative atelectasis was significantly lower in the patients receiving sugammadex (p=0.024). No differences in lung infection, hypoxia, bradycardia, nausea, vomiting, or reintubation were detected.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4114"></a>El <br> sayed 2016
</td>
<td style="text-align:center;width: 4em; ">
70
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 2-10; pediatric patient undergoing total bilateral tonsillectomy.<br>Exclude: Difficult intubation; neuromuscular disease; metabolic disorder; drug hypersensitivity; kidney or liver impairment; congenital heart disease; malignant hyperthermia.
</td>
<td style="text-align:left;width: 20em; ">
Among children undergoing total bilateral tonsillectomy, patients receiving sugammadex (n=35) experienced TOFR &gt;=0.9 significantly faster compared with patients receiving neostigmine (n=35), p&lt;0.05.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="4399"></a>Hussein <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; age 2-18 yrs; outpatient surgical procedures.<br>Exclude: Hepatic or renal failure; drug hypersensitivity; malignant hyperthermia.
</td>
<td style="text-align:left;width: 20em; ">
Among pediatric patients with cancer undergoing ambulatory surgical procedures, patients receiving sugammadex (n=40) experienced significantly shorter time to TOFR &gt;=0.9 compared with patients receiving neostigmine (n=40). Differences were not detected in arrhythmia, nausea or vomiting. No recurarization or hypoxia reported.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="631"></a>Kirkegaard-Nielsen <br> 1995
</td>
<td style="text-align:center;width: 4em; ">
40
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; pediatric; elective general or orthopedic surgery with duration 45-90 min with minimal blood loss.<br>Exclude: Neuromuscular, renal, hepatic, or cardiovascular disease; drugs affecting neuromuscular function.
</td>
<td style="text-align:left;width: 20em; ">
Five minutes following neostigmine administration, the following age groups and mean TOFR were reported: 0-2 months (88.4 +/- 10.9); 3-11 months (94.0 +/- 7.4); 2-5 yrs (89.2 +/- 6.8); 6-10 yrs (82.2 +/- 9.5); and 11-15 yrs (80.6 +/- 17.1). Ten minutes following neostigmine administration, the following age groups and mean TOFR were reported: 0-2 months (99.4 +/- 1.4); 3-11 months (99.7 +/- 1.0); 2-5 yrs (99.1 +/- 1.2); 6-10 yrs (99.3 +/- 1.0); and 11-15 yrs (97.1 +/- 5.6).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="7030"></a>Kara <br> 2014
</td>
<td style="text-align:center;width: 4em; ">
80
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I; age 2-12; elective outpatient lower abdominal or urogenital surgery.<br>Exclude: Drug hypersensitivity; kidney or liver failure; neuromuscular disease; malign hyperthermia; mental retardation.
</td>
<td style="text-align:left;width: 20em; ">
Among pediatric patients undergoing abdominal or urogenital surgery, patients receiving sugammadex (n=40) experienced significantly shorter times to TOFR &gt;0.9 compared with patients receiving neostigmine (n=40), p=0.001.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="724"></a>Watcha <br> 1995
</td>
<td style="text-align:center;width: 4em; ">
75
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-II; children; brief elective peripheral procedures (not involving body cavities) using general endotracheal anesthesia.<br>Exclude: Allergies to study medications; acute neurologic, hepatic, renal, or cardiovascular disease; risk for regurgitation and aspiration of stomach contents.
</td>
<td style="text-align:left;width: 20em; ">
Pediatric patients receiving neostigmine (n=38) experienced significantly more emesis and required significantly more rescue antiemetic therapy compared with pediatric patients reversing no reversal agents (n=37), p&lt;0.05.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="4">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Prospective Cohort
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="2767"></a>Ledowski <br> 2015
</td>
<td style="text-align:center;width: 4em; ">
64
</td>
<td style="text-align:left;width: 20em; ">
Include: Pediatric; urgent or elective surgery under general anesthesia requiring endotracheal tube.<br>Exclude: Operations outside of M-F 8 am to 6 pm; emergency procedures; planned extubation outside of OR; age &lt;12 months who were too small for electrode attachment.
</td>
<td style="text-align:left;width: 20em; ">
In this chart audit of 64 pediatric patients undergoing urgent or elective surgery involving general anesthesia and endotracheal intubation, 32 (50%) received neostigmine, 1 (1.6%) received sugammadex, and 30 (46.9%) received no reversal. TOFR &lt;0.9 occurred in 19.4% patients with no reversal and in 37.5% patients receiving neostigmine (p=0.164). TOFR &lt;0.7 occurred in 2 patients each in both the neostigmine and spontaneous groups. A difference in incidence of bronchospasm, oxygen desaturation &lt;95%, and airway obstruction were not detected between the patients with TOFR &lt;0.9 compared with patients with TOFR &gt;=0.9.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3381"></a>Alsuhebani <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
221
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 0-18; surgery with planned rocuronium or vecuronium use, reversed with sugammadex.<br>Exclude: Allergy to sugammadex; use of vasoactive or anticholinergic agents.
</td>
<td style="text-align:left;width: 20em; ">
Among 221 pediatric patients receiving sugammadex to reverse rocuronium or vecuronium, 18 (8%) developed bradycardia. Of those developing bradycardia, 7 had cardiac comorbid conditions. No patient required treatment for bradycardia.
</td>
<td style="text-align:left;width: 24em; ">
Bradycardia was defined as heart rate less than the fifth percentile for age.
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3384"></a>Arends <br> 2020
</td>
<td style="text-align:center;width: 4em; ">
99
</td>
<td style="text-align:left;width: 20em; ">
Include: Age 0-18; comorbid cardiac, cardiovascular, and congenital heart diseases; surgery with planned rocuronium or vecuronium use, reversed with sugammadex.<br>Exclude: Allergy to sugammadex.
</td>
<td style="text-align:left;width: 20em; ">
Among pediatric patients with cardiac co-morbidities (congenital heart disease, arrhythmia, valvular heart disease, cardiomyopathy, post heart transplant) (n=99), bradycardia was noted in 20 (20%) following sugammadex administration. Six of the 20 had bradycardia at baseline. Seven patients had bradycardia at baseline; adjusted bradycardia incidence is 14 of 92 (15%).
</td>
<td style="text-align:left;width: 24em; ">
Bradycardia was defined as heart rate less than the fifth percentile for age. Authors report adjusted bradycardia incidence as 14% (14 of 99).
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3574"></a>Alenezi <br> 2021
</td>
<td style="text-align:center;width: 4em; ">
30
</td>
<td style="text-align:left;width: 20em; ">
Include: ASA I-III, age &gt; 18 years.<br>Exclude: Pulmonary disease, cardiovascular comorbidities, surgeries &gt; 4 hours, cardiac, thoracic, neurological surgeries, or emergency abdominal surgery.
</td>
<td style="text-align:left;width: 20em; ">
The incidence of RNMB (TOF ratio &lt; 0.9) was in 16 patients (53.3%). The incidence of RNMB was significantly higher in female patients (p = 0.033), in patients who had not undergone quantitative neuromuscular monitoring before extubation (p = 0.046) and in patients with a shorter duration of surgery (p = 0.001).
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
<tr grouplength="1">
<td colspan="5" style="border-bottom: 0px solid;color: black !important;background-color: white !important;">
Case Control
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;width: 8em; " indentlevel="1">
<a id="3280"></a>Gaver <br> 2019
</td>
<td style="text-align:center;width: 4em; ">
1936
</td>
<td style="text-align:left;width: 20em; ">
Include: Newborn to adolescent patients receiving sugammadex; matched newborn to adolescent historical controls receiving neostigmine.<br>Exclude: Not specified.
</td>
<td style="text-align:left;width: 20em; ">
In a case control study of pediatric patients (newborn through adolescent), patients receiving sugammadex (n=968) experienced significantly less bradycardia compared with patients receiving neostigmine (n=968), p&lt;0.001. No differences were detected between the groups in hypotension, bronchospasm, anaphylaxis, or PONV.
</td>
<td style="text-align:left;width: 24em; ">
</td>
</tr>
</tbody>
</table>
<p><br/></p>
<hr style="height:2px;border-width:0;color:gray;background-color:gray">
</div>
<div id="references" class="section level1">
<h1><strong>References</strong></h1>
<div id="refs" class="references csl-bib-body">
<div id="ref-Bowdle2020" class="csl-entry">
<div class="csl-left-margin">1. </div><div class="csl-right-inline">Bowdle A, Bussey L, Michaelsen K, et al. A comparison of a prototype electromyograph vs. A mechanomyograph and an acceleromyograph for assessment of neuromuscular blockade. <em>Anaesthesia</em>. 2020;75(2):187-195. doi:<a href="https://doi.org/10.1111/anae.14872">10.1111/anae.14872</a></div>
</div>
<div id="ref-Pedersen1990" class="csl-entry">
<div class="csl-left-margin">2. </div><div class="csl-right-inline">Pedersen T, Viby-Mogensen J, Bang U, Olsen NV, Jensen E, Engboek J. Does perioperative tactile evaluation of the train-of-four response influence the frequency of postoperative residual neuromuscular blockade? <em>Anesthesiology</em>. 1990;73(5):835-839. doi:<a href="https://doi.org/10.1097/00000542-199011000-00007">10.1097/00000542-199011000-00007</a></div>
</div>
<div id="ref-Goldhill1991a" class="csl-entry">
<div class="csl-left-margin">3. </div><div class="csl-right-inline">Goldhill DR, Carter JA, Suresh D, Whitehead JP, Flynn PJ. Antagonism of atracurium with neostigmine. Effect of dose on speed of recovery. <em>Anaesthesia</em>. 1991;46(6):496-499. doi:<a href="https://doi.org/10.1111/j.1365-2044.1991.tb11696.x">10.1111/j.1365-2044.1991.tb11696.x</a></div>
</div>
<div id="ref-Goldhill1991" class="csl-entry">
<div class="csl-left-margin">4. </div><div class="csl-right-inline">Goldhill DR, Whitehead JP, Emmott RS, Griffith AP, Bracey BJ, Flynn PJ. Neuromuscular and clinical effects of mivacurium chloride in healthy adult patients during nitrous oxide-enflurane anaesthesia. <em>Br J Anaesth</em>. 1991;67(3):289-295. doi:<a href="https://doi.org/10.1093/bja/67.3.289">10.1093/bja/67.3.289</a></div>
</div>
<div id="ref-Gwinnutt1991" class="csl-entry">
<div class="csl-left-margin">5. </div><div class="csl-right-inline">Gwinnutt CL, Walker RW, Meakin G. Antagonism of intense atracurium-induced neuromuscular block in children. <em>Br J Anaesth</em>. 1991;67(1):13-16. doi:<a href="https://doi.org/10.1093/bja/67.1.13">10.1093/bja/67.1.13</a></div>
</div>
<div id="ref-Ueda1991" class="csl-entry">
<div class="csl-left-margin">6. </div><div class="csl-right-inline">Ueda N, Muteki T, Tsuda H, Inoue S, Nishina H. Is the diagnosis of significant residual neuromuscular blockade improved by using double-burst nerve stimulation? <em>Eur J Anaesthesiol</em>. 1991;8(3):213-218.</div>
</div>
<div id="ref-Devlin1993" class="csl-entry">
<div class="csl-left-margin">7. </div><div class="csl-right-inline">Devlin JC, Head-Rapson AG, Parker CJ, Hunter JM. Pharmacodynamics of mivacurium chloride in patients with hepatic cirrhosis. <em>Br J Anaesth</em>. 1993;71(2):227-231. doi:<a href="https://doi.org/10.1093/bja/71.2.227">10.1093/bja/71.2.227</a></div>
</div>
<div id="ref-Baurain1994" class="csl-entry">
<div class="csl-left-margin">8. </div><div class="csl-right-inline">Baurain MJ, Dernovoi BS, ’Hollander AA, Hennart DA. Comparison of neostigmine-induced recovery with spontaneous recovery from mivacurium-induced neuromuscular block. <em>Br J Anaesth</em>. 1994;73(6):791-794. doi:<a href="https://doi.org/10.1093/bja/73.6.791">10.1093/bja/73.6.791</a></div>
</div>
<div id="ref-Boeke1994" class="csl-entry">
<div class="csl-left-margin">9. </div><div class="csl-right-inline">Boeke AJ, Lange JJ e, Druenen B van, Langemeijer JJ. Effect of antagonizing residual neuromuscular block by neostigmine and atropine on postoperative vomiting. <em>Br J Anaesth</em>. 1994;72(6):654-656. doi:<a href="https://doi.org/10.1093/bja/72.6.654">10.1093/bja/72.6.654</a></div>
</div>
<div id="ref-Maddineni1994" class="csl-entry">
<div class="csl-left-margin">10. </div><div class="csl-right-inline">Maddineni VR, Mirakhur RK, McCoy EP. Recovery of mivacurium block with or without anticholinesterases following administration by continuous infusion. <em>Anaesthesia</em>. 1994;49(11):946-948. doi:<a href="https://doi.org/10.1111/j.1365-2044.1994.tb04309.x">10.1111/j.1365-2044.1994.tb04309.x</a></div>
</div>
<div id="ref-Gyermek1995" class="csl-entry">
<div class="csl-left-margin">11. </div><div class="csl-right-inline">Gyermek L, Cantley EM, Lee C. Antagonism of pancuronium- and pipecuronium-induced neuromuscular block. <em>Br J Anaesth</em>. 1995;74(4):410-414. doi:<a href="https://doi.org/10.1093/bja/74.4.410">10.1093/bja/74.4.410</a></div>
</div>
<div id="ref-Kirkegaard-Nielsen1995" class="csl-entry">
<div class="csl-left-margin">12. </div><div class="csl-right-inline">Kirkegaard-Nielsen H, Meretoja OA, Wirtavuori K. Reversal of atracurium-induced neuromuscular block in paediatric patients. <em>Acta Anaesthesiol Scand</em>. 1995;39(7):906-911. doi:<a href="https://doi.org/10.1111/j.1399-6576.1995.tb04196.x">10.1111/j.1399-6576.1995.tb04196.x</a></div>
</div>
<div id="ref-Mortensen1995" class="csl-entry">
<div class="csl-left-margin">13. </div><div class="csl-right-inline">Mortensen CR, Berg H, el-Mahdy A, Viby-Mogensen J. Perioperative monitoring of neuromuscular transmission using acceleromyography prevents residual neuromuscular block following pancuronium. <em>Acta Anaesthesiol Scand</em>. 1995;39(6):797-801. doi:<a href="https://doi.org/10.1111/j.1399-6576.1995.tb04173.x">10.1111/j.1399-6576.1995.tb04173.x</a></div>
</div>
<div id="ref-Shorten1995" class="csl-entry">
<div class="csl-left-margin">14. </div><div class="csl-right-inline">Shorten GD, Merk H, Sieber T. Perioperative train-of-four monitoring and residual curarization. <em>Can J Anaesth</em>. 1995;42(8):711-715. doi:<a href="https://doi.org/10.1007/bf03012670">10.1007/bf03012670</a></div>
</div>
<div id="ref-Trevien1995" class="csl-entry">
<div class="csl-left-margin">15. </div><div class="csl-right-inline">Trévien V, Lienhart A, Just B, Chandon M, Baras E, Camatte S. Effect of neostigmine at different levels of mivacurium-induced neuromuscular blockade. <em>Acta Anaesthesiol Scand Suppl</em>. 1995;106:66-69. doi:<a href="https://doi.org/10.1111/j.1399-6576.1995.tb04314.x">10.1111/j.1399-6576.1995.tb04314.x</a></div>
</div>
<div id="ref-Watcha1995" class="csl-entry">
<div class="csl-left-margin">16. </div><div class="csl-right-inline">Watcha MF, Safavi FZ, McCulloch DA, Tan TS, White PF. Effect of antagonism of mivacurium-induced neuromuscular block on postoperative emesis in children. <em>Anesth Analg</em>. 1995;80(4):713-717. doi:<a href="https://doi.org/10.1097/00000539-199504000-00011">10.1097/00000539-199504000-00011</a></div>
</div>
<div id="ref-Abdulatif1996" class="csl-entry">
<div class="csl-left-margin">17. </div><div class="csl-right-inline">Abdulatif M, Mowafi H, l-Ghamdi A, el-Sanabary M. Dose-response relationships for neostigmine antagonism of rocuronium-induced neuromuscular block in children and adults. <em>Br J Anaesth</em>. 1996;77(6):710-715. doi:<a href="https://doi.org/10.1093/bja/77.6.710">10.1093/bja/77.6.710</a></div>
</div>
<div id="ref-Kao1996" class="csl-entry">
<div class="csl-left-margin">18. </div><div class="csl-right-inline">Kao YJ, Le ND. The reversal of profound mivacurium-induced neuromuscular blockade. <em>Can J Anaesth</em>. 1996;43(11):1128-1133. doi:<a href="https://doi.org/10.1007/bf03011839">10.1007/bf03011839</a></div>
</div>
<div id="ref-Abdulatif1997" class="csl-entry">
<div class="csl-left-margin">19. </div><div class="csl-right-inline">Abdulatif M, el-Sanabary M. Blood flow and mivacurium-induced neuromuscular block at the orbicularis oculi and adductor pollicis muscles. <em>Br J Anaesth</em>. 1997;79(1):24-28. doi:<a href="https://doi.org/10.1093/bja/79.1.24">10.1093/bja/79.1.24</a></div>
</div>
<div id="ref-Dahaba1997" class="csl-entry">
<div class="csl-left-margin">20. </div><div class="csl-right-inline">Dahaba AA, Rehak PH, List WF. Assessment of accelerography with the TOF-GUARD: A comparison with electromyography. <em>Eur J Anaesthesiol</em>. 1997;14(6):623-629. doi:<a href="https://doi.org/10.1017/s026502159700104x">10.1017/s026502159700104x</a></div>
</div>
<div id="ref-Hovorka1997" class="csl-entry">
<div class="csl-left-margin">21. </div><div class="csl-right-inline">Hovorka J, Korttila K, Nelskylä K, et al. Reversal of neuromuscular blockade with neostigmine has no effect on the incidence or severity of postoperative nausea and vomiting. <em>Anesth Analg</em>. 1997;85(6):1359-1361. doi:<a href="https://doi.org/10.1097/00000539-199712000-00032">10.1097/00000539-199712000-00032</a></div>
</div>
<div id="ref-Carroll1998" class="csl-entry">
<div class="csl-left-margin">22. </div><div class="csl-right-inline">Carroll MT, Mirakhur RK, Lowry D, Glover P, Kerr CJ. A comparison of the neuromuscular blocking effects and reversibility of cisatracurium and atracurium. <em>Anaesthesia</em>. 1998;53(8):744-748. doi:<a href="https://doi.org/10.1046/j.1365-2044.1998.00530.x">10.1046/j.1365-2044.1998.00530.x</a></div>
</div>
<div id="ref-Fruergaard1998" class="csl-entry">
<div class="csl-left-margin">23. </div><div class="csl-right-inline">Fruergaard K, Viby-Mogensen J, Berg H, el-Mahdy AM. Tactile evaluation of the response to double burst stimulation decreases, but does not eliminate, the problem of postoperative residual paralysis. <em>Acta Anaesthesiol Scand</em>. 1998;42(10):1168-1174. doi:<a href="https://doi.org/10.1111/j.1399-6576.1998.tb05271.x">10.1111/j.1399-6576.1998.tb05271.x</a></div>
</div>
<div id="ref-Hodgson1998" class="csl-entry">
<div class="csl-left-margin">24. </div><div class="csl-right-inline">Hodgson RE, Rout CC, Rocke DA, Louw NJ. Mivacurium for caesarean section in hypertensive parturients receiving magnesium sulphate therapy. <em>Int J Obstet Anesth</em>. 1998;7(1):12-17. doi:<a href="https://doi.org/10.1016/s0959-289x(98)80022-8">10.1016/s0959-289x(98)80022-8</a></div>
</div>
<div id="ref-Nelskyla1998" class="csl-entry">
<div class="csl-left-margin">25. </div><div class="csl-right-inline">Nelskylä K, Yli-Hankala A, Soikkeli A, Korttila K. Neostigmine with glycopyrrolate does not increase the incidence or severity of postoperative nausea and vomiting in outpatients undergoing gynaecological laparoscopy. <em>Br J Anaesth</em>. 1998;81(5):757-760. doi:<a href="https://doi.org/10.1093/bja/81.5.757">10.1093/bja/81.5.757</a></div>
</div>
<div id="ref-Bevan1999" class="csl-entry">
<div class="csl-left-margin">26. </div><div class="csl-right-inline">Bevan JC, Collins L, Fowler C, et al. Early and late reversal of rocuronium and vecuronium with neostigmine in adults and children. <em>Anesth Analg</em>. 1999;89(2):333-339. doi:<a href="https://doi.org/10.1097/00000539-199908000-00016">10.1097/00000539-199908000-00016</a></div>
</div>
<div id="ref-Fuchs-Buder1999" class="csl-entry">
<div class="csl-left-margin">27. </div><div class="csl-right-inline">Fuchs-Buder T, Ziegenfuss T, Lysakowski K, Tassonyi E. Antagonism of vecuronium-induced neuromuscular block in patients pretreated with magnesium sulphate: Dose-effect relationship of neostigmine. <em>Br J Anaesth</em>. 1999;82(1):61-65. doi:<a href="https://doi.org/10.1093/bja/82.1.61">10.1093/bja/82.1.61</a></div>
</div>
<div id="ref-Joshi1999" class="csl-entry">
<div class="csl-left-margin">28. </div><div class="csl-right-inline">Joshi GP, Garg SA, Hailey A, Yu SY. The effects of antagonizing residual neuromuscular blockade by neostigmine and glycopyrrolate on nausea and vomiting after ambulatory surgery. <em>Anesth Analg</em>. 1999;89(3):628-631. doi:<a href="https://doi.org/10.1097/00000539-199909000-00015">10.1097/00000539-199909000-00015</a></div>
</div>
<div id="ref-Lien1999" class="csl-entry">
<div class="csl-left-margin">29. </div><div class="csl-right-inline">Lien CA, Belmont MR, Wray Roth DL, Okamoto M, Abalos A, Savarese JJ. Pharmacodynamics and the plasma concentration of mivacurium during spontaneous recovery and neostigmine-facilitated recovery. <em>Anesthesiology</em>. 1999;91(1):119-126. doi:<a href="https://doi.org/10.1097/00000542-199907000-00019">10.1097/00000542-199907000-00019</a></div>
</div>
<div id="ref-McCourt1999a" class="csl-entry">
<div class="csl-left-margin">30. </div><div class="csl-right-inline">McCourt KC, Mirakhur RK, Kerr CM. Dosage of neostigmine for reversal of rocuronium block from two levels of spontaneous recovery. <em>Anaesthesia</em>. 1999;54(7):651-655. doi:<a href="https://doi.org/10.1046/j.1365-2044.1999.00893.x">10.1046/j.1365-2044.1999.00893.x</a></div>
</div>
<div id="ref-McCourt1999" class="csl-entry">
<div class="csl-left-margin">31. </div><div class="csl-right-inline">McCourt KC, Mirakhur RK, Lowry DW, Carroll MT, Sparr HJ. Spontaneous or neostigmine-induced recovery after maintenance of neuromuscular block with org 9487 (rapacuronium) or rocuronium following an initial dose of org 9487. <em>Br J Anaesth</em>. 1999;82(5):755-756. doi:<a href="https://doi.org/10.1093/bja/82.5.755">10.1093/bja/82.5.755</a></div>
</div>
<div id="ref-Hayes2000" class="csl-entry">
<div class="csl-left-margin">32. </div><div class="csl-right-inline">Hayes A, Breslin D, Reid J, Mirakhur RK. Comparison of recovery following rapacuronium, with and without neostigmine, and succinylcholine. <em>Anaesthesia</em>. 2000;55(9):859-863. doi:<a href="https://doi.org/10.1046/j.1365-2044.2000.01541.x">10.1046/j.1365-2044.2000.01541.x</a></div>
</div>
<div id="ref-Lovstad2001" class="csl-entry">
<div class="csl-left-margin">33. </div><div class="csl-right-inline">Løvstad RZ, Thagaard KS, Berner NS, Raeder JC. Neostigmine 50 microg kg(-1) with glycopyrrolate increases postoperative nausea in women after laparoscopic gynaecological surgery. <em>Acta Anaesthesiol Scand</em>. 2001;45(4):495-500. doi:<a href="https://doi.org/10.1034/j.1399-6576.2001.045004495.x">10.1034/j.1399-6576.2001.045004495.x</a></div>
</div>
<div id="ref-Plaud2001" class="csl-entry">
<div class="csl-left-margin">34. </div><div class="csl-right-inline">Plaud B, Debaene B, Donati F. The corrugator supercilii, not the orbicularis oculi, reflects rocuronium neuromuscular blockade at the laryngeal adductor muscles. <em>Anesthesiology</em>. 2001;95(1):96-101. doi:<a href="https://doi.org/10.1097/00000542-200107000-00019">10.1097/00000542-200107000-00019</a></div>
</div>
<div id="ref-Dahaba2002" class="csl-entry">
<div class="csl-left-margin">35. </div><div class="csl-right-inline">Dahaba AA, Klobucar F von, Rehak PH, List WF. The neuromuscular transmission module versus the relaxometer mechanomyograph for neuromuscular block monitoring. <em>Anesth Analg</em>. 2002;94(3):591-6; table of contents. doi:<a href="https://doi.org/10.1097/00000539-200203000-00021">10.1097/00000539-200203000-00021</a></div>
</div>
<div id="ref-Dubois2002" class="csl-entry">
<div class="csl-left-margin">36. </div><div class="csl-right-inline">Dubois PE, Broka SM, Jamart J, Joucken KL. TOF-tube, a new protection for acceleromyography, compared with the TOF-guard/TOF-watch arm board. <em>Acta Anaesthesiol Belg</em>. 2002;53(1):33-38.</div>
</div>
<div id="ref-Gatke2002" class="csl-entry">
<div class="csl-left-margin">37. </div><div class="csl-right-inline">Gätke MR, Viby-Mogensen J, Rosenstock C, Jensen FS, Skovgaard LT. Postoperative muscle paralysis after rocuronium: Less residual block when acceleromyography is used. <em>Acta Anaesthesiol Scand</em>. 2002;46(2):207-213. doi:<a href="https://doi.org/10.1034/j.1399-6576.2002.460216.x">10.1034/j.1399-6576.2002.460216.x</a></div>
</div>
<div id="ref-Kirkegaard2002" class="csl-entry">
<div class="csl-left-margin">38. </div><div class="csl-right-inline">Kirkegaard H, Heier T, Caldwell JE. Efficacy of tactile-guided reversal from cisatracurium-induced neuromuscular block. <em>Anesthesiology</em>. 2002;96(1):45-50. doi:<a href="https://doi.org/10.1097/00000542-200201000-00013">10.1097/00000542-200201000-00013</a></div>
</div>
<div id="ref-Larsen2002" class="csl-entry">
<div class="csl-left-margin">39. </div><div class="csl-right-inline">Larsen PB, Gätke MR, Fredensborg BB, Berg H, Engbaek J, Viby-Mogensen J. Acceleromyography of the orbicularis oculi muscle II: Comparing the orbicularis oculi and adductor pollicis muscles. <em>Acta Anaesthesiol Scand</em>. 2002;46(9):1131-1136. doi:<a href="https://doi.org/10.1034/j.1399-6576.2002.460912.x">10.1034/j.1399-6576.2002.460912.x</a></div>
</div>
<div id="ref-Dotan2003" class="csl-entry">
<div class="csl-left-margin">40. </div><div class="csl-right-inline">Dotan ZA, Hana R, Simon D, Geva D, Pfeffermann RA, Ezri T. The effect of vecuronium is enhanced by a large rather than a modest dose of gentamicin as compared with no preoperative gentamicin. <em>Anesth Analg</em>. 2003;96(3):750-754, table of contents. doi:<a href="https://doi.org/10.1213/01.ane.0000050280.59508.70">10.1213/01.ane.0000050280.59508.70</a></div>
</div>
<div id="ref-Capron2004" class="csl-entry">
<div class="csl-left-margin">41. </div><div class="csl-right-inline">Capron F, Alla F, Hottier C, Meistelman C, Fuchs-Buder T. Can acceleromyography detect low levels of residual paralysis? A probability approach to detect a mechanomyographic train-of-four ratio of 0.9. <em>Anesthesiology</em>. 2004;100(5):1119-1124. doi:<a href="https://doi.org/10.1097/00000542-200405000-00013">10.1097/00000542-200405000-00013</a></div>
</div>
<div id="ref-Cardoso2005" class="csl-entry">
<div class="csl-left-margin">42. </div><div class="csl-right-inline">Cardoso LS, Martins CR, Tardelli MA. Effects of intravenous lidocaine on the pharmacodynamics of rocuronium. <em>Rev Bras Anestesiol</em>. 2005;55(4):371-380. doi:<a href="https://doi.org/10.1590/s0034-70942005000400001">10.1590/s0034-70942005000400001</a></div>
</div>
<div id="ref-Dubois2005" class="csl-entry">
<div class="csl-left-margin">43. </div><div class="csl-right-inline">Dubois PE, Gourdin M, Russell K, Jamart J. Installation of the hand influences acceleromyography measurement. A comparison with mechanomyography during neuromuscular recovery. <em>Acta Anaesthesiol Belg</em>. 2005;56(2):163-166.</div>
</div>
<div id="ref-Kopman2005a" class="csl-entry">
<div class="csl-left-margin">44. </div><div class="csl-right-inline">Kopman AF, Chin W, Cyriac J. Acceleromyography vs. Electromyography: An ipsilateral comparison of the indirectly evoked neuromuscular response to train-of-four stimulation. <em>Acta Anaesthesiol Scand</em>. 2005;49(3):316-322. doi:<a href="https://doi.org/10.1111/j.1399-6576.2005.00643.x">10.1111/j.1399-6576.2005.00643.x</a></div>
</div>
<div id="ref-Motamed2005" class="csl-entry">
<div class="csl-left-margin">45. </div><div class="csl-right-inline">Motamed C, Kirov K, Combes X, Duvaldestin P. Does repetition of post-tetanic count every 3 min during profound relaxation affect accelerographic recovery of atracurium blockade? <em>Acta Anaesthesiol Scand</em>. 2005;49(6):811-814. doi:<a href="https://doi.org/10.1111/j.1399-6576.2005.00688.x">10.1111/j.1399-6576.2005.00688.x</a></div>
</div>
<div id="ref-Samet2005" class="csl-entry">
<div class="csl-left-margin">46. </div><div class="csl-right-inline">Samet A, Capron F, Alla F, Meistelman C, Fuchs-Buder T. Single acceleromyographic train-of-four, 100-hertz tetanus or double-burst stimulation: Which test performs better to detect residual paralysis? <em>Anesthesiology</em>. 2005;102(1):51-56. doi:<a href="https://doi.org/10.1097/00000542-200501000-00011">10.1097/00000542-200501000-00011</a></div>
</div>
<div id="ref-Adamus2006" class="csl-entry">
<div class="csl-left-margin">47. </div><div class="csl-right-inline">Adamus M, Belohlavek R, Koutna J, Vujcikova M, Janaskova E. Cisatracurium vs. Rocuronium: A prospective, comparative, randomized study in adult patients under total intravenous anaesthesia. <em>Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub</em>. 2006;150(2):333-338. doi:<a href="https://doi.org/10.5507/bp.2006.051">10.5507/bp.2006.051</a></div>
</div>
<div id="ref-Capron2006" class="csl-entry">
<div class="csl-left-margin">48. </div><div class="csl-right-inline">Capron F, Fortier LP, Racine S, Donati F. Tactile fade detection with hand or wrist stimulation using train-of-four, double-burst stimulation, 50-hertz tetanus, 100-hertz tetanus, and acceleromyography. <em>Anesth Analg</em>. 2006;102(5):1578-1584. doi:<a href="https://doi.org/10.1213/01.ane.0000204288.24395.38">10.1213/01.ane.0000204288.24395.38</a></div>
</div>
<div id="ref-Sorgenfrei2006" class="csl-entry">
<div class="csl-left-margin">49. </div><div class="csl-right-inline">Sorgenfrei IF, Norrild K, Larsen PB, et al. Reversal of rocuronium-induced neuromuscular block by the selective relaxant binding agent sugammadex: A dose-finding and safety study. <em>Anesthesiology</em>. 2006;104(4):667-674. doi:<a href="https://doi.org/10.1097/00000542-200604000-00009">10.1097/00000542-200604000-00009</a></div>
</div>
<div id="ref-Suzuki2006" class="csl-entry">
<div class="csl-left-margin">50. </div><div class="csl-right-inline">Suzuki T, Masaki G, Ogawa S. Neostigmine-induced reversal of vecuronium in normal weight, overweight and obese female patients. <em>Br J Anaesth</em>. 2006;97(2):160-163. doi:<a href="https://doi.org/10.1093/bja/ael142">10.1093/bja/ael142</a></div>
</div>
<div id="ref-Trager2006" class="csl-entry">
<div class="csl-left-margin">51. </div><div class="csl-right-inline">Trager G, Michaud G, Deschamps S, Hemmerling TM. Comparison of phonomyography, kinemyography and mechanomyography for neuromuscular monitoring. <em>Can J Anaesth</em>. 2006;53(2):130-135. doi:<a href="https://doi.org/10.1007/bf03021816">10.1007/bf03021816</a></div>
</div>
<div id="ref-Boer2007" class="csl-entry">
<div class="csl-left-margin">52. </div><div class="csl-right-inline">Boer HD e, Driessen JJ, Marcus MA, Kerkkamp H, Heeringa M, Klimek M. Reversal of rocuronium-induced (1.2 mg/kg) profound neuromuscular block by sugammadex: A multicenter, dose-finding and safety study. <em>Anesthesiology</em>. 2007;107(2):239-244. doi:<a href="https://doi.org/10.1097/01.anes.0000270722.95764.37">10.1097/01.anes.0000270722.95764.37</a></div>
</div>
<div id="ref-Sacan2007" class="csl-entry">
<div class="csl-left-margin">53. </div><div class="csl-right-inline">Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of rocuronium-induced neuromuscular blockade: A comparison with neostigmine-glycopyrrolate and edrophonium-atropine. <em>Anesth Analg</em>. 2007;104(3):569-574. doi:<a href="https://doi.org/10.1213/01.ane.0000248224.42707.48">10.1213/01.ane.0000248224.42707.48</a></div>
</div>
<div id="ref-Sparr2007" class="csl-entry">
<div class="csl-left-margin">54. </div><div class="csl-right-inline">Sparr HJ, Vermeyen KM, Beaufort AM, et al. Early reversal of profound rocuronium-induced neuromuscular blockade by sugammadex in a randomized multicenter study: Efficacy, safety, and pharmacokinetics. <em>Anesthesiology</em>. 2007;106(5):935-943. doi:<a href="https://doi.org/10.1097/01.anes.0000265152.78943.74">10.1097/01.anes.0000265152.78943.74</a></div>
</div>
<div id="ref-Suy2007" class="csl-entry">
<div class="csl-left-margin">55. </div><div class="csl-right-inline">Suy K, Morias K, Cammu G, et al. Effective reversal of moderate rocuronium- or vecuronium-induced neuromuscular block with sugammadex, a selective relaxant binding agent. <em>Anesthesiology</em>. 2007;106(2):283-288. doi:<a href="https://doi.org/10.1097/00000542-200702000-00016">10.1097/00000542-200702000-00016</a></div>
</div>
<div id="ref-Suzuki2007" class="csl-entry">
<div class="csl-left-margin">56. </div><div class="csl-right-inline">Suzuki T, Mizutani H, Ishikawa K, Miyake E, Saeki S, Ogawa S. Epidurally administered mepivacaine delays recovery of train-of-four ratio from vecuronium-induced neuromuscular block. <em>Br J Anaesth</em>. 2007;99(5):721-725. doi:<a href="https://doi.org/10.1093/bja/aem253">10.1093/bja/aem253</a></div>
</div>
<div id="ref-Flockton2008" class="csl-entry">
<div class="csl-left-margin">57. </div><div class="csl-right-inline">Flockton EA, Mastronardi P, Hunter JM, et al. Reversal of rocuronium-induced neuromuscular block with sugammadex is faster than reversal of cisatracurium-induced block with neostigmine. <em>Br J Anaesth</em>. 2008;100(5):622-630. doi:<a href="https://doi.org/10.1093/bja/aen037">10.1093/bja/aen037</a></div>
</div>
<div id="ref-Jones2008" class="csl-entry">
<div class="csl-left-margin">58. </div><div class="csl-right-inline">Jones RK, Caldwell JE, Brull SJ, Soto RG. Reversal of profound rocuronium-induced blockade with sugammadex: A randomized comparison with neostigmine. <em>Anesthesiology</em>. 2008;109(5):816-824. doi:<a href="https://doi.org/10.1097/ALN.0b013e31818a3fee">10.1097/ALN.0b013e31818a3fee</a></div>
</div>
<div id="ref-Murphy2008" class="csl-entry">
<div class="csl-left-margin">59. </div><div class="csl-right-inline">Murphy GS, Szokol JW, Marymont JH, et al. Intraoperative acceleromyographic monitoring reduces the risk of residual neuromuscular blockade and adverse respiratory events in the postanesthesia care unit. <em>Anesthesiology</em>. 2008;109(3):389-398. doi:<a href="https://doi.org/10.1097/ALN.0b013e318182af3b">10.1097/ALN.0b013e318182af3b</a></div>
</div>
<div id="ref-Puhringer2008" class="csl-entry">
<div class="csl-left-margin">60. </div><div class="csl-right-inline">Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: An international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. <em>Anesthesiology</em>. 2008;109(2):188-197. doi:<a href="https://doi.org/10.1097/ALN.0b013e31817f5bc7">10.1097/ALN.0b013e31817f5bc7</a></div>
</div>
<div id="ref-Staals2008" class="csl-entry">
<div class="csl-left-margin">61. </div><div class="csl-right-inline">Staals LM, Snoeck MM, Driessen JJ, Flockton EA, Heeringa M, Hunter JM. Multicentre, parallel-group, comparative trial evaluating the efficacy and safety of sugammadex in patients with end-stage renal failure or normal renal function. <em>Br J Anaesth</em>. 2008;101(4):492-497. doi:<a href="https://doi.org/10.1093/bja/aen216">10.1093/bja/aen216</a></div>
</div>
<div id="ref-Claudius2009" class="csl-entry">
<div class="csl-left-margin">62. </div><div class="csl-right-inline">Claudius C, Skovgaard LT, Viby-Mogensen J. Is the performance of acceleromyography improved with preload and normalization? A comparison with mechanomyography. <em>Anesthesiology</em>. 2009;110(6):1261-1270. doi:<a href="https://doi.org/10.1097/ALN.0b013e3181a4f239">10.1097/ALN.0b013e3181a4f239</a></div>
</div>
<div id="ref-Dahl2009" class="csl-entry">
<div class="csl-left-margin">63. </div><div class="csl-right-inline">Dahl V, Pendeville PE, Hollmann MW, Heier T, Abels EA, Blobner M. Safety and efficacy of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in cardiac patients undergoing noncardiac surgery. <em>Eur J Anaesthesiol</em>. 2009;26(10):874-884. doi:<a href="https://doi.org/10.1097/EJA.0b013e32832c605b">10.1097/EJA.0b013e32832c605b</a></div>
</div>
<div id="ref-Plaud2009" class="csl-entry">
<div class="csl-left-margin">64. </div><div class="csl-right-inline">Plaud B, Meretoja O, Hofmockel R, et al. Reversal of rocuronium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. <em>Anesthesiology</em>. 2009;110(2):284-294. doi:<a href="https://doi.org/10.1097/ALN.0b013e318194caaa">10.1097/ALN.0b013e318194caaa</a></div>
</div>
<div id="ref-Suzuki2009" class="csl-entry">
<div class="csl-left-margin">65. </div><div class="csl-right-inline">Suzuki T, Mizutani H, Miyake E, Fukano N, Saeki S, Ogawa S. Infusion requirements and reversibility of rocuronium at the corrugator supercilii and adductor pollicis muscles. <em>Acta Anaesthesiol Scand</em>. 2009;53(10):1336-1340. doi:<a href="https://doi.org/10.1111/j.1399-6576.2009.02073.x">10.1111/j.1399-6576.2009.02073.x</a></div>
</div>
<div id="ref-White2009" class="csl-entry">
<div class="csl-left-margin">66. </div><div class="csl-right-inline">White PF, Tufanogullari B, Sacan O, et al. The effect of residual neuromuscular blockade on the speed of reversal with sugammadex. <em>Anesth Analg</em>. 2009;108(3):846-851. doi:<a href="https://doi.org/10.1213/ane.0b013e31818a9932">10.1213/ane.0b013e31818a9932</a></div>
</div>
<div id="ref-Blobner2010" class="csl-entry">
<div class="csl-left-margin">67. </div><div class="csl-right-inline">Blobner M, Eriksson LI, Scholz J, Motsch J, Della Rocca G, Prins ME. Reversal of rocuronium-induced neuromuscular blockade with sugammadex compared with neostigmine during sevoflurane anaesthesia: Results of a randomised, controlled trial. <em>Eur J Anaesthesiol</em>. 2010;27(10):874-881. doi:<a href="https://doi.org/10.1097/EJA.0b013e32833d56b7">10.1097/EJA.0b013e32833d56b7</a></div>
</div>
<div id="ref-Czarnetzki2010" class="csl-entry">
<div class="csl-left-margin">68. </div><div class="csl-right-inline">Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Time course of rocuronium-induced neuromuscular block after pre-treatment with magnesium sulphate: A randomised study. <em>Acta Anaesthesiol Scand</em>. 2010;54(3):299-306. doi:<a href="https://doi.org/10.1111/j.1399-6576.2009.02160.x">10.1111/j.1399-6576.2009.02160.x</a></div>
</div>
<div id="ref-Drobnik2010" class="csl-entry">
<div class="csl-left-margin">69. </div><div class="csl-right-inline">Drobnik L, Sparr HJ, Thörn SE, et al. A randomized simultaneous comparison of acceleromyography with a peripheral nerve stimulator for assessing reversal of rocuronium-induced neuromuscular blockade with sugammadex. <em>Eur J Anaesthesiol</em>. 2010;27(10):866-873. doi:<a href="https://doi.org/10.1097/EJA.0b013e32833b1b85">10.1097/EJA.0b013e32833b1b85</a></div>
</div>
<div id="ref-Fuchs-Buder2010" class="csl-entry">
<div class="csl-left-margin">70. </div><div class="csl-right-inline">Fuchs-Buder T, Meistelman C, Alla F, Grandjean A, Wuthrich Y, Donati F. Antagonism of low degrees of atracurium-induced neuromuscular blockade: Dose-effect relationship for neostigmine. <em>Anesthesiology</em>. 2010;112(1):34-40. doi:<a href="https://doi.org/10.1097/ALN.0b013e3181c53863">10.1097/ALN.0b013e3181c53863</a></div>
</div>
<div id="ref-Hans2010" class="csl-entry">
<div class="csl-left-margin">71. </div><div class="csl-right-inline">Hans GA, Defresne A, Ki B, et al. Effect of an intravenous infusion of lidocaine on cisatracurium-induced neuromuscular block duration: A randomized-controlled trial. <em>Acta Anaesthesiol Scand</em>. 2010;54(10):1192-1196. doi:<a href="https://doi.org/10.1111/j.1399-6576.2010.02304.x">10.1111/j.1399-6576.2010.02304.x</a></div>
</div>
<div id="ref-Khuenl-Brady2010" class="csl-entry">
<div class="csl-left-margin">72. </div><div class="csl-right-inline">Khuenl-Brady KS, Wattwil M, Vanacker BF, Lora-Tamayo JI, Rietbergen H, Alvarez-Gómez JA. Sugammadex provides faster reversal of vecuronium-induced neuromuscular blockade compared with neostigmine: A multicenter, randomized, controlled trial. <em>Anesth Analg</em>. 2010;110(1):64-73. doi:<a href="https://doi.org/10.1213/ane.0b013e3181ac53c3">10.1213/ane.0b013e3181ac53c3</a></div>
</div>
<div id="ref-Lederer2010" class="csl-entry">
<div class="csl-left-margin">73. </div><div class="csl-right-inline">Lederer W, Reiner T, Khuenl-Brady KS. Neostigmine injected 5 minutes after low-dose rocuronium accelerates the recovery of neuromuscular function. <em>J Clin Anesth</em>. 2010;22(6):420-424. doi:<a href="https://doi.org/10.1016/j.jclinane.2009.10.014">10.1016/j.jclinane.2009.10.014</a></div>
</div>
<div id="ref-Lemmens2010" class="csl-entry">
<div class="csl-left-margin">74. </div><div class="csl-right-inline">Lemmens HJ, El-Orbany MI, Berry J, Morte JB, Jr. M. Reversal of profound vecuronium-induced neuromuscular block under sevoflurane anesthesia: Sugammadex versus neostigmine. <em>BMC Anesthesiol</em>. 2010;10:15. doi:<a href="https://doi.org/10.1186/1471-2253-10-15">10.1186/1471-2253-10-15</a></div>
</div>
<div id="ref-Puhringer2010" class="csl-entry">
<div class="csl-left-margin">75. </div><div class="csl-right-inline">Pühringer FK, Gordon M, Demeyer I, et al. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: A dose-response relationship. <em>Br J Anaesth</em>. 2010;105(5):610-619. doi:<a href="https://doi.org/10.1093/bja/aeq226">10.1093/bja/aeq226</a></div>
</div>
<div id="ref-Schaller2010" class="csl-entry">
<div class="csl-left-margin">76. </div><div class="csl-right-inline">Schaller SJ, Fink H, Ulm K, Blobner M. Sugammadex and neostigmine dose-finding study for reversal of shallow residual neuromuscular block. <em>Anesthesiology</em>. 2010;113(5):1054-1060. doi:<a href="https://doi.org/10.1097/ALN.0b013e3181f4182a">10.1097/ALN.0b013e3181f4182a</a></div>
</div>
<div id="ref-Yip2010" class="csl-entry">
<div class="csl-left-margin">77. </div><div class="csl-right-inline">Yip PC, Hannam JA, Cameron AJ, Campbell D. Incidence of residual neuromuscular blockade in a post-anaesthetic care unit. <em>Anaesth Intensive Care</em>. 2010;38(1):91-95. doi:<a href="https://doi.org/10.1177/0310057x1003800116">10.1177/0310057x1003800116</a></div>
</div>
<div id="ref-Adamus2011" class="csl-entry">
<div class="csl-left-margin">78. </div><div class="csl-right-inline">Adamus M, Hrabalek L, Wanek T, Gabrhelik T, Zapletalova J. Intraoperative reversal of neuromuscular block with sugammadex or neostigmine during extreme lateral interbody fusion, a novel technique for spine surgery. <em>J Anesth</em>. 2011;25(5):716-720. doi:<a href="https://doi.org/10.1007/s00540-011-1209-1">10.1007/s00540-011-1209-1</a></div>
</div>
<div id="ref-Illman2011" class="csl-entry">
<div class="csl-left-margin">79. </div><div class="csl-right-inline">Illman HL, Laurila P, Antila H, Meretoja OA, Alahuhta S, Olkkola KT. The duration of residual neuromuscular block after administration of neostigmine or sugammadex at two visible twitches during train-of-four monitoring. <em>Anesth Analg</em>. 2011;112(1):63-68. doi:<a href="https://doi.org/10.1213/ANE.0b013e3181fdf889">10.1213/ANE.0b013e3181fdf889</a></div>
</div>
<div id="ref-Jeong2011" class="csl-entry">
<div class="csl-left-margin">80. </div><div class="csl-right-inline">Jeong SJ, Han JI, Baik HJ, Lee H, Lee GY, Kim JH. The effect of pyridostigmine on bispectral index during recovery from sevoflurane anesthesia. <em>Korean J Anesthesiol</em>. 2011;61(6):460-464. doi:<a href="https://doi.org/10.4097/kjae.2011.61.6.460">10.4097/kjae.2011.61.6.460</a></div>
</div>
<div id="ref-Lee2011" class="csl-entry">
<div class="csl-left-margin">81. </div><div class="csl-right-inline">Lee HJ, Kim KS, Shim JC, Yoon SW. A comparison of the accuracy of ulnar versus median nerve stimulation for neuromuscular monitoring. <em>Korean J Anesthesiol</em>. 2011;60(5):334-338. doi:<a href="https://doi.org/10.4097/kjae.2011.60.5.334">10.4097/kjae.2011.60.5.334</a></div>
</div>
<div id="ref-McDonagh2011" class="csl-entry">
<div class="csl-left-margin">82. </div><div class="csl-right-inline">McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy, safety, and pharmacokinetics of sugammadex for the reversal of rocuronium-induced neuromuscular blockade in elderly patients. <em>Anesthesiology</em>. 2011;114(2):318-329. doi:<a href="https://doi.org/10.1097/ALN.0b013e3182065c36">10.1097/ALN.0b013e3182065c36</a></div>
</div>
<div id="ref-Murphy2011" class="csl-entry">
<div class="csl-left-margin">83. </div><div class="csl-right-inline">Murphy GS, Szokol JW, Avram MJ, et al. Intraoperative acceleromyography monitoring reduces symptoms of muscle weakness and improves quality of recovery in the early postoperative period. <em>Anesthesiology</em>. 2011;115(5):946-954. doi:<a href="https://doi.org/10.1097/ALN.0b013e3182342840">10.1097/ALN.0b013e3182342840</a></div>
</div>
<div id="ref-Sauer2011" class="csl-entry">
<div class="csl-left-margin">84. </div><div class="csl-right-inline">Sauer M, Stahn A, Soltesz S, Noeldge-Schomburg G, Mencke T. The influence of residual neuromuscular block on the incidence of critical respiratory events. A randomised, prospective, placebo-controlled trial. <em>Eur J Anaesthesiol</em>. 2011;28(12):842-848. doi:<a href="https://doi.org/10.1097/EJA.0b013e328345cd11">10.1097/EJA.0b013e328345cd11</a></div>
</div>
<div id="ref-Schreiber2011" class="csl-entry">
<div class="csl-left-margin">85. </div><div class="csl-right-inline">Schreiber JU, Mucha E, Fuchs-Buder T. Acceleromyography to assess neuromuscular recovery: Is calibration before measurement mandatory? <em>Acta Anaesthesiol Scand</em>. 2011;55(3):328-331. doi:<a href="https://doi.org/10.1111/j.1399-6576.2010.02378.x">10.1111/j.1399-6576.2010.02378.x</a></div>
</div>
<div id="ref-Staals2011" class="csl-entry">
<div class="csl-left-margin">86. </div><div class="csl-right-inline">Staals LM, Driessen JJ, Van Egmond J, et al. Train-of-four ratio recovery often precedes twitch recovery when neuromuscular block is reversed by sugammadex. <em>Acta Anaesthesiol Scand</em>. 2011;55(6):700-707. doi:<a href="https://doi.org/10.1111/j.1399-6576.2011.02448.x">10.1111/j.1399-6576.2011.02448.x</a></div>
</div>
<div id="ref-Cammu2012" class="csl-entry">
<div class="csl-left-margin">87. </div><div class="csl-right-inline">Cammu GV, Smet V, De Jongh K, Vandeput D. A prospective, observational study comparing postoperative residual curarisation and early adverse respiratory events in patients reversed with neostigmine or sugammadex or after apparent spontaneous recovery. <em>Anaesth Intensive Care</em>. 2012;40(6):999-1006. doi:<a href="https://doi.org/10.1177/0310057x1204000611">10.1177/0310057x1204000611</a></div>
</div>
<div id="ref-Czarnetzki2012" class="csl-entry">
<div class="csl-left-margin">88. </div><div class="csl-right-inline">Czarnetzki C, Lysakowski C, Elia N, Tramèr MR. Intravenous lidocaine has no impact on rocuronium-induced neuromuscular block. Randomised study. <em>Acta Anaesthesiol Scand</em>. 2012;56(4):474-481. doi:<a href="https://doi.org/10.1111/j.1399-6576.2011.02625.x">10.1111/j.1399-6576.2011.02625.x</a></div>
</div>
<div id="ref-Gaszynski2012" class="csl-entry">
<div class="csl-left-margin">89. </div><div class="csl-right-inline">Gaszynski T, Szewczyk T, Gaszynski W. Randomized comparison of sugammadex and neostigmine for reversal of rocuronium-induced muscle relaxation in morbidly obese undergoing general anaesthesia. <em>Br J Anaesth</em>. 2012;108(2):236-239. doi:<a href="https://doi.org/10.1093/bja/aer330">10.1093/bja/aer330</a></div>
</div>
<div id="ref-Geldner2012" class="csl-entry">
<div class="csl-left-margin">90. </div><div class="csl-right-inline">Geldner G, Niskanen M, Laurila P, et al. A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery. <em>Anaesthesia</em>. 2012;67(9):991-998. doi:<a href="https://doi.org/10.1111/j.1365-2044.2012.07197.x">10.1111/j.1365-2044.2012.07197.x</a></div>
</div>
<div id="ref-Grosse-Sundrup2012" class="csl-entry">
<div class="csl-left-margin">91. </div><div class="csl-right-inline">Grosse-Sundrup M, Henneman JP, Sandberg WS, et al. Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: Prospective propensity score matched cohort study. <em>Bmj</em>. 2012;345:e6329. doi:<a href="https://doi.org/10.1136/bmj.e6329">10.1136/bmj.e6329</a></div>
</div>
<div id="ref-Kim2012" class="csl-entry">
<div class="csl-left-margin">92. </div><div class="csl-right-inline">Kim SH, So KY, Jung KT. Effect of magnesium sulfate pretreatment on onset and recovery characteristics of cisatracurium. <em>Korean J Anesthesiol</em>. 2012;62(6):518-523. doi:<a href="https://doi.org/10.4097/kjae.2012.62.6.518">10.4097/kjae.2012.62.6.518</a></div>
</div>
<div id="ref-Phillips2012" class="csl-entry">
<div class="csl-left-margin">93. </div><div class="csl-right-inline">Phillips S, Stewart PA, Freelander N, Heller G. Comparison of evoked electromyography in three muscles of the hand during recovery from non-depolarising neuromuscular blockade. <em>Anaesth Intensive Care</em>. 2012;40(4):690-696. doi:<a href="https://doi.org/10.1177/0310057x1204000416">10.1177/0310057x1204000416</a></div>
</div>
<div id="ref-Thilen2012" class="csl-entry">
<div class="csl-left-margin">94. </div><div class="csl-right-inline">Thilen SR, Hansen BE, Ramaiah R, Kent CD, Treggiari MM, Bhananker SM. Intraoperative neuromuscular monitoring site and residual paralysis. <em>Anesthesiology</em>. 2012;117(5):964-972. doi:<a href="https://doi.org/10.1097/ALN.0b013e31826f8fdd">10.1097/ALN.0b013e31826f8fdd</a></div>
</div>
<div id="ref-Watts2012" class="csl-entry">
<div class="csl-left-margin">95. </div><div class="csl-right-inline">Watts RW, London JA, Wijk RM van, Lui YL. The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital. <em>Anaesth Intensive Care</em>. 2012;40(2):333-339. doi:<a href="https://doi.org/10.1177/0310057x1204000218">10.1177/0310057x1204000218</a></div>
</div>
<div id="ref-Alkenany2013" class="csl-entry">
<div class="csl-left-margin">96. </div><div class="csl-right-inline">Alkenany HM. Evaluation of cyclodextrin (sugammadex) for reversal of intense neuromuscular block of rocuronium and vecuronium, experimental and clinical studies. <em>J Egypt Soc Parasitol</em>. 2013;43(3):705-714. doi:<a href="https://doi.org/10.12816/0006427">10.12816/0006427</a></div>
</div>
<div id="ref-Carron2013" class="csl-entry">
<div class="csl-left-margin">97. </div><div class="csl-right-inline">Carron M, Veronese S, Foletto M, Ori C. Sugammadex allows fast-track bariatric surgery. <em>Obes Surg</em>. 2013;23(10):1558-1563. doi:<a href="https://doi.org/10.1007/s11695-013-0926-y">10.1007/s11695-013-0926-y</a></div>
</div>
<div id="ref-Della-Rocca2013" class="csl-entry">
<div class="csl-left-margin">98. </div><div class="csl-right-inline">Della Rocca G, Pompei L, Pagan DEPC, et al. Reversal of rocuronium induced neuromuscular block with sugammadex or neostigmine: A large observational study. <em>Acta Anaesthesiol Scand</em>. 2013;57(9):1138-1145. doi:<a href="https://doi.org/10.1111/aas.12155">10.1111/aas.12155</a></div>
</div>
<div id="ref-Fuchs-Buder2013" class="csl-entry">
<div class="csl-left-margin">99. </div><div class="csl-right-inline">Fuchs-Buder T, Baumann C, De Guis J, Guerci P, Meistelman C. Low-dose neostigmine to antagonise shallow atracurium neuromuscular block during inhalational anaesthesia: A randomised controlled trial. <em>Eur J Anaesthesiol</em>. 2013;30(10):594-598. doi:<a href="https://doi.org/10.1097/EJA.0b013e3283631652">10.1097/EJA.0b013e3283631652</a></div>
</div>
<div id="ref-Kadoi2013" class="csl-entry">
<div class="csl-left-margin">100. </div><div class="csl-right-inline">Kadoi Y, Nishida A, Saito S. Recovery time after sugammadex reversal of rocuronium-induced muscle relaxation for electroconvulsive therapy is independent of cardiac output in both young and elderly patients. <em>J ect</em>. 2013;29(1):33-36. doi:<a href="https://doi.org/10.1097/YCT.0b013e31826cf348">10.1097/YCT.0b013e31826cf348</a></div>
</div>
<div id="ref-Kotake2013" class="csl-entry">
<div class="csl-left-margin">101. </div><div class="csl-right-inline">Kotake Y, Ochiai R, Suzuki T, et al. Reversal with sugammadex in the absence of monitoring did not preclude residual neuromuscular block. <em>Anesth Analg</em>. 2013;117(2):345-351. doi:<a href="https://doi.org/10.1213/ANE.0b013e3182999672">10.1213/ANE.0b013e3182999672</a></div>
</div>
<div id="ref-Ledowski2013" class="csl-entry">
<div class="csl-left-margin">102. </div><div class="csl-right-inline">Ledowski T, Hillyard S, O’Dea B, Archer R, Vilas-Boas F, Kyle B. Introduction of sugammadex as standard reversal agent: Impact on the incidence of residual neuromuscular blockade and postoperative patient outcome. <em>Indian J Anaesth</em>. 2013;57(1):46-51. doi:<a href="https://doi.org/10.4103/0019-5049.108562">10.4103/0019-5049.108562</a></div>
</div>
<div id="ref-Liang2013" class="csl-entry">
<div class="csl-left-margin">103. </div><div class="csl-right-inline">Liang SS, Stewart PA, Phillips S. An ipsilateral comparison of acceleromyography and electromyography during recovery from nondepolarizing neuromuscular block under general anesthesia in humans. <em>Anesth Analg</em>. 2013;117(2):373-379. doi:<a href="https://doi.org/10.1213/ANE.0b013e3182937fc4">10.1213/ANE.0b013e3182937fc4</a></div>
</div>
<div id="ref-Murphy2013" class="csl-entry">
<div class="csl-left-margin">104. </div><div class="csl-right-inline">Murphy GS, Szokol JW, Avram MJ, et al. Postoperative residual neuromuscular blockade is associated with impaired clinical recovery. <em>Anesth Analg</em>. 2013;117(1):133-141. doi:<a href="https://doi.org/10.1213/ANE.0b013e3182742e75">10.1213/ANE.0b013e3182742e75</a></div>
</div>
<div id="ref-Nitahara2013" class="csl-entry">
<div class="csl-left-margin">105. </div><div class="csl-right-inline">Nitahara K, Sugi Y, Shigematsu K, Haraga I, Abe S, Higa K. Recovery of train-of-four ratio to 0.70 and 0.90 is delayed in type 2 diabetes with vecuronium-induced neuromuscular block. <em>Eur J Anaesthesiol</em>. 2013;30(2):80-84. doi:<a href="https://doi.org/10.1097/EJA.0b013e32835b9d9b">10.1097/EJA.0b013e32835b9d9b</a></div>
</div>
<div id="ref-Norton2013" class="csl-entry">
<div class="csl-left-margin">106. </div><div class="csl-right-inline">Norton M, Xará D, Parente D, Barbosa M, Abelha FJ. Residual neuromuscular block as a risk factor for critical respiratory events in the post anesthesia care unit. <em>Rev Esp Anestesiol Reanim</em>. 2013;60(4):190-196. doi:<a href="https://doi.org/10.1016/j.redar.2012.12.011">10.1016/j.redar.2012.12.011</a></div>
</div>
<div id="ref-Pongracz2013" class="csl-entry">
<div class="csl-left-margin">107. </div><div class="csl-right-inline">Pongrácz A, Szatmári S, Nemes R, Fülesdi B, Tassonyi E. Reversal of neuromuscular blockade with sugammadex at the reappearance of four twitches to train-of-four stimulation. <em>Anesthesiology</em>. 2013;119(1):36-42. doi:<a href="https://doi.org/10.1097/ALN.0b013e318297ce95">10.1097/ALN.0b013e318297ce95</a></div>
</div>
<div id="ref-Sanfilippo2013" class="csl-entry">
<div class="csl-left-margin">108. </div><div class="csl-right-inline">Sanfilippo M, Alessandri F, Wefki Abdelgawwad Shousha AA, Sabba A, Cutolo A. Sugammadex and ideal body weight in bariatric surgery. <em>Anesthesiol Res Pract</em>. 2013;2013:389782. doi:<a href="https://doi.org/10.1155/2013/389782">10.1155/2013/389782</a></div>
</div>
<div id="ref-Quillfeldt2013" class="csl-entry">
<div class="csl-left-margin">109. </div><div class="csl-right-inline">Quillfeldt S von, Föhre B, Andrees N, et al. Rocuronium reversed by sugammadex versus mivacurium during high-risk eye surgery: An institutional anaesthetic practice evaluation. <em>J Int Med Res</em>. 2013;41(5):1740-1751. doi:<a href="https://doi.org/10.1177/0300060513489476">10.1177/0300060513489476</a></div>
</div>
<div id="ref-Woo2013" class="csl-entry">
<div class="csl-left-margin">110. </div><div class="csl-right-inline">Woo T, Kim KS, Shim YH, et al. Sugammadex versus neostigmine reversal of moderate rocuronium-induced neuromuscular blockade in korean patients. <em>Korean J Anesthesiol</em>. 2013;65(6):501-507. doi:<a href="https://doi.org/10.4097/kjae.2013.65.6.501">10.4097/kjae.2013.65.6.501</a></div>
</div>
<div id="ref-Amorim2014" class="csl-entry">
<div class="csl-left-margin">111. </div><div class="csl-right-inline">Amorim P, Lagarto F, Gomes B, et al. Neostigmine vs. Sugammadex: Observational cohort study comparing the quality of recovery using the postoperative quality recovery scale. <em>Acta Anaesthesiol Scand</em>. 2014;58(9):1101-1110. doi:<a href="https://doi.org/10.1111/aas.12389">10.1111/aas.12389</a></div>
</div>
<div id="ref-Czarnetzki2014" class="csl-entry">
<div class="csl-left-margin">112. </div><div class="csl-right-inline">Czarnetzki C, Tassonyi E, Lysakowski C, Elia N, Tramèr MR. Efficacy of sugammadex for the reversal of moderate and deep rocuronium-induced neuromuscular block in patients pretreated with intravenous magnesium: A randomized controlled trial. <em>Anesthesiology</em>. 2014;121(1):59-67. doi:<a href="https://doi.org/10.1097/aln.0000000000000204">10.1097/aln.0000000000000204</a></div>
</div>
<div id="ref-Fujita2014" class="csl-entry">
<div class="csl-left-margin">113. </div><div class="csl-right-inline">Fujita A, Ishibe N, Yoshihara T, et al. Rapid reversal of neuromuscular blockade by sugammadex after continuous infusion of rocuronium in patients with liver dysfunction undergoing hepatic surgery. <em>Acta Anaesthesiol Taiwan</em>. 2014;52(2):54-58. doi:<a href="https://doi.org/10.1016/j.aat.2014.04.007">10.1016/j.aat.2014.04.007</a></div>
</div>
<div id="ref-Hudson2014" class="csl-entry">
<div class="csl-left-margin">114. </div><div class="csl-right-inline">Hudson ME, Rietbergen H, Chelly JE. Sugammadex is effective in reversing rocuronium in the presence of antibiotics. <em>BMC Anesthesiol</em>. 2014;14:69. doi:<a href="https://doi.org/10.1186/1471-2253-14-69">10.1186/1471-2253-14-69</a></div>
</div>
<div id="ref-Llaurado2014" class="csl-entry">
<div class="csl-left-margin">115. </div><div class="csl-right-inline">Llauradó S, Sabaté A, Ferreres E, Camprubı́ I, Cabrera A. Postoperative respiratory outcomes in laparoscopic bariatric surgery: Comparison of a prospective group of patients whose neuromuscular blockade was reverted with sugammadex and a historical one reverted with neostigmine. <em>Rev Esp Anestesiol Reanim</em>. 2014;61(10):565-570. doi:<a href="https://doi.org/10.1016/j.redar.2013.11.009">10.1016/j.redar.2013.11.009</a></div>
</div>
<div id="ref-Martini2014" class="csl-entry">
<div class="csl-left-margin">116. </div><div class="csl-right-inline">Martini CH, Boon M, Bevers RF, Aarts LP, Dahan A. Evaluation of surgical conditions during laparoscopic surgery in patients with moderate vs deep neuromuscular block. <em>Br J Anaesth</em>. 2014;112(3):498-505. doi:<a href="https://doi.org/10.1093/bja/aet377">10.1093/bja/aet377</a></div>
</div>
<div id="ref-Ozgun2014" class="csl-entry">
<div class="csl-left-margin">117. </div><div class="csl-right-inline">Ozgün C, Cakan T, Baltacı B, Başar H. Comparison of reversal and adverse effects of sugammadex and combination of - anticholinergic-anticholinesterase agents in pediatric patients. <em>J Res Med Sci</em>. 2014;19(8):762-768.</div>
</div>
<div id="ref-Stewart2014" class="csl-entry">
<div class="csl-left-margin">118. </div><div class="csl-right-inline">Stewart PA, Freelander N, Liang S, Heller G, Phillips S. Comparison of electromyography and kinemyography during recovery from non-depolarising neuromuscular blockade. <em>Anaesth Intensive Care</em>. 2014;42(3):378-384. doi:<a href="https://doi.org/10.1177/0310057x1404200316">10.1177/0310057x1404200316</a></div>
</div>
<div id="ref-Todd2014" class="csl-entry">
<div class="csl-left-margin">119. </div><div class="csl-right-inline">Todd MM, Hindman BJ, King BJ. The implementation of quantitative electromyographic neuromuscular monitoring in an academic anesthesia department. <em>Anesth Analg</em>. 2014;119(2):323-331. doi:<a href="https://doi.org/10.1213/ane.0000000000000261">10.1213/ane.0000000000000261</a></div>
</div>
<div id="ref-Wu2014" class="csl-entry">
<div class="csl-left-margin">120. </div><div class="csl-right-inline">Wu X, Oerding H, Liu J, et al. Rocuronium blockade reversal with sugammadex vs. Neostigmine: Randomized study in chinese and caucasian subjects. <em>BMC Anesthesiol</em>. 2014;14:53. doi:<a href="https://doi.org/10.1186/1471-2253-14-53">10.1186/1471-2253-14-53</a></div>
</div>
<div id="ref-Brueckmann2015" class="csl-entry">
<div class="csl-left-margin">121. </div><div class="csl-right-inline">Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: A randomized, controlled study. <em>Br J Anaesth</em>. 2015;115(5):743-751. doi:<a href="https://doi.org/10.1093/bja/aev104">10.1093/bja/aev104</a></div>
</div>
<div id="ref-Cheong2015" class="csl-entry">
<div class="csl-left-margin">122. </div><div class="csl-right-inline">Cheong SH, Ki S, Lee J, et al. The combination of sugammadex and neostigmine can reduce the dosage of sugammadex during recovery from the moderate neuromuscular blockade. <em>Korean J Anesthesiol</em>. 2015;68(6):547-555. doi:<a href="https://doi.org/10.4097/kjae.2015.68.6.547">10.4097/kjae.2015.68.6.547</a></div>
</div>
<div id="ref-Souza2015" class="csl-entry">
<div class="csl-left-margin">123. </div><div class="csl-right-inline">Souza CM e, Tardelli MA, Tedesco H, et al. Efficacy and safety of sugammadex in the reversal of deep neuromuscular blockade induced by rocuronium in patients with end-stage renal disease: A comparative prospective clinical trial. <em>Eur J Anaesthesiol</em>. 2015;32(10):681-686. doi:<a href="https://doi.org/10.1097/eja.0000000000000312">10.1097/eja.0000000000000312</a></div>
</div>
<div id="ref-Germano-Filho2015" class="csl-entry">
<div class="csl-left-margin">124. </div><div class="csl-right-inline">Germano Filho PA, Cavalcanti IL, Barrucand L, Verçosa N. Effect of magnesium sulphate on sugammadex reversal time for neuromuscular blockade: A randomised controlled study. <em>Anaesthesia</em>. 2015;70(8):956-961. doi:<a href="https://doi.org/10.1111/anae.12987">10.1111/anae.12987</a></div>
</div>
<div id="ref-Ghoneim2015" class="csl-entry">
<div class="csl-left-margin">125. </div><div class="csl-right-inline">Ghoneim AA, El Beltagy MA. Comparative study between sugammadex and neostigmine in neurosurgical anesthesia in pediatric patients. <em>Saudi J Anaesth</em>. 2015;9(3):247-252. doi:<a href="https://doi.org/10.4103/1658-354x.154696">10.4103/1658-354x.154696</a></div>
</div>
<div id="ref-Joshi2015" class="csl-entry">
<div class="csl-left-margin">126. </div><div class="csl-right-inline">Joshi SB, Upadhyaya KV, Manjuladevi M. Comparison of neostigmine induced reversal of vecuronium in normal weight, overweight and obese female patients. <em>Indian J Anaesth</em>. 2015;59(3):165-170. doi:<a href="https://doi.org/10.4103/0019-5049.153038">10.4103/0019-5049.153038</a></div>
</div>
<div id="ref-Karwacki2015" class="csl-entry">
<div class="csl-left-margin">127. </div><div class="csl-right-inline">Karwacki Z, Niewiadomski S, Rzaska M. The use of sugammadex for the reversal of vecuronium-induced neuromuscular block following intracranial surgery. <em>Anaesthesiol Intensive Ther</em>. 2015;47(4):297-302. doi:<a href="https://doi.org/10.5603/ait.2015.0042">10.5603/ait.2015.0042</a></div>
</div>
<div id="ref-Koyuncu2015" class="csl-entry">
<div class="csl-left-margin">128. </div><div class="csl-right-inline">Koyuncu O, Turhanoglu S, Ozbakis Akkurt C, et al. Comparison of sugammadex and conventional reversal on postoperative nausea and vomiting: A randomized, blinded trial. <em>J Clin Anesth</em>. 2015;27(1):51-56. doi:<a href="https://doi.org/10.1016/j.jclinane.2014.08.010">10.1016/j.jclinane.2014.08.010</a></div>
</div>
<div id="ref-Ledowski2015" class="csl-entry">
<div class="csl-left-margin">129. </div><div class="csl-right-inline">Ledowski T, O’Dea B, Meyerkort L, Hegarty M, Ungern-Sternberg BS von. Postoperative residual neuromuscular paralysis at an australian tertiary children’s hospital. <em>Anesthesiol Res Pract</em>. 2015;2015:410248. doi:<a href="https://doi.org/10.1155/2015/410248">10.1155/2015/410248</a></div>
</div>
<div id="ref-Lee2015" class="csl-entry">
<div class="csl-left-margin">130. </div><div class="csl-right-inline">Lee HJ, Kim KS, Jeong JS, Kim KN, Lee BC. The influence of mild hypothermia on reversal of rocuronium-induced deep neuromuscular block with sugammadex. <em>BMC Anesthesiol</em>. 2015;15:7. doi:<a href="https://doi.org/10.1186/1471-2253-15-7">10.1186/1471-2253-15-7</a></div>
</div>
<div id="ref-McLean2015" class="csl-entry">
<div class="csl-left-margin">131. </div><div class="csl-right-inline">McLean DJ, Diaz-Gil D, Farhan HN, Ladha KS, Kurth T, Eikermann M. Dose-dependent association between intermediate-acting neuromuscular-blocking agents and postoperative respiratory complications. <em>Anesthesiology</em>. 2015;122(6):1201-1213. doi:<a href="https://doi.org/10.1097/aln.0000000000000674">10.1097/aln.0000000000000674</a></div>
</div>
<div id="ref-Panhuizen2015" class="csl-entry">
<div class="csl-left-margin">132. </div><div class="csl-right-inline">Panhuizen IF, Gold SJ, Buerkle C, et al. Efficacy, safety and pharmacokinetics of sugammadex 4 mg kg-1 for reversal of deep neuromuscular blockade in patients with severe renal impairment. <em>Br J Anaesth</em>. 2015;114(5):777-784. doi:<a href="https://doi.org/10.1093/bja/aet586">10.1093/bja/aet586</a></div>
</div>
<div id="ref-Raft2015" class="csl-entry">
<div class="csl-left-margin">133. </div><div class="csl-right-inline">Raft J, Guerci P, Harter V, Fuchs-Buder T, Meistelman C. Biological evaluation of the effect of sugammadex on hemostasis and bleeding. <em>Korean J Anesthesiol</em>. 2015;68(1):17-21. doi:<a href="https://doi.org/10.4097/kjae.2015.68.1.17">10.4097/kjae.2015.68.1.17</a></div>
</div>
<div id="ref-Rahe-Meyer2015" class="csl-entry">
<div class="csl-left-margin">134. </div><div class="csl-right-inline">Rahe-Meyer N, Berger C, Wittmann M, et al. Recovery from prolonged deep rocuronium-induced neuromuscular blockade: A randomized comparison of sugammadex reversal with spontaneous recovery. <em>Anaesthesist</em>. 2015;64(7):506-512. doi:<a href="https://doi.org/10.1007/s00101-015-0048-0">10.1007/s00101-015-0048-0</a></div>
</div>
<div id="ref-Song2015" class="csl-entry">
<div class="csl-left-margin">135. </div><div class="csl-right-inline">Song IA, Seo KS, Oh AY, et al. Timing of reversal with respect to three nerve stimulator end-points from cisatracurium-induced neuromuscular block. <em>Anaesthesia</em>. 2015;70(7):797-802. doi:<a href="https://doi.org/10.1111/anae.13044">10.1111/anae.13044</a></div>
</div>
<div id="ref-Tassonyi2015" class="csl-entry">
<div class="csl-left-margin">136. </div><div class="csl-right-inline">Tassonyi E, Pongrácz A, Nemes R, Asztalos L, Lengyel S, Fülesdi B. Reversal of pipecuronium-induced moderate neuromuscular block with sugammadex in the presence of a sevoflurane anesthetic: A randomized trial. <em>Anesth Analg</em>. 2015;121(2):373-380. doi:<a href="https://doi.org/10.1213/ane.0000000000000766">10.1213/ane.0000000000000766</a></div>
</div>
<div id="ref-Unal2015" class="csl-entry">
<div class="csl-left-margin">137. </div><div class="csl-right-inline">Ünal DY, Baran İ, Mutlu M, Ural G, Akkaya T, Özlü O. Comparison of sugammadex versus neostigmine costs and respiratory complications in patients with obstructive sleep apnoea. <em>Turk J Anaesthesiol Reanim</em>. 2015;43(6):387-395. doi:<a href="https://doi.org/10.5152/tjar.2015.35682">10.5152/tjar.2015.35682</a></div>
</div>
<div id="ref-Yamamoto2015" class="csl-entry">
<div class="csl-left-margin">138. </div><div class="csl-right-inline">Yamamoto S, Yamamoto Y, Kitajima O, Maeda T, Suzuki T. Reversal of neuromuscular block with sugammadex: A comparison of the corrugator supercilii and adductor pollicis muscles in a randomized dose-response study. <em>Acta Anaesthesiol Scand</em>. 2015;59(7):892-901. doi:<a href="https://doi.org/10.1111/aas.12549">10.1111/aas.12549</a></div>
</div>
<div id="ref-Badaoui2016" class="csl-entry">
<div class="csl-left-margin">139. </div><div class="csl-right-inline">Badaoui R, Cabaret A, Alami Y, et al. Reversal of neuromuscular blockade by sugammadex in laparoscopic bariatric surgery: In support of dose reduction. <em>Anaesth Crit Care Pain Med</em>. 2016;35(1):25-29. doi:<a href="https://doi.org/10.1016/j.accpm.2015.09.003">10.1016/j.accpm.2015.09.003</a></div>
</div>
<div id="ref-Batistaki2016" class="csl-entry">
<div class="csl-left-margin">140. </div><div class="csl-right-inline">Batistaki C, Tentes P, Deligiannidi P, Karakosta A, Florou P, Kostopanagiotou G. Residual neuromuscular blockade in a real life clinical setting: Correlation with sugammadex or neostigmine administration. <em>Minerva Anestesiol</em>. 2016;82(5):550-558.</div>
</div>
<div id="ref-Bulka2016" class="csl-entry">
<div class="csl-left-margin">141. </div><div class="csl-right-inline">Bulka CM, Terekhov MA, Martin BJ, Dmochowski RR, Hayes RM, Ehrenfeld JM. Nondepolarizing neuromuscular blocking agents, reversal, and risk of postoperative pneumonia. <em>Anesthesiology</em>. 2016;125(4):647-655. doi:<a href="https://doi.org/10.1097/aln.0000000000001279">10.1097/aln.0000000000001279</a></div>
</div>
<div id="ref-Colegrave2016" class="csl-entry">
<div class="csl-left-margin">142. </div><div class="csl-right-inline">Colegrave N, Billard V, Motamed C, Bourgain JL. Comparison of the TOF-scan<span><span></span></span>acceleromyograph to TOF-watch SX<span><span></span></span>: Influence of calibration. <em>Anaesth Crit Care Pain Med</em>. 2016;35(3):223-227. doi:<a href="https://doi.org/10.1016/j.accpm.2016.01.003">10.1016/j.accpm.2016.01.003</a></div>
</div>
<div id="ref-De-Robertis2016" class="csl-entry">
<div class="csl-left-margin">143. </div><div class="csl-right-inline">De Robertis E, Zito Marinosci G, Romano GM, et al. The use of sugammadex for bariatric surgery: Analysis of recovery time from neuromuscular blockade and possible economic impact. <em>Clinicoecon Outcomes Res</em>. 2016;8:317-322. doi:<a href="https://doi.org/10.2147/ceor.S109951">10.2147/ceor.S109951</a></div>
</div>
<div id="ref-Errando2016" class="csl-entry">
<div class="csl-left-margin">144. </div><div class="csl-right-inline">Errando CL, Garutti I, Mazzinari G, Dı́az-Cambronero Ó, Bebawy JF. Residual neuromuscular blockade in the postanesthesia care unit: Observational cross-sectional study of a multicenter cohort. <em>Minerva Anestesiol</em>. 2016;82(12):1267-1277.</div>
</div>
<div id="ref-Hakimoglu2016" class="csl-entry">
<div class="csl-left-margin">145. </div><div class="csl-right-inline">Hakimoğlu S, Tuzcu K, Davarcı I, et al. Comparison of sugammadex and neostigmine-atropine on intraocular pressure and postoperative effects. <em>Kaohsiung J Med Sci</em>. 2016;32(2):80-85. doi:<a href="https://doi.org/10.1016/j.kjms.2016.01.009">10.1016/j.kjms.2016.01.009</a></div>
</div>
<div id="ref-Kaufhold2016" class="csl-entry">
<div class="csl-left-margin">146. </div><div class="csl-right-inline">Kaufhold N, Schaller SJ, Stäuble CG, et al. Sugammadex and neostigmine dose-finding study for reversal of residual neuromuscular block at a train-of-four ratio of 0.2 (SUNDRO20)†. <em>Br J Anaesth</em>. 2016;116(2):233-240. doi:<a href="https://doi.org/10.1093/bja/aev437">10.1093/bja/aev437</a></div>
</div>
<div id="ref-Khandkar2016" class="csl-entry">
<div class="csl-left-margin">147. </div><div class="csl-right-inline">Khandkar C, Liang S, Phillips S, Lee CY, Stewart PA. Comparison of kinemyography and electromyography during spontaneous recovery from non-depolarising neuromuscular blockade. <em>Anaesth Intensive Care</em>. 2016;44(6):745-751. doi:<a href="https://doi.org/10.1177/0310057x1604400618">10.1177/0310057x1604400618</a></div>
</div>
<div id="ref-Kim2016" class="csl-entry">
<div class="csl-left-margin">148. </div><div class="csl-right-inline">Kim KS, Oh YN, Kim TY, Oh SY, Sin YH. Relationship between first-twitch depression and train-of-four ratio during sugammadex reversal of rocuronium-induced neuromuscular blockade. <em>Korean J Anesthesiol</em>. 2016;69(3):239-243. doi:<a href="https://doi.org/10.4097/kjae.2016.69.3.239">10.4097/kjae.2016.69.3.239</a></div>
</div>
<div id="ref-Martinez-Ubieto2016" class="csl-entry">
<div class="csl-left-margin">149. </div><div class="csl-right-inline">Martinez-Ubieto J, Ortega-Lucea S, Pascual-Bellosta A, et al. Prospective study of residual neuromuscular block and postoperative respiratory complications in patients reversed with neostigmine versus sugammadex. <em>Minerva Anestesiol</em>. 2016;82(7):735-742.</div>
</div>
<div id="ref-Oh2016" class="csl-entry">
<div class="csl-left-margin">150. </div><div class="csl-right-inline">Oh CS, Rhee KY, Yoon TG, Woo NS, Hong SW, Kim SH. Postoperative delirium in elderly patients undergoing hip fracture surgery in the sugammadex era: A retrospective study. <em>Biomed Res Int</em>. 2016;2016:1054597. doi:<a href="https://doi.org/10.1155/2016/1054597">10.1155/2016/1054597</a></div>
</div>
<div id="ref-Park2016" class="csl-entry">
<div class="csl-left-margin">151. </div><div class="csl-right-inline">Park ES, Lim BG, Lee WJ, Lee IO. Sugammadex facilitates early recovery after surgery even in the absence of neuromuscular monitoring in patients undergoing laryngeal microsurgery: A single-center retrospective study. <em>BMC Anesthesiol</em>. 2016;16(1):48. doi:<a href="https://doi.org/10.1186/s12871-016-0221-2">10.1186/s12871-016-0221-2</a></div>
</div>
<div id="ref-Preault2016" class="csl-entry">
<div class="csl-left-margin">152. </div><div class="csl-right-inline">Preault A, Capron F, Chantereau C, Donati F, Dimet J. Under sevoflurane anaesthesia, a reduced dose of neostigmine can antagonize a shallow neuromuscular block: A double-blind, randomised study. <em>Anaesth Crit Care Pain Med</em>. 2016;35(4):269-273. doi:<a href="https://doi.org/10.1016/j.accpm.2015.11.008">10.1016/j.accpm.2015.11.008</a></div>
</div>
<div id="ref-Putz2016" class="csl-entry">
<div class="csl-left-margin">153. </div><div class="csl-right-inline">Putz L, Dransart C, Jamart J, Marotta ML, Delnooz G, Dubois PE. Operating room discharge after deep neuromuscular block reversed with sugammadex compared with shallow block reversed with neostigmine: A randomized controlled trial. <em>J Clin Anesth</em>. 2016;35:107-113. doi:<a href="https://doi.org/10.1016/j.jclinane.2016.07.030">10.1016/j.jclinane.2016.07.030</a></div>
</div>
<div id="ref-Vega2016" class="csl-entry">
<div class="csl-left-margin">154. </div><div class="csl-right-inline">Vega EA, Ibacache ME, Anderson BJ, et al. Rocuronium pharmacokinetics and pharmacodynamics in the adductor pollicis and masseter muscles. <em>Acta Anaesthesiol Scand</em>. 2016;60(6):734-746. doi:<a href="https://doi.org/10.1111/aas.12703">10.1111/aas.12703</a></div>
</div>
<div id="ref-Yazar2016" class="csl-entry">
<div class="csl-left-margin">155. </div><div class="csl-right-inline">Yazar E, Yılmaz C, Bilgin H, et al. A comparision of the effect of sugammadex on the recovery period and postoperative residual block in young elderly and middle-aged elderly patients. <em>Balkan Med J</em>. 2016;33(2):181-187. doi:<a href="https://doi.org/10.5152/balkanmedj.2016.16383">10.5152/balkanmedj.2016.16383</a></div>
</div>
<div id="ref-Alsaeed2017" class="csl-entry">
<div class="csl-left-margin">156. </div><div class="csl-right-inline">Alsaeed A, Bamehriz F, Eldin S, Alzahrani T, Alharbi A, Eldawlatly A. Sugammadex versus two doses of neostigmine for reversal of rocuronium in gastric sleeve surgery. <em>Saudi J Anaesth</em>. 2017;11(3):309-311. doi:<a href="https://doi.org/10.4103/sja.SJA{\_}113{\_}17">10.4103/sja.SJA{\_}113{\_}17</a></div>
</div>
<div id="ref-Ammar2017" class="csl-entry">
<div class="csl-left-margin">157. </div><div class="csl-right-inline">Ammar AS, Mahmoud KM, Kasemy ZA. A comparison of sugammadex and neostigmine for reversal of rocuronium-induced neuromuscular blockade in children. <em>Acta Anaesthesiol Scand</em>. 2017;61(4):374-380. doi:<a href="https://doi.org/10.1111/aas.12868">10.1111/aas.12868</a></div>
</div>
<div id="ref-Asztalos2017" class="csl-entry">
<div class="csl-left-margin">158. </div><div class="csl-right-inline">Asztalos L, Szabó-Maák Z, Gajdos A, et al. Reversal of vecuronium-induced neuromuscular blockade with low-dose sugammadex at train-of-four count of four: A randomized controlled trial. <em>Anesthesiology</em>. 2017;127(3):441-449. doi:<a href="https://doi.org/10.1097/aln.0000000000001744">10.1097/aln.0000000000001744</a></div>
</div>
<div id="ref-Choi2017" class="csl-entry">
<div class="csl-left-margin">159. </div><div class="csl-right-inline">Choi ES, Oh AY, Koo BW, et al. Comparison of reversal with neostigmine of low-dose rocuronium vs. Reversal with sugammadex of high-dose rocuronium for a short procedure. <em>Anaesthesia</em>. 2017;72(10):1185-1190. doi:<a href="https://doi.org/10.1111/anae.13894">10.1111/anae.13894</a></div>
</div>
<div id="ref-Nemes2017" class="csl-entry">
<div class="csl-left-margin">160. </div><div class="csl-right-inline">Nemes R, Fülesdi B, Pongrácz A, et al. Impact of reversal strategies on the incidence of postoperative residual paralysis after rocuronium relaxation without neuromuscular monitoring: A partially randomised placebo controlled trial. <em>Eur J Anaesthesiol</em>. 2017;34(9):609-616. doi:<a href="https://doi.org/10.1097/eja.0000000000000585">10.1097/eja.0000000000000585</a></div>
</div>
<div id="ref-P2017" class="csl-entry">
<div class="csl-left-margin">161. </div><div class="csl-right-inline">P SL, Miskan MM, Y ZC, Zaki RA. Staggering the dose of sugammadex lowers risks for severe emergence cough: A randomized control trial. <em>BMC Anesthesiol</em>. 2017;17(1):137. doi:<a href="https://doi.org/10.1186/s12871-017-0430-3">10.1186/s12871-017-0430-3</a></div>
</div>
<div id="ref-Sheshadri2017" class="csl-entry">
<div class="csl-left-margin">162. </div><div class="csl-right-inline">Sheshadri V, Radhakrishnan A, Halemani K, Keshavan VH. Infusion dose requirement of rocuronium in patients on phenytoin therapy - a prospective comparative study. <em>Indian J Anaesth</em>. 2017;61(10):793-797. doi:<a href="https://doi.org/10.4103/ija.IJA{\_}218{\_}17">10.4103/ija.IJA{\_}218{\_}17</a></div>
</div>
<div id="ref-Tas-Tuna2017" class="csl-entry">
<div class="csl-left-margin">163. </div><div class="csl-right-inline">Tas Tuna A, Palabiyik O, Orhan M, Sonbahar T, Sayhan H, Tomak Y. Does sugammadex administration affect postoperative nausea and vomiting after laparoscopic cholecystectomy: A prospective, double-blind, randomized study. <em>Surg Laparosc Endosc Percutan Tech</em>. 2017;27(4):237-240. doi:<a href="https://doi.org/10.1097/sle.0000000000000439">10.1097/sle.0000000000000439</a></div>
</div>
<div id="ref-Unterbuchner2017" class="csl-entry">
<div class="csl-left-margin">164. </div><div class="csl-right-inline">Unterbuchner C, Blobner M, Pühringer F, et al. Development of an algorithm using clinical tests to avoid post-operative residual neuromuscular block. <em>BMC Anesthesiol</em>. 2017;17(1):101. doi:<a href="https://doi.org/10.1186/s12871-017-0393-4">10.1186/s12871-017-0393-4</a></div>
</div>
<div id="ref-Veiga-Ruiz2017" class="csl-entry">
<div class="csl-left-margin">165. </div><div class="csl-right-inline">Veiga Ruiz G, Garcı́a Cayuela J, Orozco Montes J, Parreño Caparrós M, Garcı́a Rojo B, Aguayo Albasini JL. Monitoring intraoperative neuromuscular blockade and blood pressure with one device (TOF-cuff): A comparative study with mechanomyography and invasive blood pressure. <em>Rev Esp Anestesiol Reanim</em>. 2017;64(10):560-567. doi:<a href="https://doi.org/10.1016/j.redar.2017.03.013">10.1016/j.redar.2017.03.013</a></div>
</div>
<div id="ref-Yagan2017" class="csl-entry">
<div class="csl-left-margin">166. </div><div class="csl-right-inline">Yağan Ö, Taş N, Mutlu T, Hancı V. Comparison of the effects of sugammadex and neostigmine on postoperative nausea and vomiting. <em>Braz J Anesthesiol</em>. 2017;67(2):147-152. doi:<a href="https://doi.org/10.1016/j.bjane.2015.08.003">10.1016/j.bjane.2015.08.003</a></div>
</div>
<div id="ref-Abdulatif2018" class="csl-entry">
<div class="csl-left-margin">167. </div><div class="csl-right-inline">Abdulatif M, Lotfy M, Mousa M, Afifi MH, Yassen K. Sugammadex antagonism of rocuronium-induced neuromuscular blockade in patients with liver cirrhosis undergoing liver resection: A randomized controlled study. <em>Minerva Anestesiol</em>. 2018;84(8):929-937. doi:<a href="https://doi.org/10.23736/s0375-9393.18.12217-6">10.23736/s0375-9393.18.12217-6</a></div>
</div>
<div id="ref-Adembesa2018" class="csl-entry">
<div class="csl-left-margin">168. </div><div class="csl-right-inline">Adembesa I, Mung’ayi V, Premji Z, Kamya D. A randomized control trial comparing train of four ratio &gt; 0.9 to clinical assessment of return of neuromuscular function before endotracheal extubation on critical respiratory events in adult patients undergoing elective surgery at a tertiary hospital in nairobi. <em>Afr Health Sci</em>. 2018;18(3):807-816. doi:<a href="https://doi.org/10.4314/ahs.v18i3.40">10.4314/ahs.v18i3.40</a></div>
</div>
<div id="ref-Goyal2018" class="csl-entry">
<div class="csl-left-margin">169. </div><div class="csl-right-inline">Goyal S, Kothari N, Chaudhary D, Verma S, Bihani P, Rodha MS. Reversal agents: Do we need to administer with neuromuscular monitoring - an observational study. <em>Indian J Anaesth</em>. 2018;62(3):219-224. doi:<a href="https://doi.org/10.4103/ija.IJA{\_}652{\_}17">10.4103/ija.IJA{\_}652{\_}17</a></div>
</div>
<div id="ref-Muramatsu2018" class="csl-entry">
<div class="csl-left-margin">170. </div><div class="csl-right-inline">Muramatsu T, Isono S, Ishikawa T, et al. Differences of recovery from rocuronium-induced deep paralysis in response to small doses of sugammadex between elderly and nonelderly patients. <em>Anesthesiology</em>. 2018;129(5):901-911. doi:<a href="https://doi.org/10.1097/aln.0000000000002412">10.1097/aln.0000000000002412</a></div>
</div>
<div id="ref-Murphy2018" class="csl-entry">
<div class="csl-left-margin">171. </div><div class="csl-right-inline">Murphy GS, Szokol JW, Avram MJ, et al. Comparison of the TOFscan and the TOF-watch SX during recovery of neuromuscular function. <em>Anesthesiology</em>. 2018;129(5):880-888. doi:<a href="https://doi.org/10.1097/aln.0000000000002400">10.1097/aln.0000000000002400</a></div>
</div>
<div id="ref-Paech2018" class="csl-entry">
<div class="csl-left-margin">172. </div><div class="csl-right-inline">Paech MJ, Kaye R, Baber C, Nathan EA. Recovery characteristics of patients receiving either sugammadex or neostigmine and glycopyrrolate for reversal of neuromuscular block: A randomised controlled trial. <em>Anaesthesia</em>. 2018;73(3):340-347. doi:<a href="https://doi.org/10.1111/anae.14174">10.1111/anae.14174</a></div>
</div>
<div id="ref-Thilen2018" class="csl-entry">
<div class="csl-left-margin">173. </div><div class="csl-right-inline">Thilen SR, Ng IC, Cain KC, Treggiari MM, Bhananker SM. Management of rocuronium neuromuscular block using a protocol for qualitative monitoring and reversal with neostigmine. <em>Br J Anaesth</em>. 2018;121(2):367-377. doi:<a href="https://doi.org/10.1016/j.bja.2018.03.029">10.1016/j.bja.2018.03.029</a></div>
</div>
<div id="ref-Alday2019" class="csl-entry">
<div class="csl-left-margin">174. </div><div class="csl-right-inline">Alday E, Muñoz M, Planas A, Mata E, Alvarez C. Effects of neuromuscular block reversal with sugammadex versus neostigmine on postoperative respiratory outcomes after major abdominal surgery: A randomized-controlled trial. <em>Can J Anaesth</em>. 2019;66(11):1328-1337. doi:<a href="https://doi.org/10.1007/s12630-019-01419-3">10.1007/s12630-019-01419-3</a></div>
</div>
<div id="ref-Arslantas2019" class="csl-entry">
<div class="csl-left-margin">175. </div><div class="csl-right-inline">Arslantas R, Cevik BE. Retrospective investigation of grafted kidney function after reversal of neuromuscular blockade using neostigmine or sugammadex. <em>Transplant Proc</em>. 2019;51(7):2265-2267. doi:<a href="https://doi.org/10.1016/j.transproceed.2019.03.051">10.1016/j.transproceed.2019.03.051</a></div>
</div>
<div id="ref-Claroni2019" class="csl-entry">
<div class="csl-left-margin">176. </div><div class="csl-right-inline">Claroni C, Covotta M, Torregiani G, et al. Recovery from anesthesia after robotic-assisted radical cystectomy: Two different reversals of neuromuscular blockade. <em>J Clin Med</em>. 2019;8(11). doi:<a href="https://doi.org/10.3390/jcm8111774">10.3390/jcm8111774</a></div>
</div>
<div id="ref-Domenech2019" class="csl-entry">
<div class="csl-left-margin">177. </div><div class="csl-right-inline">Domenech G, Kampel MA, Garcı́a Guzzo ME, Novas DS, Terrasa SA, Fornari GG. Usefulness of intra-operative neuromuscular blockade monitoring and reversal agents for postoperative residual neuromuscular blockade: A retrospective observational study. <em>BMC Anesthesiol</em>. 2019;19(1):143. doi:<a href="https://doi.org/10.1186/s12871-019-0817-4">10.1186/s12871-019-0817-4</a></div>
</div>
<div id="ref-Gaver2019" class="csl-entry">
<div class="csl-left-margin">178. </div><div class="csl-right-inline">Gaver RS, Brenn BR, Gartley A, Donahue BS. Retrospective analysis of the safety and efficacy of sugammadex versus neostigmine for the reversal of neuromuscular blockade in children. <em>Anesth Analg</em>. 2019;129(4):1124-1129. doi:<a href="https://doi.org/10.1213/ane.0000000000004207">10.1213/ane.0000000000004207</a></div>
</div>
<div id="ref-Gunes2019" class="csl-entry">
<div class="csl-left-margin">179. </div><div class="csl-right-inline">Gunes ME, Dural AC, Akarsu C, et al. Effect of intraoperative neuromonitoring on efficacy and safety using sugammadex in thyroid surgery: Randomized clinical trial. <em>Ann Surg Treat Res</em>. 2019;97(6):282-290. doi:<a href="https://doi.org/10.4174/astr.2019.97.6.282">10.4174/astr.2019.97.6.282</a></div>
</div>
<div id="ref-Kameyama2019" class="csl-entry">
<div class="csl-left-margin">180. </div><div class="csl-right-inline">Kameyama Y, Takagi S, Seto K, et al. Efficiency of the TOF-cuff<span><span></span></span>for the evaluation of rocuronium-induced neuromuscular block and its reversal with sugammadex: A comparative study vs. acceleromyography. <em>J Anesth</em>. 2019;33(1):80-84. doi:<a href="https://doi.org/10.1007/s00540-018-2587-4">10.1007/s00540-018-2587-4</a></div>
</div>
<div id="ref-Kim2019" class="csl-entry">
<div class="csl-left-margin">181. </div><div class="csl-right-inline">Kim NY, Koh JC, Lee KY, et al. Influence of reversal of neuromuscular blockade with sugammadex or neostigmine on postoperative quality of recovery following a single bolus dose of rocuronium: A prospective, randomized, double-blinded, controlled study. <em>J Clin Anesth</em>. 2019;57:97-102. doi:<a href="https://doi.org/10.1016/j.jclinane.2019.02.014">10.1016/j.jclinane.2019.02.014</a></div>
</div>
<div id="ref-Korkmaz2019" class="csl-entry">
<div class="csl-left-margin">182. </div><div class="csl-right-inline">Korkmaz MO, Sayhan H, Guven M. Does sugammadex decrease the severity of agitation and complications in pediatric patients undergoing adenotonsillectomy? <em>Saudi Med J</em>. 2019;40(9):907-913. doi:<a href="https://doi.org/10.15537/smj.2019.9.24485">10.15537/smj.2019.9.24485</a></div>
</div>
<div id="ref-Mazzinari2019" class="csl-entry">
<div class="csl-left-margin">183. </div><div class="csl-right-inline">Mazzinari G, Errando CL, Dı́az-Cambronero O, Martin-Flores M. Influence of tetanic stimulation on the staircase phenomenon and the acceleromyographic time-course of neuromuscular block: A randomized controlled trial. <em>J Clin Monit Comput</em>. 2019;33(2):325-332. doi:<a href="https://doi.org/10.1007/s10877-018-0157-9">10.1007/s10877-018-0157-9</a></div>
</div>
<div id="ref-Oh2019" class="csl-entry">
<div class="csl-left-margin">184. </div><div class="csl-right-inline">Oh TK, Ji E, Na HS. The effect of neuromuscular reversal agent on postoperative pain after laparoscopic gastric cancer surgery: Comparison between the neostigmine and sugammadex. <em>Medicine (Baltimore)</em>. 2019;98(26):e16142. doi:<a href="https://doi.org/10.1097/md.0000000000016142">10.1097/md.0000000000016142</a></div>
</div>
<div id="ref-Oh2019a" class="csl-entry">
<div class="csl-left-margin">185. </div><div class="csl-right-inline">Oh TK, Oh AY, Ryu JH, et al. Retrospective analysis of 30-day unplanned readmission after major abdominal surgery with reversal by sugammadex or neostigmine. <em>Br J Anaesth</em>. 2019;122(3):370-378. doi:<a href="https://doi.org/10.1016/j.bja.2018.11.028">10.1016/j.bja.2018.11.028</a></div>
</div>
<div id="ref-Quang2019" class="csl-entry">
<div class="csl-left-margin">186. </div><div class="csl-right-inline">Quang TL, Thu HNT, Quoc KN, et al. Neuromuscular blockade agents reversal with sugammadex compared to neostigmine in the living kidney donors. <em>Open Access Maced J Med Sci</em>. 2019;7(24):4420-4425. doi:<a href="https://doi.org/10.3889/oamjms.2019.874">10.3889/oamjms.2019.874</a></div>
</div>
<div id="ref-Schepens2019" class="csl-entry">
<div class="csl-left-margin">187. </div><div class="csl-right-inline">Schepens T, Janssens K, Maes S, et al. Respiratory muscle activity after spontaneous, neostigmine- or sugammadex-enhanced recovery of neuromuscular blockade: A double blind prospective randomized controlled trial. <em>BMC Anesthesiol</em>. 2019;19(1):187. doi:<a href="https://doi.org/10.1186/s12871-019-0863-y">10.1186/s12871-019-0863-y</a></div>
</div>
<div id="ref-Wardhana2019" class="csl-entry">
<div class="csl-left-margin">188. </div><div class="csl-right-inline">Wardhana A, Kurniawaty J, Uyun Y. Optimised reversal without train-of-four monitoring versus reversal using quantitative train-of-four monitoring: An equivalence study. <em>Indian J Anaesth</em>. 2019;63(5):361-367. doi:<a href="https://doi.org/10.4103/ija.IJA{\_}94{\_}19">10.4103/ija.IJA{\_}94{\_}19</a></div>
</div>
<div id="ref-Xia2019" class="csl-entry">
<div class="csl-left-margin">189. </div><div class="csl-right-inline">Xia R, Kachru N, Tuazon DM, Bostan F, Fuentes A. Evaluation of neuromuscular blockade reversal on postoperative mechanical ventilation time in a cardiovascular surgery population. <em>J Cardiothorac Vasc Anesth</em>. 2019;33(12):3348-3357. doi:<a href="https://doi.org/10.1053/j.jvca.2019.06.025">10.1053/j.jvca.2019.06.025</a></div>
</div>
<div id="ref-Abola2020" class="csl-entry">
<div class="csl-left-margin">190. </div><div class="csl-right-inline">Abola RE, Romeiser J, Rizwan S, Lung B, Gupta R, Bennett-Guerrero E. A randomized-controlled trial of sugammadex versus neostigmine: Impact on early postoperative strength. <em>Can J Anaesth</em>. 2020;67(8):959-969. doi:<a href="https://doi.org/10.1007/s12630-020-01695-4">10.1007/s12630-020-01695-4</a></div>
</div>
<div id="ref-Arends2020" class="csl-entry">
<div class="csl-left-margin">191. </div><div class="csl-right-inline">Arends J, Hubbard R, Shafy SZ, et al. Heart rate changes following the administration of sugammadex to infants and children with comorbid cardiac, cardiovascular, and congenital heart diseases. <em>Cardiol Res</em>. 2020;11(5):274-279. doi:<a href="https://doi.org/10.14740/cr1045">10.14740/cr1045</a></div>
</div>
<div id="ref-Blobner2020" class="csl-entry">
<div class="csl-left-margin">192. </div><div class="csl-right-inline">Blobner M, Hunter JM, Meistelman C, et al. Use of a train-of-four ratio of 0.95 versus 0.9 for tracheal extubation: An exploratory analysis of POPULAR data. <em>Br J Anaesth</em>. 2020;124(1):63-72. doi:<a href="https://doi.org/10.1016/j.bja.2019.08.023">10.1016/j.bja.2019.08.023</a></div>
</div>
<div id="ref-Boggett2020" class="csl-entry">
<div class="csl-left-margin">193. </div><div class="csl-right-inline">Boggett S, Chahal R, Griffiths J, et al. A randomised controlled trial comparing deep neuromuscular blockade reversed with sugammadex with moderate neuromuscular block reversed with neostigmine. <em>Anaesthesia</em>. 2020;75(9):1153-1163. doi:<a href="https://doi.org/10.1111/anae.15094">10.1111/anae.15094</a></div>
</div>
<div id="ref-Deana2020" class="csl-entry">
<div class="csl-left-margin">194. </div><div class="csl-right-inline">Deana C, Barbariol F, D’Incà S, Pompei L, Rocca GD. SUGAMMADEX versus neostigmine after ROCURONIUM continuous infusion in patients undergoing liver transplantation. <em>BMC Anesthesiol</em>. 2020;20(1):70. doi:<a href="https://doi.org/10.1186/s12871-020-00986-z">10.1186/s12871-020-00986-z</a></div>
</div>
<div id="ref-Han2020" class="csl-entry">
<div class="csl-left-margin">195. </div><div class="csl-right-inline">Han J, Ryu JH, Koo BW, Nam SW, Cho SI, Oh AY. Effects of sugammadex on post-operative pulmonary complications in laparoscopic gastrectomy: A retrospective cohort study. <em>J Clin Med</em>. 2020;9(4). doi:<a href="https://doi.org/10.3390/jcm9041232">10.3390/jcm9041232</a></div>
</div>
<div id="ref-John2020" class="csl-entry">
<div class="csl-left-margin">196. </div><div class="csl-right-inline">John J, Perry G, Perry J, et al. Impact of neostigmine and sugammadex on time to leaving the operating room in a community hospital. <em>Innov Pharm</em>. 2020;11(3). doi:<a href="https://doi.org/10.24926/iip.v11i3.3329">10.24926/iip.v11i3.3329</a></div>
</div>
<div id="ref-Kheterpal2020" class="csl-entry">
<div class="csl-left-margin">197. </div><div class="csl-right-inline">Kheterpal S, Vaughn MT, Dubovoy TZ, et al. Sugammadex versus neostigmine for reversal of neuromuscular blockade and postoperative pulmonary complications (STRONGER): A multicenter matched cohort analysis. <em>Anesthesiology</em>. 2020;132(6):1371-1381. doi:<a href="https://doi.org/10.1097/aln.0000000000003256">10.1097/aln.0000000000003256</a></div>
</div>
<div id="ref-Krause2020" class="csl-entry">
<div class="csl-left-margin">198. </div><div class="csl-right-inline">Krause M, McWilliams SK, Bullard KJ, et al. Neostigmine versus sugammadex for reversal of neuromuscular blockade and effects on reintubation for respiratory failure or newly initiated noninvasive ventilation: An interrupted time series design. <em>Anesth Analg</em>. 2020;131(1):141-151. doi:<a href="https://doi.org/10.1213/ane.0000000000004505">10.1213/ane.0000000000004505</a></div>
</div>
<div id="ref-Le-Merrer2020" class="csl-entry">
<div class="csl-left-margin">199. </div><div class="csl-right-inline">Le Merrer M, Frasca D, Dupuis M, Debaene B, Boisson M. A comparison between the flexor hallucis brevis and adductor pollicis muscles in atracurium-induced neuromuscular blockade using acceleromyography: A prospective observational study. <em>Eur J Anaesthesiol</em>. 2020;37(1):38-43. doi:<a href="https://doi.org/10.1097/eja.0000000000001090">10.1097/eja.0000000000001090</a></div>
</div>
<div id="ref-Lee2020" class="csl-entry">
<div class="csl-left-margin">200. </div><div class="csl-right-inline">Lee YJ, Oh AY, Koo BW, et al. Postoperative residual neuromuscular blockade after reversal based on a qualitative peripheral nerve stimulator response: A randomised controlled trial. <em>Eur J Anaesthesiol</em>. 2020;37(3):196-202. doi:<a href="https://doi.org/10.1097/eja.0000000000001157">10.1097/eja.0000000000001157</a></div>
</div>
<div id="ref-Markle2020" class="csl-entry">
<div class="csl-left-margin">201. </div><div class="csl-right-inline">Markle A, Graf N, Horn K, Welter JE, Dullenkopf A. Neuromuscular monitoring using TOF-cuff<span><span></span></span>versus TOF-scan<span><span></span></span>: An observational study under clinical anesthesia conditions. <em>Minerva Anestesiol</em>. 2020;86(7):704-711. doi:<a href="https://doi.org/10.23736/s0375-9393.20.14272-x">10.23736/s0375-9393.20.14272-x</a></div>
</div>
<div id="ref-Min2020" class="csl-entry">
<div class="csl-left-margin">202. </div><div class="csl-right-inline">Min BH, Oh TK, Song IA, Jeon YT. Comparison of the effects of sugammadex and neostigmine on hospital stay in robot-assisted laparoscopic prostatectomy: A retrospective study. <em>BMC Anesthesiol</em>. 2020;20(1):178. doi:<a href="https://doi.org/10.1186/s12871-020-01088-6">10.1186/s12871-020-01088-6</a></div>
</div>
<div id="ref-Moon2020" class="csl-entry">
<div class="csl-left-margin">203. </div><div class="csl-right-inline">Moon TS, Reznik S, Pak T, et al. Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular blockade: A randomized, double-blinded study of thoracic surgical patients evaluating hypoxic episodes in the early postoperative period. <em>J Clin Anesth</em>. 2020;64:109804. doi:<a href="https://doi.org/10.1016/j.jclinane.2020.109804">10.1016/j.jclinane.2020.109804</a></div>
</div>
<div id="ref-Murphy2020" class="csl-entry">
<div class="csl-left-margin">204. </div><div class="csl-right-inline">Murphy GS, Avram MJ, Greenberg SB, et al. Neuromuscular and clinical recovery in thoracic surgical patients reversed with neostigmine or sugammadex. <em>Anesth Analg</em>. Published online 2020. doi:<a href="https://doi.org/10.1213/ane.0000000000005294">10.1213/ane.0000000000005294</a></div>
</div>
<div id="ref-Niu2020" class="csl-entry">
<div class="csl-left-margin">205. </div><div class="csl-right-inline">Niu L, Wang Y, Yao C, Sun Y, Yao S, Lin Y. Efficacy and safety of neuromuscular blockade in overweight patients undergoing nasopharyngeal surgery. <em>Med Sci Monit</em>. 2020;26:e926452. doi:<a href="https://doi.org/10.12659/msm.926452">10.12659/msm.926452</a></div>
</div>
<div id="ref-Orihara2020" class="csl-entry">
<div class="csl-left-margin">206. </div><div class="csl-right-inline">Orihara M, Takazawa T, Horiuchi T, et al. Comparison of incidence of anaphylaxis between sugammadex and neostigmine: A retrospective multicentre observational study. <em>Br J Anaesth</em>. 2020;124(2):154-163. doi:<a href="https://doi.org/10.1016/j.bja.2019.10.016">10.1016/j.bja.2019.10.016</a></div>
</div>
<div id="ref-Paredes2020" class="csl-entry">
<div class="csl-left-margin">207. </div><div class="csl-right-inline">Paredes S, Porter SB, Porter IE, 2nd R. Sugammadex use in patients with end-stage renal disease: A historical cohort study. <em>Can J Anaesth</em>. 2020;67(12):1789-1797. doi:<a href="https://doi.org/10.1007/s12630-020-01812-3">10.1007/s12630-020-01812-3</a></div>
</div>
<div id="ref-Sfeir-Machado2020" class="csl-entry">
<div class="csl-left-margin">208. </div><div class="csl-right-inline">Sfeir Machado E, Keli-Barcelos G, Dupuis-Lozeron E, Tramèr MR, Czarnetzki C. Assessment of spontaneous neuromuscular recovery: A comparison of the TOF-cuff(<span><span></span></span>) with the TOF watch SX(<span><span></span></span>). <em>Acta Anaesthesiol Scand</em>. 2020;64(2):173-179. doi:<a href="https://doi.org/10.1111/aas.13487">10.1111/aas.13487</a></div>
</div>
<div id="ref-Shaydenfish2020" class="csl-entry">
<div class="csl-left-margin">209. </div><div class="csl-right-inline">Shaydenfish D, Scheffenbichler FT, Kelly BJ, et al. Effects of anticholinesterase reversal under general anesthesia on postoperative cardiovascular complications: A retrospective cohort study. <em>Anesth Analg</em>. 2020;130(3):685-695. doi:<a href="https://doi.org/10.1213/ane.0000000000004099">10.1213/ane.0000000000004099</a></div>
</div>
<div id="ref-Thudium2020" class="csl-entry">
<div class="csl-left-margin">210. </div><div class="csl-right-inline">Thudium M, Kornilov E, Raczeck L, Boehm O. Pulmonary function decline in immediate postoperative period is not necessarily related to residual neuromuscular block: An observational study. <em>Eur J Anaesthesiol</em>. 2020;37(11):1008-1013. doi:<a href="https://doi.org/10.1097/eja.0000000000001221">10.1097/eja.0000000000001221</a></div>
</div>
<div id="ref-Togioka2020" class="csl-entry">
<div class="csl-left-margin">211. </div><div class="csl-right-inline">Togioka BM, Yanez D, Aziz MF, Higgins JR, Tekkali P, Treggiari MM. Randomised controlled trial of sugammadex or neostigmine for reversal of neuromuscular block on the incidence of pulmonary complications in older adults undergoing prolonged surgery. <em>Br J Anaesth</em>. 2020;124(5):553-561. doi:<a href="https://doi.org/10.1016/j.bja.2020.01.016">10.1016/j.bja.2020.01.016</a></div>
</div>
<div id="ref-Williams2020" class="csl-entry">
<div class="csl-left-margin">212. </div><div class="csl-right-inline">Williams WH, 3rd C, J. P. L, J. D. N, N. F, L. G. Effect of reversal of deep neuromuscular block with sugammadex or moderate block by neostigmine on shoulder pain in elderly patients undergoing robotic prostatectomy. <em>Br J Anaesth</em>. 2020;124(2):164-172. doi:<a href="https://doi.org/10.1016/j.bja.2019.09.043">10.1016/j.bja.2019.09.043</a></div>
</div>
<div id="ref-Xiaobing2020" class="csl-entry">
<div class="csl-left-margin">213. </div><div class="csl-right-inline">Xiaobing L, Yan J, Wangping Z, Rufang Z, Jia L, Rong W. Effects of sugammadex on postoperative respiratory management in children with congenital heart disease: A randomized controlled study. <em>Biomed Pharmacother</em>. 2020;127:110180. doi:<a href="https://doi.org/10.1016/j.biopha.2020.110180">10.1016/j.biopha.2020.110180</a></div>
</div>
<div id="ref-Zhu2020" class="csl-entry">
<div class="csl-left-margin">214. </div><div class="csl-right-inline">Zhu B, Sun D, Yang L, Sun Z, Feng Y, Deng C. The effects of neostigmine on postoperative cognitive function and inflammatory factors in elderly patients - a randomized trial. <em>BMC Geriatr</em>. 2020;20(1):387. doi:<a href="https://doi.org/10.1186/s12877-020-01793-4">10.1186/s12877-020-01793-4</a></div>
</div>
<div id="ref-Alenezi2021" class="csl-entry">
<div class="csl-left-margin">215. </div><div class="csl-right-inline">Alenezi FK, Alnababtah K, Alqahtani MM, Olayan L, Alharbi M. The association between residual neuromuscular blockade (RNMB) and critical respiratory events: A prospective cohort study. <em>Perioper Med (Lond)</em>. 2021;10(1):14. doi:<a href="https://doi.org/10.1186/s13741-021-00183-7">10.1186/s13741-021-00183-7</a></div>
</div>
<div id="ref-Chang2021" class="csl-entry">
<div class="csl-left-margin">216. </div><div class="csl-right-inline">Chang HW, Lee IO, Kang H, Won YJ, Lim YS. Coagulation effect of sugammadex as determined by thromboelastography in a randomized controlled study of surgical patients. <em>Int J Med Sci</em>. 2021;18(6):1318-1324. doi:<a href="https://doi.org/10.7150/ijms.42563">10.7150/ijms.42563</a></div>
</div>
<div id="ref-Farag2021" class="csl-entry">
<div class="csl-left-margin">217. </div><div class="csl-right-inline">Farag E, Rivas E, Bravo M, et al. Sugammadex versus neostigmine for reversal of rocuronium neuromuscular block in patients having catheter-based neurointerventional procedures: A randomized trial. <em>Anesth Analg</em>. 2021;132(6):1666-1676. doi:<a href="https://doi.org/10.1213/ane.0000000000005533">10.1213/ane.0000000000005533</a></div>
</div>
<div id="ref-Han2021a" class="csl-entry">
<div class="csl-left-margin">218. </div><div class="csl-right-inline">Han J, Jeon YT, Ryu JH, et al. Effects of magnesium on the dose of rocuronium for deep neuromuscular blockade: A randomised controlled trial. <em>Eur J Anaesthesiol</em>. 2021;38(4):432-437. doi:<a href="https://doi.org/10.1097/eja.0000000000001329">10.1097/eja.0000000000001329</a></div>
</div>
<div id="ref-Han2021" class="csl-entry">
<div class="csl-left-margin">219. </div><div class="csl-right-inline">Han J, Oh AY, Jeon YT, et al. Quality of recovery after laparoscopic cholecystectomy following neuromuscular blockade reversal with neostigmine or sugammadex: A prospective, randomized, controlled trial. <em>J Clin Med</em>. 2021;10(5). doi:<a href="https://doi.org/10.3390/jcm10050938">10.3390/jcm10050938</a></div>
</div>
<div id="ref-Horrow2021" class="csl-entry">
<div class="csl-left-margin">220. </div><div class="csl-right-inline">Horrow JC, Li W, Blobner M, et al. Actual versus ideal body weight dosing of sugammadex in morbidly obese patients offers faster reversal of rocuronium- or vecuronium-induced deep or moderate neuromuscular block: A randomized clinical trial. <em>BMC Anesthesiol</em>. 2021;21(1):62. doi:<a href="https://doi.org/10.1186/s12871-021-01278-w">10.1186/s12871-021-01278-w</a></div>
</div>
<div id="ref-Lee2021" class="csl-entry">
<div class="csl-left-margin">221. </div><div class="csl-right-inline">Lee TY, Jeong SY, Jeong JH, Kim JH, Choi SR. Comparison of postoperative pulmonary complications between sugammadex and neostigmine in lung cancer patients undergoing video-assisted thoracoscopic lobectomy: A prospective double-blinded randomized trial. <em>Anesth Pain Med (Seoul)</em>. 2021;16(1):60-67. doi:<a href="https://doi.org/10.17085/apm.20056">10.17085/apm.20056</a></div>
</div>
<div id="ref-Li2021b" class="csl-entry">
<div class="csl-left-margin">222. </div><div class="csl-right-inline">Li D, Wang Y, Zhou Y, Yin C. Efficacy and safety of sugammadex doses calculated on the basis of corrected body weight and total body weight for the reversal of deep neuromuscular blockade in morbidly obese patients. <em>J Int Med Res</em>. 2021;49(1):300060520985679. doi:<a href="https://doi.org/10.1177/0300060520985679">10.1177/0300060520985679</a></div>
</div>
<div id="ref-Li2021" class="csl-entry">
<div class="csl-left-margin">223. </div><div class="csl-right-inline">Li L, Jiang Y, Zhang W. Sugammadex for fast-track surgery in children undergoing cardiac surgery: A randomized controlled study. <em>J Cardiothorac Vasc Anesth</em>. 2021;35(5):1388-1392. doi:<a href="https://doi.org/10.1053/j.jvca.2020.08.069">10.1053/j.jvca.2020.08.069</a></div>
</div>
<div id="ref-Motamed2021" class="csl-entry">
<div class="csl-left-margin">224. </div><div class="csl-right-inline">Motamed C, Demiri M, Colergrave N. Comparison of train of four measurements with kinemyography NMT DATEX and accelerography TOFscan. <em>Med Sci (Basel)</em>. 2021;9(2). doi:<a href="https://doi.org/10.3390/medsci9020021">10.3390/medsci9020021</a></div>
</div>
<div id="ref-Paula-Garcia2021" class="csl-entry">
<div class="csl-left-margin">225. </div><div class="csl-right-inline">Paula-Garcia WN, Oliveira-Paula GH, Boer HD e, Garcia LV. Lidocaine combined with magnesium sulfate preserved hemodynamic stability during general anesthesia without prolonging neuromuscular blockade: A randomized, double-blind, controlled trial. <em>BMC Anesthesiol</em>. 2021;21(1):91. doi:<a href="https://doi.org/10.1186/s12871-021-01311-y">10.1186/s12871-021-01311-y</a></div>
</div>
<div id="ref-Renew2021" class="csl-entry">
<div class="csl-left-margin">226. </div><div class="csl-right-inline">Renew JR, Hernandez-Torres V, Logvinov I, et al. Comparison of the TetraGraph and TOFscan for monitoring recovery from neuromuscular blockade in the post anesthesia care unit. <em>J Clin Anesth</em>. 2021;71:110234. doi:<a href="https://doi.org/10.1016/j.jclinane.2021.110234">10.1016/j.jclinane.2021.110234</a></div>
</div>
<div id="ref-Serrano2021" class="csl-entry">
<div class="csl-left-margin">227. </div><div class="csl-right-inline">Serrano AB, DÍaz-Cambronero Ó, Melchor-RipollÉs J, et al. Neuromuscular blockade management and postoperative outcomes in enhanced recovery colorectal surgery: Secondary analysis of POWER trial. <em>Minerva Anestesiol</em>. 2021;87(1):13-25. doi:<a href="https://doi.org/10.23736/s0375-9393.20.14589-9">10.23736/s0375-9393.20.14589-9</a></div>
</div>
<div id="ref-Song2021" class="csl-entry">
<div class="csl-left-margin">228. </div><div class="csl-right-inline">Song SW, Yoo KY, Ro YS, Pyeon T, Bae HB, Kim J. Sugammadex is associated with shorter hospital length of stay after open lobectomy for lung cancer: A retrospective observational study. <em>J Cardiothorac Surg</em>. 2021;16(1):45. doi:<a href="https://doi.org/10.1186/s13019-021-01427-9">10.1186/s13019-021-01427-9</a></div>
</div>
<div id="ref-Yu2021" class="csl-entry">
<div class="csl-left-margin">229. </div><div class="csl-right-inline">Yu J, Park JY, Lee Y, Hwang JH, Kim YK. Sugammadex versus neostigmine on postoperative pulmonary complications after robot-assisted laparoscopic prostatectomy: A propensity score-matched analysis. <em>J Anesth</em>. 2021;35(2):262-269. doi:<a href="https://doi.org/10.1007/s00540-021-02910-2">10.1007/s00540-021-02910-2</a></div>
</div>
<div id="ref-Burbridge2020" class="csl-entry">
<div class="csl-left-margin">230. </div><div class="csl-right-inline">Burbridge MA. Incidence of anaphylaxis to sugammadex in a single-center cohort of 19,821 patients. <em>Anesthesia and Analgesia</em>. Published online 2020:93-97. doi:<a href="https://doi.org/10.1213/ANE.0000000000004752">10.1213/ANE.0000000000004752</a></div>
</div>
<div id="ref-Chae2019" class="csl-entry">
<div class="csl-left-margin">231. </div><div class="csl-right-inline">Chae YJ, Joe HB, Oh J, Lee E, Yi IK. Thirty-day postoperative outcomes following sugammadex use in colorectal surgery patients: Retrospective study. <em>Journal of Clinical Medicine</em>. 2019;8(1). doi:<a href="https://doi.org/10.3390/jcm8010097">10.3390/jcm8010097</a></div>
</div>
<div id="ref-Cho2017" class="csl-entry">
<div class="csl-left-margin">232. </div><div class="csl-right-inline">Cho HC, Lee JH, Lee SC, Park SY, Rim JC, Choi SR. Use of sugammadex in lung cancer patients undergoing video-assisted thoracoscopic lobectomy. <em>Korean Journal of Anesthesiology</em>. 2017;70(4):420-425. doi:<a href="https://doi.org/10.4097/kjae.2017.70.4.420">10.4097/kjae.2017.70.4.420</a></div>
</div>
<div id="ref-Citil2019" class="csl-entry">
<div class="csl-left-margin">233. </div><div class="csl-right-inline">Çitil AB, Tuncel ZA, Yapici N, Kudsioǧlu T, Aykaç Z, Kavakli AS. Reversal of rocuronium induced neuromuscular blockade in lung resection surgery: A comparison of sugammadex and neostigmine. <em>Gogus-Kalp-Damar Anestezi ve Yogun Bakim Dernegi Dergisi</em>. 2019;25(1):23-30. doi:<a href="https://doi.org/10.5222/GKDAD.2019.49369">10.5222/GKDAD.2019.49369</a></div>
</div>
<div id="ref-El-sayed2016" class="csl-entry">
<div class="csl-left-margin">234. </div><div class="csl-right-inline">El sayed M, Hassan S. Does sugammadex facilitate recovery after outpatient tonsillectomy in children? <em>Egyptian Journal of Anaesthesia</em>. 2016;32(4):447-450. doi:<a href="https://doi.org/10.1016/j.egja.2016.08.021">10.1016/j.egja.2016.08.021</a></div>
</div>
<div id="ref-Eriksson1991" class="csl-entry">
<div class="csl-left-margin">235. </div><div class="csl-right-inline">Eriksson LI, Lennmarken C, Jensen E, Viby-Mogensen J. Twitch tension and train-of-four ratio during prolonged neuromuscular monitoring at different peripheral temperatures. <em>Acta Anaesthesiologica Scandinavica</em>. 1991;35(3):247-252. <a href="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L21128452&amp;from=export">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L21128452&amp;from=export</a></div>
</div>
<div id="ref-Evron2017" class="csl-entry">
<div class="csl-left-margin">236. </div><div class="csl-right-inline">Evron S, Abelansky Y, Ezri T, Izakson A. Respiratory events with sugammadex vs. Neostigmine following laparoscopic sleeve gastrectomy: A prospective pilot study assessing neuromuscular reversal strategies. <em>Romanian Journal of Anaesthesia and Intensive Care</em>. 2017;24(2):111-114. doi:<a href="https://doi.org/10.21454/rjaic.7518.242.evr">10.21454/rjaic.7518.242.evr</a></div>
</div>
<div id="ref-Gaffar2013" class="csl-entry">
<div class="csl-left-margin">237. </div><div class="csl-right-inline">Gaffar EA, Fattah SA, Atef HM, Omera MA, Abdel-Aziz MA. Kinemyography (KMG) versus electromyography (EMG) neuromuscular monitoring in pediatric patients receiving cisatracurium during general anesthesia. <em>Egyptian Journal of Anaesthesia</em>. 2013;29(3):247-253. doi:<a href="https://doi.org/10.1016/j.egja.2013.02.006">10.1016/j.egja.2013.02.006</a></div>
</div>
<div id="ref-Grivoyannis2021" class="csl-entry">
<div class="csl-left-margin">238. </div><div class="csl-right-inline">Grivoyannis AD, Tangel V, Lien CA. Vigilance: The behavioral impact of quantitative monitoring on administration and antagonism of neuromuscular blocking agents. <em>Journal of Clinical Monitoring and Computing</em>. Published online 2021. doi:<a href="https://doi.org/10.1007/s10877-021-00729-6">10.1007/s10877-021-00729-6</a></div>
</div>
<div id="ref-Hussein2020" class="csl-entry">
<div class="csl-left-margin">239. </div><div class="csl-right-inline">Hussein A, Hegazy MM, Elramely MA, Mohamed AG. Sugammadex versus neostigmine in pediatric cancer patients undergoing outpatient surgical procedures. <em>International Journal of Research in Pharmaceutical Sciences</em>. 2020;11(2):2741-2746. doi:<a href="https://doi.org/10.26452/ijrps.v11i2.2335">10.26452/ijrps.v11i2.2335</a></div>
</div>
<div id="ref-Johnson2018" class="csl-entry">
<div class="csl-left-margin">240. </div><div class="csl-right-inline">Johnson M, Khan OA, McGlone ER, Roman AA, Qureshi JS, Kayal A. Sugammadex is associated with better respiratory recovery than neostigmine following reversal of anaesthesia-associated neuromuscular blockade in the morbidly obese patients following elective laparoscopic surgery. <em>Laparoscopic, Endoscopic, and Robotic Surgery</em>. 2018;1(2):33-36. doi:<a href="https://doi.org/10.1016/j.lers.2018.03.002">10.1016/j.lers.2018.03.002</a></div>
</div>
<div id="ref-Kim2020" class="csl-entry">
<div class="csl-left-margin">241. </div><div class="csl-right-inline">Kim JH, Lim MS, Choi JW, Kim H, Kwon YS, Lee JJ. Comparison of the effects of sugammadex, neostigmine, and pyridostigmine on postoperative nausea and vomiting: A propensity matched study of five hospitals. <em>Journal of Clinical Medicine</em>. 2020;9(11):1-11. doi:<a href="https://doi.org/10.3390/jcm9113477">10.3390/jcm9113477</a></div>
</div>
<div id="ref-Kurcaloglu2020" class="csl-entry">
<div class="csl-left-margin">242. </div><div class="csl-right-inline">Kurçaloğlu M, Sarıhasan BB, Çetinoğlu EÇ. Comparing the effects of sugammadex and neostigmine on neuromuscular block and bispectral index in recovery from intracranial mass resection operations. <em>Eastern Journal of Medicine</em>. 2020;25(3):371-377. doi:<a href="https://doi.org/10.5505/ejm.2020.99705">10.5505/ejm.2020.99705</a></div>
</div>
<div id="ref-Ledowski2021" class="csl-entry">
<div class="csl-left-margin">243. </div><div class="csl-right-inline">Ledowski T, Szabó-Maák Z, Loh PS, et al. Reversal of residual neuromuscular block with neostigmine or sugammadex and postoperative pulmonary complications: A prospective, randomised, double-blind trial in high-risk older patients. <em>British Journal of Anaesthesia</em>. Published online 2021. doi:<a href="https://doi.org/10.1016/j.bja.2021.04.026">10.1016/j.bja.2021.04.026</a></div>
</div>
<div id="ref-Li2021a" class="csl-entry">
<div class="csl-left-margin">244. </div><div class="csl-right-inline">Li G, Freundlich RE, Gupta RK, et al. Postoperative pulmonary complications’ association with sugammadex versus neostigmine: A retrospective registry analysis. <em>Anesthesiology</em>. Published online 2021:862-873. doi:<a href="https://doi.org/10.1097/ALN.0000000000003735">10.1097/ALN.0000000000003735</a></div>
</div>
<div id="ref-Mekawy2012" class="csl-entry">
<div class="csl-left-margin">245. </div><div class="csl-right-inline">Mekawy N, Fouad Ali EA. Improved recovery profiles in sinonasal surgery sugammadex: Does it have a role? <em>Egyptian Journal of Anaesthesia</em>. 2012;28(3):175-178. doi:<a href="https://doi.org/10.1016/j.egja.2011.12.007">10.1016/j.egja.2011.12.007</a></div>
</div>
<div id="ref-Motamed2021a" class="csl-entry">
<div class="csl-left-margin">246. </div><div class="csl-right-inline">Motamed C, Bourgain JL. Comparison of the time to extubation and length of stay in the PACU after sugammadex and neostigmine use in two types of surgery: A monocentric retrospective analysis. <em>Journal of Clinical Medicine</em>. 2021;10(4):1-9. doi:<a href="https://doi.org/10.3390/jcm10040815">10.3390/jcm10040815</a></div>
</div>
<div id="ref-Oh2021" class="csl-entry">
<div class="csl-left-margin">247. </div><div class="csl-right-inline">Oh C, Jo Y, Sim S, et al. Post-operative respiratory outcomes associated with the use of sugammadex in laparoscopic colorectal cancer surgery: A retrospective, propensity score matched cohort study. <em>Signa Vitae</em>. 2021;17(1):117-123. doi:<a href="https://doi.org/10.22514/sv.2020.16.0116">10.22514/sv.2020.16.0116</a></div>
</div>
<div id="ref-Olesnicky2017" class="csl-entry">
<div class="csl-left-margin">248. </div><div class="csl-right-inline">Olesnicky BL, Traill C, Marroquinharris FB. The effect of routine availability of sugammadex on postoperative respiratory complications: A historical cohort study. <em>Minerva Anestesiologica</em>. 2017;83(3):248-254. doi:<a href="https://doi.org/10.23736/S0375-9393.16.11489-0">10.23736/S0375-9393.16.11489-0</a></div>
</div>
<div id="ref-Omar2012" class="csl-entry">
<div class="csl-left-margin">249. </div><div class="csl-right-inline">Omar AM. Effect of systemic lidocaine infusion on train-of-four ratios during recovery from general anesthesia. <em>Egyptian Journal of Anaesthesia</em>. 2012;28(4):281-286. doi:<a href="https://doi.org/10.1016/j.egja.2012.07.002">10.1016/j.egja.2012.07.002</a></div>
</div>
<div id="ref-Ornek2020" class="csl-entry">
<div class="csl-left-margin">250. </div><div class="csl-right-inline">Ornek DH, Tezcan AH, Terzi HO, Yildiz BD. Dosage of sugammadex in morbidly obese patients. <em>Annals of Clinical and Analytical Medicine</em>. 2020;11:S52-S56. doi:<a href="https://doi.org/10.4328/ACAM.20128">10.4328/ACAM.20128</a></div>
</div>
<div id="ref-Pecek2015" class="csl-entry">
<div class="csl-left-margin">251. </div><div class="csl-right-inline">Peček B, Polh D, Priman T. New way of dosing sugammadex for termination of vecuronium induced neuromuscular block. <em>Zdravniski Vestnik</em>. 2015;84(6):439-446. <a href="https://www.embase.com/search/results?subaction=viewrecord&amp;id=L605120638&amp;from=export">https://www.embase.com/search/results?subaction=viewrecord&amp;id=L605120638&amp;from=export</a></div>
</div>
<div id="ref-Sugi2013" class="csl-entry">
<div class="csl-left-margin">252. </div><div class="csl-right-inline">Sugi Y, Nitahara K, Katori K, Kusumoto G, Shigematsu K, Higa K. Acceleromyography at the flexor hallucis brevis muscle underestimates residual neuromuscular blockade. <em>Open Anesthesiology Journal</em>. 2013;7(1):26-29. doi:<a href="https://doi.org/10.2174/1874321801307010026">10.2174/1874321801307010026</a></div>
</div>
<div id="ref-Tas2015" class="csl-entry">
<div class="csl-left-margin">253. </div><div class="csl-right-inline">Taş N, Korkmaz H, Yağan Ö, Korkmaz M. Effect of sugammadex on postoperative bleeding and coagulation parameters after septoplasty: A randomized prospective study. <em>Medical Science Monitor</em>. 2015;21:2382-2386. doi:<a href="https://doi.org/10.12659/MSM.894971">10.12659/MSM.894971</a></div>
</div>
<div id="ref-Van-Dong2020" class="csl-entry">
<div class="csl-left-margin">254. </div><div class="csl-right-inline">Van Dong L, Giang NT, Luong NV, et al. Reversal of deep effect of rocuronium by sugammadex or neostigmine after abdominal laparoscopic surgery: A single center experience in vietnam. <em>Open Access Macedonian Journal of Medical Sciences</em>. 2020;8(B):295-300. doi:<a href="https://doi.org/10.3889/oamjms.2020.4236">10.3889/oamjms.2020.4236</a></div>
</div>
<div id="ref-Zhao2021" class="csl-entry">
<div class="csl-left-margin">255. </div><div class="csl-right-inline">Zhao D, Fang J, Xiong W, Lin J, Chen W, Wu C. Effects of sugammadex versus neostigmine on intraoperative coagulation profiles in patients with thyroidectomy. <em>Drug Design, Development and Therapy</em>. 2021;15:829-834. doi:<a href="https://doi.org/10.2147/DDDT.S286803">10.2147/DDDT.S286803</a></div>
</div>
<div id="ref-Armendariz-Buil2015" class="csl-entry">
<div class="csl-left-margin">256. </div><div class="csl-right-inline">Armendáriz-Buil I, Lobato-Solores F, Celorrio LA, Zabala DD, Londoño AG, Jimenez EF. Neuromuscular block reversal with sugammadex in type 2 diabetic patients. <em>Perioperative Care and Operating Room Management</em>. 2015;1(1-2):13-18. doi:<a href="https://doi.org/10.1016/j.pcorm.2015.11.002">10.1016/j.pcorm.2015.11.002</a></div>
</div>
<div id="ref-Sabo2011" class="csl-entry">
<div class="csl-left-margin">257. </div><div class="csl-right-inline">Sabo D, Jones RK, Berry J, et al. Residual neuromuscular blockade at extubation: A randomized comparison of sugammadex and neostigmine reversal of rocuronium-induced blockade in patients undergoing abdominal surgery. <em>Journal of Anesthesia and Clinical Research</em>. 2011;2(6). doi:<a href="https://doi.org/10.4172/2155-6148.1000140">10.4172/2155-6148.1000140</a></div>
</div>
<div id="ref-Baykara2010" class="csl-entry">
<div class="csl-left-margin">258. </div><div class="csl-right-inline">Baykara N. High incidence of residual curarization after rocuronium despite administration of neostigmine. <em>Turk Klinik J Med Sci</em>. 2010;30(4):1325-1331.</div>
</div>
<div id="ref-Duranteau2021" class="csl-entry">
<div class="csl-left-margin">259. </div><div class="csl-right-inline">Duranteau O, Fernandez W, Tuna T, Engelman E, Van Obbergh L, Tabolcea I. Earlier and lower dose administration of sugammadex: A randomised placebo-controlled trial. <em>European Journal of Anaesthesiology <span><span class="math inline">\(|\)</span></span> EJA</em>. 2021;38(8):865-871. doi:<a href="https://doi.org/10.1097/eja.0000000000001502">10.1097/eja.0000000000001502</a></div>
</div>
<div id="ref-Kara2014" class="csl-entry">
<div class="csl-left-margin">260. </div><div class="csl-right-inline">Kara T, Ozbagriacik O, Turk HS, et al. Sugammadex versus neostigmine in pediatric patients: A prospective randomized study. <em>Braz J Anesthesiol (English Edition)</em>. 2014;64(6):400-405. doi:<a href="https://doi.org/10.1016/j.bjane.2014.03.001">10.1016/j.bjane.2014.03.001</a></div>
</div>
<div id="ref-Ke2018" class="csl-entry">
<div class="csl-left-margin">261. </div><div class="csl-right-inline">Ke YH, Chew ST, Ti LK. Postoperative residual neuromuscular blockade (rNMB) following low-dose (&lt;2×ED95) atracurium in patients receiving laryngeal mask airway - an audit study. <em>Med Saf Glob Health</em>. 2018;7:142. doi:<a href="https://doi.org/10.4172/2574-0407/1000142">10.4172/2574-0407/1000142</a></div>
</div>
<div id="ref-Rao-Kadam2018" class="csl-entry">
<div class="csl-left-margin">262. </div><div class="csl-right-inline">Rao Kadam V, Howell S. Unrestricted and restricted access to sugammadex and side effect profile in a teaching hospital centre for year 2014- database audit study. <em>Anesth Pain Med</em>. 2018;8(1):e63066. doi:<a href="https://doi.org/10.5812/aapm.63066">10.5812/aapm.63066</a></div>
</div>
<div id="ref-Santanen1999" class="csl-entry">
<div class="csl-left-margin">263. </div><div class="csl-right-inline">Santanen OA, Paloheimo MP. Effects of small peripheral temperature changes on evoked baseline electromyographic response. <em>Acta Anaesthesiol Scand</em>. 1999;43(3):338-342. doi:<a href="https://doi.org/10.1034/j.1399-6576.1999.430316.x">https://doi.org/10.1034/j.1399-6576.1999.430316.x</a></div>
</div>
<div id="ref-Suganuma2021" class="csl-entry">
<div class="csl-left-margin">264. </div><div class="csl-right-inline">Suganuma E, Ishikawa T, Kitamura Y, et al. Recovery of lower oesophageal barrier function: A pilot study comparing a mixture of atropine and neostigmine and sugammadex: A randomised controlled pilot study. <em>Eur J Anaesthesiol</em>. 2021;38(8):856-864. doi:<a href="https://doi.org/10.1097/eja.0000000000001464">10.1097/eja.0000000000001464</a></div>
</div>
<div id="ref-Xie2014" class="csl-entry">
<div class="csl-left-margin">265. </div><div class="csl-right-inline">Xie M, Wang DX, Geng ZY. Prevalence and risk factors of postoperative residual curarization in patients arriving at postanesthesia care unit after general anesthesia: A prospective cohort study. <em>J Anesth Periop Med</em>. 2014;1(2):72-78. doi:<a href="https://doi.org/DOI:10.24015/JAPM.2014.0012">DOI:10.24015/JAPM.2014.0012</a></div>
</div>
<div id="ref-Castro2014" class="csl-entry">
<div class="csl-left-margin">266. </div><div class="csl-right-inline">Castro D, Leão P, Borges S, Gomes L, Pacheco M, Figueiredo P. Sugammadex reduces postoperative pain after laparoscopic bariatric surgery: A randomized trial. <em>Surg Laparosc, Endosc Percutan Tech</em>. 2014;24(5):420-423. doi:<a href="https://doi.org/10.1097/SLE.0000000000000049">10.1097/SLE.0000000000000049</a></div>
</div>
<div id="ref-Kopman2005" class="csl-entry">
<div class="csl-left-margin">267. </div><div class="csl-right-inline">Kopman AF. Normalization of the acceleromyographic train-of-four fade ratio. <em>Acta Anaesthesiol Scand</em>. 2005;49(10):1575-1576. doi:<a href="https://doi.org/10.1111/j.1399-6576.2005.00880.x">10.1111/j.1399-6576.2005.00880.x</a></div>
</div>
<div id="ref-El-Sherbeny2017" class="csl-entry">
<div class="csl-left-margin">268. </div><div class="csl-right-inline">El Sherbeny MA, Elrahman EAA, Kamal RK, Abozena MAM. Efficacy and safety of sugammadex in reversing nmb (rocuronium) in adults. <em>N Y Sci J</em>. 2017;10(6):22-29. doi:<a href="https://doi.org/10.7537/marsnys100617.04">10.7537/marsnys100617.04</a></div>
</div>
<div id="ref-Renew2021a" class="csl-entry">
<div class="csl-left-margin">269. </div><div class="csl-right-inline">Renew JR, Hernandez-Torres V, Logvinov I, et al. Comparison of the TetraGraph and TOFscan for monitoring recovery from neuromuscular blockade in the post anesthesia care unit. <em>J Clin Anesth</em>. 2021;71:110234. doi:<a href="https://doi.org/10.1016/j.jclinane.2021.110234">10.1016/j.jclinane.2021.110234</a></div>
</div>
</div>
<br>
<p>
<button type="button" class="btn btn-default btn-workflowr btn-workflowr-sessioninfo" data-toggle="collapse" data-target="#workflowr-sessioninfo" style="display: block;">
<span class="glyphicon glyphicon-wrench" aria-hidden="true"></span> Session information
</button>
</p>
<div id="workflowr-sessioninfo" class="collapse">
<pre><code>R version 4.1.2 (2021-11-01)
Platform: x86_64-apple-darwin17.0 (64-bit)
Running under: macOS Big Sur 10.16

Matrix products: default
BLAS:   /Library/Frameworks/R.framework/Versions/4.1/Resources/lib/libRblas.0.dylib
LAPACK: /Library/Frameworks/R.framework/Versions/4.1/Resources/lib/libRlapack.dylib

locale:
[1] en_US.UTF-8/en_US.UTF-8/en_US.UTF-8/C/en_US.UTF-8/en_US.UTF-8

attached base packages:
[1] stats     graphics  grDevices utils     datasets  methods   base     

other attached packages:
 [1] meta_5.1-1        formattable_0.2.1 naniar_0.6.1      forcats_0.5.1    
 [5] stringr_1.4.0     dplyr_1.0.7       purrr_0.3.4       readr_2.1.1      
 [9] tidyr_1.1.4       tibble_3.1.6      ggplot2_3.3.5     tidyverse_1.3.1  
[13] Cairo_1.5-14      countrycode_1.3.0 janitor_2.1.0     kableExtra_1.3.4 

loaded via a namespace (and not attached):
 [1] nlme_3.1-153           fs_1.5.2               bit64_4.0.5           
 [4] lubridate_1.8.0        webshot_0.5.2          httr_1.4.2            
 [7] rprojroot_2.0.2        tools_4.1.2            backports_1.4.1       
[10] bslib_0.3.1            metafor_3.0-2          utf8_1.2.2            
[13] R6_2.5.1               DBI_1.1.2              colorspace_2.0-2      
[16] withr_2.4.3            tidyselect_1.1.1       bit_4.0.4             
[19] compiler_4.1.2         git2r_0.29.0           cli_3.1.0             
[22] rvest_1.0.2            xml2_1.3.3             sass_0.4.0            
[25] scales_1.1.1           systemfonts_1.0.3      digest_0.6.29         
[28] minqa_1.2.4            rmarkdown_2.11         svglite_2.0.0         
[31] pkgconfig_2.0.3        htmltools_0.5.2        lme4_1.1-27.1         
[34] dbplyr_2.1.1           fastmap_1.1.0          htmlwidgets_1.5.4     
[37] rlang_0.4.12           readxl_1.3.1           rstudioapi_0.13.0-9000
[40] jquerylib_0.1.4        generics_0.1.1         jsonlite_1.7.2        
[43] vroom_1.5.7            magrittr_2.0.1         Matrix_1.4-0          
[46] Rcpp_1.0.7             munsell_0.5.0          fansi_0.5.0           
[49] lifecycle_1.0.1        visdat_0.5.3           stringi_1.7.6         
[52] whisker_0.4            yaml_2.2.1             CompQuadForm_1.4.3    
[55] snakecase_0.11.0       mathjaxr_1.4-0         MASS_7.3-54           
[58] grid_4.1.2             parallel_4.1.2         promises_1.2.0.1      
[61] crayon_1.4.2           lattice_0.20-45        haven_2.4.3           
[64] splines_4.1.2          hms_1.1.1              knitr_1.37            
[67] pillar_1.6.4           boot_1.3-28            reprex_2.0.1          
[70] glue_1.6.0             evaluate_0.14          modelr_0.1.8          
[73] nloptr_1.2.2.3         vctrs_0.3.8            tzdb_0.2.0            
[76] httpuv_1.6.5           cellranger_1.1.0       gtable_0.3.0          
[79] assertthat_0.2.1       xfun_0.29              broom_0.7.11          
[82] later_1.3.0            viridisLite_0.4.0      workflowr_1.7.0       
[85] ellipsis_0.3.2        </code></pre>
</div>
</div>


<!-- Adjust MathJax settings so that all math formulae are shown using
TeX fonts only; see
https://docs.mathjax.org/en/latest/web/configuration.html. This will make
the presentation more consistent at the cost of the webpage sometimes
taking slightly longer to load. Note that this only works because the
footer is added to webpages before the MathJax javascript. -->
<script type="text/x-mathjax-config">
  MathJax.Hub.Config({
    "HTML-CSS": { availableFonts: ["TeX"] }
  });
</script>




</div>
</div>

</div>

<script>

// add bootstrap table styles to pandoc tables
function bootstrapStylePandocTables() {
  $('tr.odd').parent('tbody').parent('table').addClass('table table-condensed');
}
$(document).ready(function () {
  bootstrapStylePandocTables();
});


</script>

<!-- tabsets -->

<script>
$(document).ready(function () {
  window.buildTabsets("TOC");
});

$(document).ready(function () {
  $('.tabset-dropdown > .nav-tabs > li').click(function () {
    $(this).parent().toggleClass('nav-tabs-open');
  });
});
</script>

<!-- code folding -->

<script>
$(document).ready(function ()  {

    // temporarily add toc-ignore selector to headers for the consistency with Pandoc
    $('.unlisted.unnumbered').addClass('toc-ignore')

    // move toc-ignore selectors from section div to header
    $('div.section.toc-ignore')
        .removeClass('toc-ignore')
        .children('h1,h2,h3,h4,h5').addClass('toc-ignore');

    // establish options
    var options = {
      selectors: "h1,h2,h3",
      theme: "bootstrap3",
      context: '.toc-content',
      hashGenerator: function (text) {
        return text.replace(/[.\\/?&!#<>]/g, '').replace(/\s/g, '_');
      },
      ignoreSelector: ".toc-ignore",
      scrollTo: 0
    };
    options.showAndHide = true;
    options.smoothScroll = true;

    // tocify
    var toc = $("#TOC").tocify(options).data("toc-tocify");
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    script.src  = "https://mathjax.rstudio.com/latest/MathJax.js?config=TeX-AMS-MML_HTMLorMML";
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>

</body>
</html>
